NCT06032923,"""26 September 2023""","""001621-H;10001621""","""Pilot Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus""","""Pilot Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus""","""https://clinicaltrials.gov/ct2/show/NCT06032923""",""" ; ; ""","""NIH Clinical Center Office of Patient Recruitment (OPR);Michael N Sack, M.D.;Rebecca D Huffstutler, C.R.N.P.""",NULL,"""ccopr@nih.gov;;rebecca.huffstutler@nih.gov""","""800-411-1222;;(301) 594-1281""","""National Heart, Lung, and Blood Institute (NHLBI);""",""" ; ; ""","""NIH Clinical Center Office of Patient Recruitment (OPR);Michael N Sack, M.D.;Rebecca D Huffstutler, C.R.N.P.""",NULL,"""ccopr@nih.gov;;rebecca.huffstutler@nih.gov""","""800-411-1222;;(301) 594-1281""","""National Heart, Lung, and Blood Institute (NHLBI);""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ""","""Phase 1/Phase 2""","""9/9/2023""","""September 28, 2023""","""78""","""Not yet recruiting""","""National Heart, Lung, and Blood Institute (NHLBI)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Systemic Lupus Erythematosus (Sle)""","""Dietary Supplement: Nicotinamide Riboside""","""18 Years""","""120 Years""","""Female""","""<br>        -  INCLUSION CRITERIA:<br><br>        In order to be eligible to participate in this study, an individual must meet all of the<br>        following criteria:<br><br>        SLE subjects:<br><br>          -  Female subjects 18 years or older who meets > 3 of 11 modified Am. Coll. of<br>             Rheumatology (ACR) (1997) Revised Criteria for SLE and mild/moderate disease activity<br>             defined as an SLE Disease Activity Index 2000(SLEDAI 2K) more than or equal to 2 and<br>             less than or equal to 14 at screening;<br><br>          -  If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable<br>             for at least 4 weeks prior to screening;<br><br>          -  If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine,<br>             dose must have been stable for the 12 weeks prior to screening. The max. allowed doses<br>             - hydroxychloroquine 400 mg/day, chloroquine phosphate 500 mg/day and quinacrine 100<br>             mg/day;<br><br>          -  Subjects of childbearing potential must agree to practice effective birth control for<br>             the duration of the study;<br><br>          -  Stated willingness to comply with all study procedures and availability for the<br>             duration of the study;<br><br>          -  Agreement to adhere to Lifestyle Considerations throughout study duration;<br><br>          -  Ability of subject to understand and the willingness to sign a written informed<br>             consent document.<br><br>        Control subjects:<br><br>          -  Female subjects 18 years or older<br><br>          -  No history of autoimmune or inflammatory disease;<br><br>        EXCLUSION CRITERIA:<br><br>        SLE Subjects:<br><br>          -  Active renal or central nervous system disease or major renal or hepatic dysfunction;<br><br>          -  Treatment with rituximab, belimumab or any other biologic agent within the 6 months<br>             prior to screening<br><br>          -  Current treatment with specific immunosuppressive drugs (methotrexate, azathioprine,<br>             mycophenolate mofetil, cyclosporine, tacrolimus);<br><br>          -  Treatment with cyclophosphamide or IVIG within the 6 months prior to screening and or<br>             increase in glucocorticoid dose within 4 weeks of screening;<br><br>          -  Dietary vitamin B3 or tryptophan supplementation within 6 weeks of screening.<br><br>          -  Pregnancy or lactation (nursing)<br><br>          -  Treatment with another investigational drug or other intervention within 6 months of<br>             screening<br><br>        Control Subjects:<br><br>          -  Inability to sign consent<br><br>          -  Dietary vitamin B3 or tryptophan supplementation within 6 weeks<br><br>          -  Pregnancy or nursing<br><br>        Pregnant women are excluded from participation on this study. Self-reported pregnancy<br>        status may be accepted from female control participants of child-bearing potential for a<br>        blood draw which is considered a minimal risk procedure.<br>      """,NULL,"""The primary end point will be to assess the effect of NR on blunting type I IFN signaling and cytokine secretion from placebo vs. NR supplemented subjects in monocytes comparing baseline (visit 1 to visit 3).""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06039228,"""26 September 2023""","""KPF23GWP12""","""School-based Group Acceptance and Commitment Therapy for Adolescents""","""Thriving Through the Storms: A School-based Mental Health Promotion Program for Building Psychological Flexibility and Resilience""","""https://clinicaltrials.gov/ct2/show/NCT06039228""",""" ; ""","""Jennifer Tang, PhD;Jennifer Tang, PhD""",NULL,"""jymtang@cuhk.edu.hk;jymtang@cuhk.edu.hk""","""39433753;39433753""","""""",""" ; ""","""Jennifer Tang, PhD;Jennifer Tang, PhD""",NULL,"""jymtang@cuhk.edu.hk;jymtang@cuhk.edu.hk""","""39433753;39433753""","""""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/9/2023""","""July 1, 2023""","""100""","""Recruiting""","""Chinese University of Hong Kong""",NULL,"""Please refer to primary and secondary sponsors""","""Hong Kong""","""Depressive Symptoms;Anxiety;Stress""","""Behavioral: Acceptance and commitment therapy""","""12 Years""","""18 Years""","""All""","""<br>        Inclusion Criteria:<br><br>        Eligible participants are adolescents who reported mild to moderate severity of<br>        psychological distress, including those who report:<br><br>          -  a score of 5-19 on the Patient Health Questionnaire (PHQ-9), or<br><br>          -  a score of 5-14 on the General Anxiety Disorder-7, or<br><br>          -  a score =14 on the Perceived Stress Scale.<br><br>        Exclusion Criteria:<br><br>        Adolescents will be excluded if they exhibit or report:<br><br>          -  violent or aggressive behavior, or<br><br>          -  active self-injurious or suicidal thought, or<br><br>          -  active psychotic symptom.<br>      """,NULL,"""Acceptance and Action Questionnaire - II;The 14-item Resilience Scale;Patient Health Questionnaire - 9;General Anxiety Disorder - 7;Perceived Stress Scale""","""Satisfaction with Life Scale;Pittsburgh Sleep Quality Index""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06040294,"""26 September 2023""","""YLH-IRB-11210""","""Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills""","""Evaluation of a Dementia and Disability Simulation Program for Senior Activity Facilitation Skills Among College Nursing Students""","""https://clinicaltrials.gov/ct2/show/NCT06040294""",""" ""","""Huei-Chuan Sung, PhD""",NULL,"""""","""""","""Tzu Chi University of Science and Technology""",""" ""","""Huei-Chuan Sung, PhD""",NULL,"""""","""""","""Tzu Chi University of Science and Technology""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Single (Outcomes Assessor). ""","""N/A""","""9/9/2023""","""September 7, 2023""","""52""","""Enrolling by invitation""","""Tzu Chi University of Science and Technology""",NULL,"""Please refer to primary and secondary sponsors""","""Taiwan""","""Dementia""","""Other: DDS program;Other: dementia course with no DDS""","""19 Years""","""40 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  college nursing students with age ranged from 19 to 40 years,<br><br>          -  Taiwanese nationality,<br><br>          -  Sophomore and above<br><br>          -  provide informed consent to participate in the study.<br><br>        Exclusion Criteria:<br><br>        -college nursing students who do not meet the inclusion criteria<br>      """,NULL,"""Dementia Knowledge Assessment Scale (DKAS);Approaches to Dementia Questionnaire (ADQ);Jefferson Scale of Empathy (JSE);Rubrics of activity design skills for seniors""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06042504,"""26 September 2023""","""2206E""","""Effects of Family Status of Osteopathic Medical Students on Their Perceived Level of Stress.""","""Effects of Family Status of Osteopathic Medical Students on Their Perceived Level of Stress.""","""https://clinicaltrials.gov/ct2/show/NCT06042504""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Observational""","""""","""""","""9/9/2023""","""January 25, 2022""","""100""","""Completed""","""The Touro College and University System""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Stress, Psychological""","""Other: Survey""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Medical Students<br><br>        Exclusion Criteria:<br><br>          -  Not current Medical Students<br>      """,NULL,"""Total PSS Score""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06043115,"""26 September 2023""","""Akdeniz University Faculty""","""Factors Affecting Mortality in Covid-19 Disease""","""Factors Affecting Mortality in Covid-19 Disease""","""https://clinicaltrials.gov/ct2/show/NCT06043115""",""" ""","""Burcu Ozer, MD""",NULL,"""""","""""","""Akdeniz University School of Medicine, Department of Anesthesiology and Reanimation, Turkey""",""" ""","""Burcu Ozer, MD""",NULL,"""""","""""","""Akdeniz University School of Medicine, Department of Anesthesiology and Reanimation, Turkey""","""Observational""","""""","""""","""9/9/2023""","""May 11, 2022""","""619""","""Completed""","""Melike Cengiz""",NULL,"""Please refer to primary and secondary sponsors""","""Turkey""","""COVID-19 Pneumonia;Mortality""","""Other: covid-19 survival cohort;Other: covid-19 mortality cohort""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Patients aged =18 years with a confrmed diagnosis of the severe acute respiratory<br>             syndrome coronavirus-2 infection by a positive real-time reverse-transcription<br>             polymerase chain reaction test<br><br>        Exclusion Criteria:<br><br>          -  Patients whose SARS-CoV-2 RT-PCR test was negative<br><br>          -  Chest computed tomography findings or symptoms were not compatible with COVID-19<br>      """,NULL,"""factors affecting mortality in COVID-19""","""difference between the pandemic waves""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06045949,"""26 September 2023""","""DRHFafterLDLT""","""Prediction of Early Recovery of Liver Function After LDLT in Children: An Ambispective Cohort Study""","""Prediction of Early Recovery of Liver Function After Living Donor Liver Transplantation in Children: An Ambispective Cohort Study""","""https://clinicaltrials.gov/ct2/show/NCT06045949""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Observational [Patient Registry]""","""""","""""","""9/9/2023""","""July 31, 2022""","""230""","""Completed""","""Huiwu Xing""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Liver and Biliary Tract Disorders in Duration of Pregnancy;Other End-stage Liver Diseases in Children""",NULL,"""0 Years""","""18 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. children with the indication of LDLT [cholestatic liver disease (such as BA),<br>             metabolic liver disease (such as Wilson's disease and Ornithine transcarbamylase<br>             deficiency), acute liver failure (such as drug induced), neoplastic disease (such as<br>             hepatoblastoma), vascular disease (such as cavernous transformation of portal vein and<br>             congenital absence of portal vein), re-transplantation and others];<br><br>          2. the relatives of the children voluntarily donated part of the liver which met the<br>             requirements of LDLT.<br><br>        Exclusion Criteria:<br><br>          1. recipients with contraindications of LDLT (such as coagulation dysfunction, acute<br>             infection, cardiopulmonary failure);<br><br>          2. failure to complete LDLT due to various reasons (such as death during or within 3 days<br>             after operation);<br><br>          3. recipients or donors with incomplete necessary data.<br>      """,NULL,"""DRHF""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06048042,"""26 September 2023""","""ghadashatra123""","""Evaluation of Autogenous Demineralized Dentin Graft Vs Autogenous Bone Graft in Management of Intrabony Defects""","""Clinical and Radiographic Evaluation of Autogenous Demineralized Dentin Graft Versus Autogenous Bone Graft in Management of Periodontal Intrabony Defects Using Modified Minimally Invasive Surgical Technique: A Non-Randomized Clinical Trial""","""https://clinicaltrials.gov/ct2/show/NCT06048042""",""" ; ; ; ""","""Ghada M. Abouhussein, Bachelor;Weam El-Battawy, Ass professor;Nesma Shemais, Ass lecturer;Ghada M. Abouhussein, Bachelor""",NULL,""";;;ghada.mohammed@dentistry.cu.edu.eg""",""";;;+02 01004966156""","""Cairo University;Cairo University;Cairo University;""",""" ; ; ; ""","""Ghada M. Abouhussein, Bachelor;Weam El-Battawy, Ass professor;Nesma Shemais, Ass lecturer;Ghada M. Abouhussein, Bachelor""",NULL,""";;;ghada.mohammed@dentistry.cu.edu.eg""",""";;;+02 01004966156""","""Cairo University;Cairo University;Cairo University;""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ""","""Phase 4""","""9/9/2023""","""September 2023""","""24""","""Not yet recruiting""","""Cairo University""",NULL,"""Please refer to primary and secondary sponsors""","""Egypt""","""Intrabony Periodontal Defect""","""Biological: Autogenous Demineralized Dentin Graft;Biological: Autogenous Bone Graft""","""18 Years""","""50 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Patient-related criteria:<br><br>               -  Motivated patient 18 years of age or order.<br><br>               -  Patient consulting in the outpatient clinic.<br><br>               -  Patient ready to perform oral hygiene instructions.<br><br>               -  Provide informed consent.<br><br>               -  Accepts the 6 months follow-up period.<br><br>          -  Teeth related criteria:<br><br>               -  Tooth with two or three-walled intra-bony defect, probing depth = 5mm with intra<br>                  osseous defect = 3mm.<br><br>               -  Mature permanent tooth.<br><br>               -  Unrestorable tooth or fractured tooth beyond restoration, impacted third molar or<br>                  supernumerary tooth to be extracted and used as whole tooth graft inside the<br>                  intrabony defect.<br><br>        Exclusion Criteria:<br><br>          -  Patient-related criteria:<br><br>               -  Medically compromised patients.<br><br>               -  Pregnant women.<br><br>               -  Uncooperative patients.<br><br>               -  Smokers.<br><br>               -  Systemic diseases that may compromise healing or bone metabolism (e.g diabetes,<br>                  hyperthyroidism).<br><br>               -  Failure to maintain good oral hygiene.<br><br>          -  Teeth related criteria:<br><br>               -  Teeth with supra-bony defects.<br><br>               -  Teeth with grade III mobility.<br><br>               -  Teeth having interproximal craters, grade III furcation involvement, and grade<br>                  III mobility.<br><br>               -  Presence of caries or overhanging restorations.<br><br>               -  Presence of peri-apical injuries.<br>      """,NULL,"""Clinical attachment level (CAL) gain change from baseline to 6 months.""","""Linear bone fill change from baseline to 6 months;Gingival index (GI) change from baseline to 6 months;Plaque index (PI) change from baseline to 6 months;Probing pocket depth (PPD) change from baseline to 6 months;Gingival recession (GR) change from baseline to 6 months;Bleeding on probing (BoP) change from baseline to 6 months;Postoperative Pain;Patient satisfaction""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06048445,"""26 September 2023""","""BDSPBIAP""","""Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children""","""Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children: A Prospective Study""","""https://clinicaltrials.gov/ct2/show/NCT06048445""",""" ""","""Weili Wang, MD""",NULL,"""1519185@zju.edu.cn""","""19883132292""","""""",""" ""","""Weili Wang, MD""",NULL,"""1519185@zju.edu.cn""","""19883132292""","""""","""Observational""","""""","""""","""9/9/2023""","""October 1, 2023""","""108""","""Not yet recruiting""","""Zhejiang University""",NULL,"""Please refer to primary and secondary sponsors""",NULL,"""Liver Transplant; Complications""","""Device: intraoperative plancement of Biliary Drainage Stent""","""1 Year""","""6 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. The patient underwent liver transplantation surgery at the First Affiliated Hospital<br>             of Zhejiang University School of Medicine;<br><br>          2. Age = 6 years old;<br><br>          3. First liver transplantation;<br><br>          4. Willing to sign an informed consent form.<br><br>        Exclusion Criteria:<br><br>        - Existence of mental illnesses that can affect cognition and coordination.<br>      """,NULL,"""duct-jejunum anastomotic stoma stricture""","""biliary tract infection""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06053151,"""26 September 2023""","""MOST 111-2410-H-715 -001 -MY3""","""Cloud Platform Integration Model for Pregnant Women Exercise Consultation""","""Cloud Platform Integration Model for Pregnant Women Exercise Consultation: Development, Construction and Evaluation""","""https://clinicaltrials.gov/ct2/show/NCT06053151""",""" ; ""","""Ching Fang Lee, PhD;Ching Fang Lee, PhD""",NULL,""";chingfang@mmc.edu.tw""",""";+886 26360323""","""Mackay Medical College;""",""" ; ""","""Ching Fang Lee, PhD;Ching Fang Lee, PhD""",NULL,""";chingfang@mmc.edu.tw""",""";+886 26360323""","""Mackay Medical College;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). ""","""N/A""","""9/9/2023""","""December 15, 2023""","""154""","""Not yet recruiting""","""Mackay Medical College""",NULL,"""Please refer to primary and secondary sponsors""",NULL,"""Exercise;Pregnancy Related""","""Behavioral: exercise counselling""","""20 Years""","""45 Years""","""Female""","""<br>        Inclusion Criteria:<br><br>          -  pregnant women who less than 17 gestation and able to understand basic technologies<br>             such as smartphone and computer<br><br>        Exclusion Criteria:<br><br>          -  women who had a diagnosis of pregnancy related compliactions and absolute limited<br>             exercise, such as preterm contraction, ruputer of menbrance, evidence of intrauterus<br>             growth retardation, heart and lung disease, cervical incompetence and/or medical<br>             conditions that influence exercise.<br>      """,NULL,"""increase physiacl activity;decrese symptom distress;decrease pregnancy related complications""","""construct exercise counseling model""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06053489,"""26 September 2023""","""2023-09-10""","""Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients""","""Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients Who Underwent Ophthalmic Surgery Under General Anesthesia""","""https://clinicaltrials.gov/ct2/show/NCT06053489""",""" ; ""","""Hee Young Kim, MD, PhD;Hee Young Kim, MD, PhD""",NULL,""";anekhy@gmail.com""",""";82-10-7641-1774""","""Pusan National University Yangsan Hospital, Yangsan, South Korea;""",""" ; ""","""Hee Young Kim, MD, PhD;Hee Young Kim, MD, PhD""",NULL,""";anekhy@gmail.com""",""";82-10-7641-1774""","""Pusan National University Yangsan Hospital, Yangsan, South Korea;""","""Observational""","""""","""""","""9/9/2023""","""September 25, 2023""","""100""","""Not yet recruiting""","""Pusan National University Yangsan Hospital""",NULL,"""Please refer to primary and secondary sponsors""","""Korea, Republic of""","""Ophthalmic Abnormalities;Pediatric Disorder""","""Other: general anesthesia with remimazolam""","""3 Years""","""18 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Patients aged between 3 and 18 years old who underwent ophthalmic surgery under<br>             general anesthesia<br><br>          -  When anesthesia was induced and maintained with remimazolam, or anesthesia was induced<br>             with propofol and maintained with sevoflurane.<br><br>        Exclusion Criteria:<br><br>        - none<br>      """,NULL,"""Time to extubation""","""Time for post-anesthesia recovery;Postoperative pain;Incidence of emergence delirium;Adverse events and complications""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05536804,"""26 September 2023""","""I8F-MC-GPIG;2021-005273-47;2023-506082-60-00;17217""","""A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes""","""Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging""","""https://clinicaltrials.gov/ct2/show/NCT05536804""",""" ; ; ""","""Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST);There may be multiple sites in this clinical trial. 1-877-CTLILLY (1877-285-4559) or;""",NULL,""";ClinicalTrials.gov@lilly.com;""",""";1-317-615-4559;4530913383""","""Eli Lilly and Company;""",""" ; ; ""","""Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST);There may be multiple sites in this clinical trial. 1-877-CTLILLY (1877-285-4559) or;""",NULL,""";ClinicalTrials.gov@lilly.com;""",""";1-317-615-4559;4530913383""","""Eli Lilly and Company;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ""","""Phase 2""","""9/9/2022""","""February 8, 2023""","""140""","""Recruiting""","""Eli Lilly and Company""",NULL,"""Please refer to primary and secondary sponsors""","""United States;Austria;Canada;Denmark;Mexico;Netherlands;Austria;Canada;Denmark;Mexico;Netherlands;United States""","""Overweight;Obesity;Chronic Kidney Disease;Type 2 Diabetes;T2D""","""Drug: Tirzepatide;Drug: Placebo""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>        All participants with or without diabetes:<br><br>          -  Have a Body Mass Index (BMI) =27 kilogram/square meter (kg/m²) at screening<br><br>          -  Diagnosed with chronic kidney disease (CKD)<br><br>          -  Has an estimated glomerular filtration rate (eGFR) =30 to =60 ml/min/1.73 m² or eGFR<br>             =30 to =75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (UACR) >30<br>             milligram/gram (mg/g)<br><br>          -  Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor<br>             blockers (ARB) that is considered the maximal appropriate dose by the investigator for<br>             treatment of chronic kidney disease or hypertension (unless the participant has low<br>             blood pressure or hypotension)<br><br>        Participants without diabetes:<br><br>          -  Have Hemoglobin A1c (HbA1c) <6.5% at screening<br><br>        Participants with Type 2 diabetes:<br><br>          -  Have been diagnosed at least 180 days prior to screening<br><br>          -  Have HbA1c =7.0% to =10.5% at screening<br><br>        Exclusion Criteria:<br><br>        All participants:<br><br>          -  Have a self-reported change in body weight >5 kilogram (kg) within 90 days prior to<br>             screening.<br><br>          -  Have a prior or planned surgical treatment for obesity<br><br>          -  Have or plan to have endoscopic and/or device-based therapy for obesity or have had<br>             device removal within the last 180 days<br><br>          -  Have eGFR <30 mL/min/1.73m² calculated by using creatinine-based chronic kidney<br>             disease epidemiology collaboration (CKD-EPI) equations, as determined by central<br>             laboratory at screening.<br><br>          -  Have a history of unstable or rapidly progressing renal disease according to<br>             investigator judgment<br><br>          -  Have a known clinically significant gastric emptying abnormality (for example, severe<br>             diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that<br>             directly affect GI motility)<br><br>          -  Have had a history of chronic or acute pancreatitis<br><br>        Participants with T2D:<br><br>          -  Have history of proliferative diabetic retinopathy or diabetic macular edema or<br>             non-proliferative diabetic retinopathy that requires acute treatment.<br><br>          -  Have been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or<br>             hyperosmolar state/coma<br>      """,NULL,"""Change from Baseline in Kidney Oxygenation in Participants With or Without T2D""","""Change from Baseline in Kidney Oxygenation in Participants with T2D (BOLD MRI);Change from Baseline in Kidney Oxygenation in Participants without T2D (BOLD MRI);Percent Change from Baseline in Body Weight;Percent Change from Baseline in Renal Sinus Fat Content (MRI);Percent Change from Baseline in Renal Fat Content (MRI Proton Density Fat Fraction);Percent Change from Baseline in Renal Blood Flow (Phase-Contrast MRI);Change from Baseline in Apparent Diffusion Coefficient (ADC) MRI;Change from Baseline in Glomerular Filtration Rate (GFR) Iohexol Clearance in Milliliter/Minute/Square Meter (ml/min/m²);Change from Baseline in 24-hour Urinary Albumin Excretion (UAE) in Milligram/24 Hours (mg/24h);Percent Change from Baseline in Urine Albumin-to-Creatine Ratio (UACR)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05698368,"""26 September 2023""","""69227""","""Digital Knee Osteoarthritis Mindset Intervention""","""A Digital Mindset Intervention to Improve Pain and Exercise Participation in Individuals With Knee Osteoarthritis: A Randomized, Parallel-group Study""","""https://clinicaltrials.gov/ct2/show/NCT05698368""",""" ; ; ""","""Melissa Boswell, PhD;Scott Delp, PhD;Alia Crum, PhD""",NULL,""";;""",""";;""","""Stanford University;Stanford University;Stanford University""",""" ; ; ""","""Melissa Boswell, PhD;Scott Delp, PhD;Alia Crum, PhD""",NULL,""";;""",""";;""","""Stanford University;Stanford University;Stanford University""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Investigator, Outcomes Assessor). ""","""N/A""","""9/9/2022""","""April 10, 2023""","""527""","""Completed""","""Stanford University""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Knee Osteoarthritis""","""Behavioral: Mindset intervention;Other: Active comparator""","""45 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Over 45 years of age<br><br>          -  Self-reported doctor's diagnosis of knee osteoarthritis OR meets the National<br>             Institute for - - Health and Care Excellence osteoarthritis clinical criteria<br>             (activity-related knee pain and no knee morning stiffness lasting = 30 minutes)<br><br>          -  Knee pain for at least 3 months<br><br>          -  Ability to walk unaided<br><br>          -  Can read and write in English<br><br>          -  Consistent internet access<br><br>          -  Willingness and ability to comply with the study requirements<br><br>        Exclusion criteria:<br><br>          -  Past total knee arthroplasty or scheduled surgical procedure on any back or lower limb<br>             with osteoarthritis within the next 12 months<br><br>          -  Recent serious injury (within the past 2 months) on the knee(s) with osteoarthritis<br><br>          -  Any condition making it unsafe to participate in physical activity<br><br>          -  Intra-articular therapy within the past 6 months (e.g. injections such as<br>             corticosteroids and hyaluronic acid)<br><br>          -  Participates in physical exercise for 30 minutes or more 5 days per week<br>      """,NULL,"""Change from baseline in knee pain measured by Numeric Pain Rating Scale;Change from baseline in physical activity measured by Physical Activity Scale for the Elderly;Change from baseline in mindset about the Process of Health - Physical Activity (MPH-Physical Activity) scale;Change from baseline in osteoarthritis mindset by the Illness Mindset Inventory""","""Change from baseline in knee pain and functioning by the Short version of Western Ontario and McMaster Universities Arthritis Index (shortMAC);Change from baseline in knee osteoarthritis knowledge by the Knee Osteoarthritis Knowledge Scale;Change from baseline in perceived need for surgery by a surgery perception question;Change from baseline in symptom management strategy by an osteoarthritis symptom management question;Change from baseline in fear of movement by the Brief Fear of Movement Scale for Osteoarthritis;Change from baseline in arthritis self-efficacy: pain and other symptoms by the Arthritis self-efficacy pain and other symptoms subscales;Change from baseline in physical and mental health: Global Health: Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 - Global Health (Physical and mental health sub-scales);Change from baseline in body mindset by the Illness Mindset Inventory;Change from baseline in self-fulfilling meta-mindset by the Self-fulfilling Meta-Mindset Scale;Change from baseline in controllable meta-mindset by the Controllable Meta-Mindset Scale;Change from baseline in adequacy mindset by the Adequacy of Activity Mindset Measure""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05538130,"""26 September 2023""","""C4901001""","""A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors""","""A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS""","""https://clinicaltrials.gov/ct2/show/NCT05538130""",""" ; ""","""Pfizer CT.gov Call Center;Pfizer CT.gov Call Center""",NULL,""";ClinicalTrials.gov_Inquiries@pfizer.com""",""";1-800-718-1021""","""Pfizer;""",""" ; ""","""Pfizer CT.gov Call Center;Pfizer CT.gov Call Center""",NULL,""";ClinicalTrials.gov_Inquiries@pfizer.com""",""";1-800-718-1021""","""Pfizer;""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/9/2022""","""November 30, 2022""","""124""","""Recruiting""","""Pfizer""",NULL,"""Please refer to primary and secondary sponsors""","""United States;Canada;United States""","""Melanoma;Glioma;Thyroid Cancer;Non-Small Cell Lung Cancer;Malignant Neoplasms;Brain Neoplasms;Colorectal Cancer""","""Drug: PF-07799544;Drug: PF-07284890;Drug: PF-07799933;Drug: encorafenib""","""16 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Diagnosis of advanced/metastatic solid tumor including primary brain tumor for<br>             monotherapy phase 1a dose escalation<br><br>          -  Disease progressed during/following last prior treatment and no satisfactory<br>             alternative treatment options for monotherapy phase 1a dose escalation<br><br>          -  For Substudy A and B, histological or cytological diagnosis of advanced/metastatic<br>             melanoma<br><br>          -  For Substudy A and B, measurable disease by RECIST version 1.1<br><br>          -  For Substudy A, evidence of a BRAF V600 mutation in tumor tissue and/or blood<br><br>          -  For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II alteration in tumor<br>             tissue and/or blood<br><br>        Exclusion Criteria:<br><br>          -  Brain metastasis larger than 4 cm<br><br>          -  Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of<br>             study treatment.<br><br>          -  For participants who may get binimetinib on study, history or current evidence of<br>             retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with<br>             elevated creatine kinase (CK)<br>      """,NULL,"""Number of participants with dose limiting toxicities (DLTs) Phase 1a monotherapy and Phase 1b combination therapy dose escalation;Overall response rate (ORR) (phase 1b expansion);Number of participants with treatment-emergent adverse events (AEs) (phase 1a and 1b dose escalation phases);Number of participants with clinically significant change from baseline in laboratory abnormalities (phase 1a and phase 1b dose escalation phase);Number of participants with clinically significant change from baseline in vital sign abnormalities (phase 1a and phase 1b dose escalation phase);Number of participants with clinically significant change from baseline in physical exam abnormalities (phase 1a and phase 1b dose escalation phase)""","""ORR (phase 1a and phase 1b dose escalation);Intracranial response (all phases);Duration of response;Number of participants with treatment-emergent adverse events (AEs);Number of participants with clinically significant change from baseline in laboratory abnormalities;PK parameters of PF-07799544, Single dose, maximum observed concentration (Cmax);PK parameters of PF-07799544, Single dose, time to maximum plasma concentration (Tmax);PK parameters of PF-07799544, Single dose, area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast);PK parameters of PF-07799544, Single dose, area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf);PK parameters of PF-07799544, Single dose, terminal elimination half life (t½);PK parameters of PF-07799544, Single dose, apparent oral clearance (CL/F);PK parameters of PF-07799544, Single dose, apparent volume of distribution (Vz/F);PK parameters of PF-07799544, Multiple dose, maximum observed concentration (Cmax);PK parameters of PF-07799544, Multiple dose, time to maximum plasma concentration (Tmax);PK parameters of PF-07799544, Multiple dose, area under the plasma concentration-time curve over the dosing interval (AUCt);PK parameters of PF-07799544, Multiple dose, terminal elimination half life (t½);PK parameters of PF-07799544, Multiple dose, apparent oral clearance (CL/F);PK parameters of PF-07799544, Multiple dose, apparent volume of distribution (Vz/F);PK parameters of PF-07284890, Single dose, maximum observed concentration (Cmax);PK parameters of PF-07284890, Single dose, time to maximum plasma concentration (Tmax);PK parameters of PF-07284890, Single dose, area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast);PK parameters of PF-07284890, Single dose, area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf);PK parameters of PF-07284890, Single dose, terminal elimination half life (t½);PK parameters of PF-07284890, Single dose, apparent oral clearance (CL/F);PK parameters of PF-07284890, Single dose, apparent volume of distribution (Vz/F);PK parameters of PF-07284890, Multiple dose, maximum observed concentration (Cmax);PK parameters of PF-07284890, Multiple dose, time to maximum plasma concentration (Tmax);PK parameters of PF-07284890, Multiple dose, area under the plasma concentration-time curve over the dosing interval (AUCt);PK parameters of PF-07284890, Multiple dose, terminal elimination half life (t½);PK parameters of PF-07284890, Multiple dose, apparent oral clearance (CL/F);PK parameters of PF-07284890, Multiple dose, apparent volume of distribution (Vz/F);PK parameters of PF-07799933, Single dose, maximum observed concentration (Cmax);PK parameters of PF-07799933, Single dose, time to maximum plasma concentration (Tmax);PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast);PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf);PK parameters of PF-07799933, Single dose, terminal elimination half life (t½);PK parameters of PF-07799933, Single dose, apparent oral clearance (CL/F);PK parameters of PF-07799933, Single dose, apparent volume of distribution (Vz/F);PK parameters of PF-07799933, Multiple dose, maximum observed concentration (Cmax);PK parameters of PF-07799933, Multiple dose, time to maximum plasma concentration (Tmax);PK parameters of PF-07799933, Multiple dose, area under the plasma concentration-time curve over the dosing interval (AUCt);PK parameters of PF-07799933, Multiple dose, terminal elimination half life (t½);PK parameters of PF-07799933, Multiple dose, apparent oral clearance (CL/F);PK parameters of PF-07799933, Multiple dose, apparent volume of distribution (Vz/F);Number of participants with clinically significant change from baseline in vital sign abnormalities""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05540210,"""26 September 2023""","""87RI22_0021 (AB-PSP-006)""","""Analytical Validation of the abioSCOPE Device With the in Vitro Device (IVD) CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood""","""Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood""","""https://clinicaltrials.gov/ct2/show/NCT05540210""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ""","""N/A""","""9/9/2022""","""August 29, 2022""","""100""","""Completed""","""University Hospital, Limoges""",NULL,"""Please refer to primary and secondary sponsors""","""France""","""Pancreatic Stone Protein;Device""","""Device: measurement of PSP""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Provide signed and dated written informed consent by patient or close / family /<br>             trusted person prior to any mandatory study-specific procedures, sample collection, or<br>             analysis;<br><br>          2. Male or female, 18 years of age or older;<br><br>          3. Patient admitted to hospital<br><br>          4. Need for venous and arterial blood samples as part of standard of care<br><br>          5. Covered by a social security scheme.<br><br>        Exclusion Criteria:<br><br>          1. Subject suffering from a hematological pathology (coagulation disorder, severe anemia)<br>             that could interfere with the blood draw procedure;<br><br>          2. Subject under juridical protection.<br>      """,NULL,"""PSP measurement""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05544903,"""26 September 2023""","""20-0151""","""Point of Care Ultrasound to Predict Intensive Care Unit Admission of Patients Presenting With Sepsis to the Emergency Department""","""The Use of Point of Care Ultrasound to Predict Intensive Care Unit Admission of Patients Presenting With Sepsis to the Emergency Department""","""https://clinicaltrials.gov/ct2/show/NCT05544903""",""" ; ; ""","""Allison Cohen, MD;Timmy Li, PhD;Timmy Li, PhD""",NULL,""";tli2@northwell.edu;tli2@northwell.edu""",""";516-240-3933;516-240-3933""","""North Shore University Hospital;""",""" ; ; ""","""Allison Cohen, MD;Timmy Li, PhD;Timmy Li, PhD""",NULL,""";tli2@northwell.edu;tli2@northwell.edu""",""";516-240-3933;516-240-3933""","""North Shore University Hospital;""","""Observational""","""""","""""","""9/9/2022""","""September 1, 2022""","""150""","""Recruiting""","""Northwell Health""","""Flosonics Medical""","""Please refer to primary and secondary sponsors""","""United States""","""Sepsis""",NULL,"""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Emergency department patient<br><br>          -  18+ years old<br><br>          -  Systolic blood pressure less than 100mmHg<br><br>          -  Respiratory rate greater than 22 breaths per minutes<br><br>          -  Temperature greater than 38 degrees Celsius or less than 36 degrees Celsius<br><br>          -  Heart rate greater than 90 beats per minute<br><br>        Exclusion Criteria:<br><br>          -  Already intubated prior to emergency department arrival<br><br>          -  Ventilator-dependent<br><br>          -  Patients transferred from another hospital<br><br>          -  Pregnancy<br>      """,NULL,"""Mortality;ICU admission;Rapid response team activation""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05548699,"""26 September 2023""","""HermannsNorbert2022-07-14VADM""","""Precision Mental Health in Diabetes - Subtypes of Mental Health, Trajectories, and Patterns With Glycaemic Control""","""PRO-MENTAL: Precision Mental Health in Diabetes - Subtypes of Mental Health, Trajectories, and Patterns With Glycaemic Control""","""https://clinicaltrials.gov/ct2/show/NCT05548699""",""" ; ; ""","""Norbert Hermanns, Prof, PhD;Bernhard Kulzer, Prof, PhD;Norbert Hermanns, Prof, PhD""",NULL,""";;hermanns@fidam.de""",""";;+49 7931 9619253""","""Research Institute Diabetes Academy Mergentheim (FIDAM);Research Institute Diabetes Academy Mergentheim (FIDAM);""",""" ; ; ""","""Norbert Hermanns, Prof, PhD;Bernhard Kulzer, Prof, PhD;Norbert Hermanns, Prof, PhD""",NULL,""";;hermanns@fidam.de""",""";;+49 7931 9619253""","""Research Institute Diabetes Academy Mergentheim (FIDAM);Research Institute Diabetes Academy Mergentheim (FIDAM);""","""Observational""","""""","""""","""9/9/2022""","""May 2, 2023""","""1500""","""Recruiting""","""Forschungsinstitut der Diabetes Akademie Mergentheim""",NULL,"""Please refer to primary and secondary sponsors""","""Germany""","""Diabetes Mellitus;Depressive Disorder;Depressive Symptoms;Anxiety Disorders;Anxiety and Fear;Eating Disorders;Eating Disorder Symptom;Eating Behavior;Hyperglycemia;Emotional Distress""",NULL,"""18 Years""","""75 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Age between 18 and 75 years<br><br>          -  Diagnosis of type 1 diabetes (T1D) or type 2 diabetes (T2D)<br><br>          -  Diabetes duration = 1 year<br><br>          -  Sufficient German language skills<br><br>          -  Written informed consent<br><br>        Exclusion Criteria:<br><br>          -  Inability to consent,<br><br>          -  Significant cognitive impairment (e.g., cognitive disorder, dementia)<br><br>          -  Severe somatic disease or mental disorder likely to impede study participation or<br>             confound results (e.g., severe heart failure = NYHA III; cancer requiring treatment;<br>             dialysis-dependent nephropathy; schizophrenia/psychotic disorder)<br><br>          -  Terminal illness<br><br>          -  Being bedridden<br>      """,NULL,"""Prevalence of affective disorders at baseline (per diagnostic interview);Prevalence of anxiety disorders at baseline (per diagnostic interview);Prevalence of eating disorders at baseline (per diagnostic interview);Depressive symptoms: incidence at 24-month FU;Depressive symptoms: recovery at 24-month FU;Anxiety symptoms: incidence at 24-month FU;Anxiety symptoms: recovery;Diabetes distress over time;Daily diabetes burdens over time;Eating problems: incidence;Glycated hemoglobin (HbA1c) over time;Glycemic levels (CGM glucose) over time;Daily stress levels over time""","""General health state over time;Subjective health over time;Wellbeing over time;General sleep quality over time;Daily sleep quality over time;Fear of diabetes complications over time;Fear of hypoglycemia over time;Diabetes acceptance over time;Daily eating problems over time;Diabetes self-management over time;Alcohol misuse over time""","""DRKS00030278                                      ""","""parent    """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05044546,"""26 September 2023""","""NCI-2021-07469;2020-0972;2020-0972""","""A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers""","""Pilot Study to Evaluate a Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers""","""https://clinicaltrials.gov/ct2/show/NCT05044546""",""" ; ; ""","""Jan Blalock, MD;Jan Blalock, MD;Jan Blalock, MD""",NULL,""";jablaloc@mdanderson.org;jablaloc@mdanderson.org""",""";713-745-1728;713-745-1728""","""M.D. Anderson Cancer Center;""",""" ; ; ""","""Jan Blalock, MD;Jan Blalock, MD;Jan Blalock, MD""",NULL,""";jablaloc@mdanderson.org;jablaloc@mdanderson.org""",""";713-745-1728;713-745-1728""","""M.D. Anderson Cancer Center;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ""","""N/A""","""9/9/2021""","""October 19, 2021""","""99""","""Recruiting""","""M.D. Anderson Cancer Center""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Depression;Tobacco Use Disorder""","""Behavioral: Behavioral Activation Therapy;Procedure: Discussion;Behavioral: Health Education;Other: Questionnaire Administration;Other: Tobacco Cessation Counseling""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>        Inclusion criteria for Aims 1, 3 and 4:<br><br>          1. Pregnant (or within 4 months post-partum for aim 1 only)<br><br>          2. Score = 10 on the PHQ-9 at baseline.<br><br>          3. = 18 years of age<br><br>          4. Have a telephone<br><br>          5. Self report smoking, even a puff, cigarettes, little cigars and/or cigarillos in the<br>             past 30 days.<br><br>          6. Aim 1 Criteria: Approximately two thirds of the sample will be gestational age up to<br>             36 weeks, and approximately one third will be within 4 months postpartum Aim 3<br>             Criteria: gestational age between 32 to 36 weeks Aim 4 Criteria: gestational age up to<br>             28 weeks<br><br>          7. Able to speak and read English<br><br>        Exclusion Criteria:<br><br>        Exclusion criteria for Aims 1:<br><br>          1. Rated on the Columbia-Suicide Severity Rating Scale113 at screening as in the past<br>             month having had active suicidal ideation with some intent to act or active suicidal<br>             ideation with specific plan and intent (indicated by answering YES on both Q3 and<br>             Q4, and/or 5) and/or endorsing YES to having engaged in preparatory acts towards or<br>             attempting suicide in the past 3 months (as indicated by answering YES to both parts<br>             of Q6)<br><br>          2. Have a lifetime or current diagnosis of Psychotic Disorder as assessed by specified<br>             Mini International Neuropsychiatric Interview (MINI) 7.0.2 modules.<br><br>          3. Have a past or current diagnosis of Bipolar Disorder I or II or have a past or current<br>             diagnosis of Other specified Bipolar and related disorder as assessed by specified<br>             MINI 7.0.2 modules.<br><br>          4. Any otherwise not specified medical or psychiatric condition, illness, disorder, or<br>             concomitant medication that could compromise participant safety or treatment, as<br>             determined by the Principal Investigator and/or Study Physician.<br><br>          5. Participant considered by the investigator as unsuitable candidate for full<br>             participation in the study.<br><br>        Exclusion criteria for Aims 3 and 4:<br><br>          1. Currently participating in individual psychotherapy<br><br>          2. Currently participating in other smoking cessation treatments and refuses to refrain<br>             from use for the duration of the study<br><br>          3. Currently using psychotropic medication<br><br>          4. Rated on the Columbia-Suicide Severity Rating Scale113 at screening as in the past<br>             month having had active suicidal ideation with some intent to act or active suicidal<br>             ideation with specific plan and intent (indicated by answering YES on both Q3 and<br>             Q4, and/or 5) and/or endorsing YES to having engaged in preparatory acts towards or<br>             attempting suicide in the past 3 months (as indicated by answering YES to both parts<br>             of Q6)<br><br>          5. Have a lifetime or current diagnosis of Psychotic Disorder as assessed by specified<br>             Mini International Neuropsychiatric Interview (MINI) 7.0.2 modules.<br><br>          6. Have a past or current diagnosis of Bipolar Disorder I or II or have a past or current<br>             diagnosis of Other specified Bipolar and related disorder as assessed by specified<br>             MINI 7.0.2 modules.<br><br>          7. Any otherwise not specified medical or psychiatric condition, illness, disorder, or<br>             concomitant medication that could compromise participant safety or treatment, as<br>             determined by the Principal Investigator and/or Study Physician.<br><br>          8. Participant considered by the investigator as unsuitable candidate for full<br>             participation in the study.<br><br>        Inclusion criterion for Secondary Aim 2:<br><br>        Women enrolled in the study who dropped out of the study during the first month of the<br>        postpartum treatment phase or women who completed at least 6 of the 8 postpartum treatment<br>        sessions Because study therapists will be asked to complete the WAI and acceptability of<br>        treatment ratings as part of Aim 4 work, they will be considered study participants and<br>        will provide verbal consent to complete these measures.<br><br>        Inclusion criterion for Study Therapists<br><br>          1. Masters degree in psychology, social work, or other counseling degree<br><br>          2. Training in the delivery of psychotherapy and counseling interventions<br>      """,NULL,"""Focus group""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05048784,"""26 September 2023""","""20210093""","""A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants""","""An Open-label, Randomized, Two-way Crossover, Bioequivalence Study in Healthy Volunteers to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib""","""https://clinicaltrials.gov/ct2/show/NCT05048784""",""" ""","""MD""",NULL,"""""","""""","""Amgen""",""" ""","""MD""",NULL,"""""","""""","""Amgen""","""Interventional""","""Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: None (Open Label). ""","""Phase 1""","""9/9/2021""","""August 16, 2021""","""145""","""Completed""","""Amgen""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Healthy Participants""","""Drug: Sotorasib""","""18 Years""","""60 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Healthy male participants or female participants, between 18 and 60 years of age<br>             (inclusive), at the time of Screening.<br><br>          -  Body mass index, between 18 and 30 kg/m^2 (inclusive), at the time of Screening.<br><br>          -  Females of nonchildbearing potential.<br><br>        Exclusion Criteria:<br><br>          -  Inability to swallow oral medication or history of malabsorption syndrome.<br><br>          -  History of hypersensitivity, intolerance, or allergy to any drug compound, food, or<br>             other substance, unless approved by the Investigator (or designee) and in consultation<br>             with the Sponsor.<br><br>          -  Poor peripheral venous access.<br><br>          -  History or evidence, at Screening or Check in, of clinically significant disorder,<br>             condition, or disease, including history of myolysis, not otherwise excluded that, in<br>             the opinion of the Investigator (or designee), would pose a risk to participant safety<br>             or interfere with the study evaluation, procedures, or completion.<br>      """,NULL,"""Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B;Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B;Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B""","""Number of Participants Who Experienced a Treatment-emergent AE (TEAE);Food Effect: Cmax of Sotorasib;Food Effect: AUClast of Sotorasib;Food Effect: AUCinf of Sotorasib""","""                                                  ""","""          """,NULL,NULL,1,NULL,"""https://clinicaltrials.gov/ct2/show/results/NCT05048784""",NULL,9/18/2023,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Yes""",NULL,NULL,NULL,NULL,NULL,NULL
NCT05048797,"""26 September 2023""","""2021-000634-33;D967SC00001""","""A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations""","""An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)""","""https://clinicaltrials.gov/ct2/show/NCT05048797""",""" ""","""AstraZeneca Clinical Study Information Center""",NULL,"""information.center@astrazeneca.com""","""1-877-240-9479""","""""",""" ""","""AstraZeneca Clinical Study Information Center""",NULL,"""information.center@astrazeneca.com""","""1-877-240-9479""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 3""","""9/9/2021""","""October 28, 2021""","""264""","""Recruiting""","""AstraZeneca""","""Daiichi Sankyo, Inc.""","""Please refer to primary and secondary sponsors""","""United States;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;Turkey;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;Turkey;United States;Sweden""","""Locally Advanced or Metastatic Non-Small Cell Lung Cancer""","""Drug: Trastuzumab Deruxtecan;Drug: Cisplatin;Drug: Carboplatin;Drug: Pembrolizumab;Drug: Pemetrexed""","""18 Years""","""123 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Participants at least 18 years of age<br><br>          -  Locally advanced not amenable to curative therapy, or metastatic disease<br><br>          -  Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by<br>             tissue NGS or ctDNA<br><br>          -  Treatment-naïve for palliative intent systemic therapy for locally advanced or<br>             metastatic disease<br><br>          -  Left ventricular ejection fraction (LVEF) = 50%<br><br>          -  Measurable disease assessed by Investigator based on RECIST 1.1<br><br>          -  Protocol-defined adequate organ function including cardiac, renal, hepatic function<br><br>          -  ECOG 0-1<br><br>          -  Having tumour tissue available for central testing<br><br>        Exclusion Criteria:<br><br>          -  Tumors with targetable alterations to EGFR (or other targetable mutations including<br>             but not limited to ALK, if routinely tested as a targetable alteration with approved<br>             available therapy)<br><br>          -  Any clinically active brain metastases; previously treated brain metastases allowed<br><br>          -  Active autoimmune or inflammatory disorders<br><br>          -  Medical history of myocardial infarction within 6 months prior to randomization<br><br>          -  History of non-infectious pneumonitis/ILD, current or suspected ILD<br><br>          -  Lung-specific intercurrent clinical significant severe illness<br><br>          -  Contraindication to platinum-based doublet chemotherapy or pembrolizumab<br>      """,NULL,"""Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)""","""Overall Survival (OS);Progression Free Survival (PFS) by investigator assessment;Objective Response Rate (ORR);Duration of Response (DoR);Time to second progression or death (PFS2);Landmark analysis of PFS (PFS12);Landmark analysis of OS (OS24);Central Nervous System (CNS) - Progression Free Survival (PFS);Safety and tolerability of T-DXd versus Standard of Care treatment;Pharmacokinetics (PK) of T-DXd, total anti-HER2 antibody and DXd in serum;Immunogenicity of T-DXd;Patient-reported pulmonary symptoms associated with Non-Small Cell Lung Cancer;Patient-reported tolerability of T-DXd described using symptomatic AEs;Patient-reported tolerability of T-DXd described using overall side-effect bother;Patient-reported tolerability of T-DXd described using physical function""","""CTRI/2022/02/040116                               ""","""parent    ""","""JPRN-jRCT2011210058""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05049850,"""26 September 2023""","""18-HMedIdeS-16""","""A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation""","""An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With Imlifidase""","""https://clinicaltrials.gov/ct2/show/NCT05049850""",""" ; ""","""Clinical Operations;Central Contact""",NULL,""";clinicalstudyinfo@hansabiopharma.com""",""";+46 46 16 56 70""","""Hansa Biopharma AB;""",""" ; ""","""Clinical Operations;Central Contact""",NULL,""";clinicalstudyinfo@hansabiopharma.com""",""";+46 46 16 56 70""","""Hansa Biopharma AB;""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2""","""9/9/2021""","""December 16, 2022""","""12""","""Recruiting""","""Hansa Biopharma AB""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Kidney Transplantation in Highly Sensitized Patients""","""Drug: Imlifidase""","""18 Years""","""70 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Signed Informed Consent obtained before any trial-related procedures<br><br>          -  Male or female age 18 to 70 years at the time of screening<br><br>          -  Highly sensitized patients registered on the UNOS waiting list for kidney<br>             transplantation, with either of the following:<br><br>               -  cPRA = 99.9%<br><br>               -  cPRA = 98% and have been in kidney paired donation or kidney paired exchange<br>                  programs for at least 1 year<br><br>          -  A positive crossmatch towards a living donor<br><br>          -  Willingness and ability to comply with the protocol<br><br>        Exclusion Criteria:<br><br>          -  Previous treatment with imlifidase<br><br>          -  Previous high dose IVIg treatment (2 g/kg) within 28 days prior to imlifidase<br>             treatment<br><br>          -  Breast-feeding or pregnancy<br><br>          -  Women of child-bearing potential not willing or able to practice FDA-approved forms of<br>             contraception. Two medically acceptable methods of highly effective contraception must<br>             be used for the duration of the study (e.g. oral, transdermal, intravaginal,<br>             injectable or implantable contraceptive; intrauterine device; intrauterine<br>             hormone-releasing system; vasectomized partner; bilateral tubal occlusion; or<br>             double-barrier method). For a woman to be considered postmenopausal this ascertainment<br>             must be made according to medical records and clinical history and may be aided by<br>             measurement of elevated postmenopausal serum gonadotropin levels (FSH).<br><br>          -  ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted<br>             for B recipients)<br><br>          -  Positive serology for HIV<br><br>          -  Clinical signs of HBV, HCV, CMV, or EBV infection<br><br>          -  EBV seronegative or with unknown EBV serostatus<br><br>          -  Positive SARS-CoV-2 tests at any time point from screening to transplantation<br><br>          -  Active tuberculosis<br><br>          -  Ongoing serious infections as judged by the investigator<br><br>          -  Severe other conditions requiring treatment and close monitoring e.g. cardiac failure<br>             = grade 4 (New York Heart Association), unstable coronary disease or oxygen dependent<br>             respiratory disease<br><br>          -  A history of a proven hypercoagulable condition<br><br>          -  Present, or history of, thrombotic thrombocytopenic purpura (TTP) or known familial<br>             history of TTP<br><br>          -  Intake of investigational drugs (other than imlifidase) within 5 half-lives<br><br>          -  Contemporaneous participation in a medical device study<br><br>          -  Known allergy/sensitivity (except local reactions) to imlifidase or to any drug (or<br>             the excipients) specified in the protocol<br><br>          -  Known mental incapacity or language barriers precluding adequate understanding of the<br>             Informed Consent information and the trial activities<br><br>          -  Inability by the judgement of the investigator to participate in the trial for any<br>             other reason<br>      """,NULL,"""Proportion of patients with DSA rebound""","""Proportion of patients with kidney biopsy proven AMR;Proportion of patient with DSA rebound;Proportion of patients with negative FCXM;Levels of DSA;Levels complement binding (C1q) DSA;Graft survival;Patients survival;Safety as measured by adverse events (AEs);Kidney function assessed by creatinine;Kidney function assessed by estimated glomerular filtration rate (eGFR);Kidney function assessed by protein/creatinine ratio in urine;Imlifidase pharmacokinetics (AUC);Imlifidase pharmacokinetics (Cmax);Imlifidase pharmacokinetics (tmax);Imlifidase pharmacokinetics (t1/2);Imlifidase pharmacokinetics (CL);Imlifidase pharmacokinetics (Vz);Pharmacodynamics;Anti-drug antibodies (ADA) levels;Change in patient-reported life participation, as measured PROMIS-SF-8a""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05049993,"""26 September 2023""","""20A-W-PYC-RM""","""Pyrocarbon Clinical Follow-up Study""","""Pyrocarbon Clinical Follow-up Study""","""https://clinicaltrials.gov/ct2/show/NCT05049993""",""" ""","""Rebecca Gibson""",NULL,"""""","""""","""Stryker Nordic""",""" ""","""Rebecca Gibson""",NULL,"""""","""""","""Stryker Nordic""","""Observational""","""""","""""","""9/9/2021""","""October 27, 2021""","""100""","""Enrolling by invitation""","""Stryker Trauma GmbH""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Osteoarthritis of the Shoulder;Avascular Necrosis;Traumatic Arthritis""","""Device: Aequalis Pyrocarbon Humeral Head""","""22 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Subject in the Pyrocarbon IDE Study and has not had the device explanted.<br><br>          -  Patient informed, willing, and able to sign an informed consent form approved by IRB<br>             or EC<br><br>          -  Willing and able to comply with the requirements of the study protocol<br><br>        Exclusion Criteria:<br><br>        • Subjects who are not able to comply with the study procedures based on the judgment of<br>        the assessor will be excluded (e.g. cannot comprehend study questions, inability to keep<br>        scheduled assessment times)<br>      """,NULL,"""Change from Baseline to last follow-up visit in ASES scores""","""Change from Baseline to last follow-up visit in Constant Murley scores;Change from Baseline to last follow-up visit in SANE scores;Change from Baseline to last follow-up visit in Subject Satisfaction scores;Change from Baseline to last follow-up visit in EQ-5D scores;Number of device associated and procedure associated adverse events.;Evaluation of operated shoulder range of motion;Rates of revision surgeries.""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05050084,"""26 September 2023""","""NCI-2021-08760;NRG-GU010;NRG-GU010;U10CA180868;NRG-GU010""","""Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score""","""Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)""","""https://clinicaltrials.gov/ct2/show/NCT05050084""",""" ; ""","""Neil B Desai, MD;Alejandro Berlin, MD""",NULL,""";""",""";""","""NRG Oncology;NRG Oncology""",""" ; ""","""Neil B Desai, MD;Alejandro Berlin, MD""",NULL,""";""",""";""","""NRG Oncology;NRG Oncology""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 3""","""9/9/2021""","""November 3, 2021""","""2050""","""Recruiting""","""NRG Oncology""","""National Cancer Institute (NCI)""","""Please refer to primary and secondary sponsors""","""United States;Canada;United States""","""Prostate Adenocarcinoma""","""Drug: Bicalutamide;Drug: Buserelin;Drug: Darolutamide;Drug: Degarelix;Drug: Flutamide;Drug: Goserelin;Drug: Histrelin;Drug: Leuprolide;Radiation: Radiation Therapy;Drug: Relugolix;Drug: Triptorelin""","""18 Years""","""N/A""","""Male""","""<br>        Inclusion Criteria:<br><br>          -  Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of<br>             the prostate within 270 days prior to registration<br><br>          -  Unfavorable intermediate risk prostate cancer, defined as having ALL the following<br>             bulleted criteria:<br><br>               -  Has at least one intermediate risk factor (IRF):<br><br>                    -  PSA 10-20 ng/mL<br><br>                    -  Clinical stage T2b-c (digital rectal examination [DRE] and/or imaging) by<br>                       American Joint Committee on Cancer (AJCC) 8th edition<br><br>                    -  Gleason score 7 (Gleason 3+4 or 4+3 [ International Society of Urological<br>                       Pathology (ISUP) Grade Group 2-3])<br><br>               -  Has ONE or more of the following 'unfavorable' intermediate-risk designators:<br><br>                    -  > 1 immature reticulocyte fraction (IRF)<br><br>                    -  Gleason 4+3=7 (ISUP Grade Group 3)<br><br>                    -  >= 50% of biopsy cores positive<br><br>                         -  Biopsies may include 'sextant' sampling of right/left regions of the<br>                            prostate, often labeled base, mid-gland and apex. All such 'sextant'<br>                            biopsy cores should be counted. Men may also undergo 'targeted'<br>                            sampling of prostate lesions (guided by MRI, ultrasound or other<br>                            approaches). A targeted lesion that is biopsied more than once and<br>                            demonstrates cancer (regardless of number of targeted cores involved)<br>                            should count as a single additional positive core sampled and positive.<br>                            In cases of uncertainty, count the biopsy sampling as sextant core(s)<br><br>               -  Absence of high-risk features<br><br>          -  Appropriate stage for study entry based on the following diagnostic workup:<br><br>               -  History/physical examination within 120 days prior to registration;<br><br>               -  Negative bone imaging (M0) within 120 days prior to registration; Note: Tc-99m<br>                  bone scan or sodium fluoride (NaF) positron emission tomography (PET) are<br>                  allowed. Equivocal bone scan findings are allowed if plain films X-ray, computed<br>                  tomography (CT) or magnetic resonance imaging (MRI) are negative for metastasis<br>                  at the concerned site(s). While a negative fluciclovine, choline, or prostate<br>                  specific membrane antigen (PSMA) PET may be counted as acceptable substitute for<br>                  bone imaging, any suspicious findings must be confirmed and correlated with<br>                  conventional imaging (Tc-99m bone scan, NaF PET, CT, X-ray, or MRI) to determine<br>                  eligibility based on the latter modalities (e.g. M0 based on conventional imaging<br>                  modalities)<br><br>               -  Clinically negative lymph nodes (N0) as established by conventional imaging<br>                  (pelvic +/- abdominal CT or MR), within 120 days prior to registration. Patients<br>                  with lymph nodes equivocal or questionable by imaging are eligible if the nodes<br>                  are =< 1.0 cm in short axis and/or if biopsy is negative.<br><br>        Note: While a negative fluciclovine, choline, or prostate specific membrane antigen (PSMA)<br>        PET may be counted as acceptable substitute for pelvic imaging, any suspicious findings<br>        must be confirmed by conventional imaging (CT, MRI or biopsy). If the findings do not meet<br>        pathological criteria based on the latter modalities (e.g. node =< 10 mm in short axis,<br>        negative biopsy), the patient will still be eligible<br><br>          -  Age >= 18<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 120 days<br>             prior to registration<br><br>          -  Non-castrate testosterone level (> 50 ng/dL) within 120 days prior to registration<br><br>          -  Absolute neutrophil >= 1,000 cells/mm^3 (within 120 days prior to registration)<br><br>          -  Hemoglobin >= 8.0 g/dL, independent of transfusion and/or growth factors (within 120<br>             days prior to registration)<br><br>          -  Platelet count >= 100,000 cells/mm^3 independent of transfusion and/or growth factors<br>             (within 120 days prior to registration)<br><br>          -  Creatinine clearance (CrCl) >= 30 mL/min estimated by Cockcroft-Gault equation (within<br>             120 days prior to registration)<br><br>               -  For African American patients specifically whose renal function is not considered<br>                  adequate by the formula above, an alternative formula that takes race into<br>                  account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula)<br>                  should be used for calculating the related estimated glomerular filtration rate<br>                  (GFR) with a correction factor for African American race creatinine clearance for<br>                  trial eligibility, where GFR >= 30 mL/min/1.73m^2 will be considered adequate<br><br>          -  Total bilirubin: 1.5 =< institutional upper limit of normal (ULN) (within 120 days<br>             prior to registration) (Note: In subjects with Gilbert's syndrome, if total bilirubin<br>             is > 1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is less<br>             than or equal to 1.5 x ULN, subject is eligible)<br><br>          -  Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) and<br>             alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]): =< 2.5 x<br>             institutional ULN (within 120 days prior to registration)<br><br>          -  Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral<br>             therapy with undetectable viral load within 6 months are eligible for this trial;<br>             Note: HIV testing is not required for eligibility for this protocol<br><br>          -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral<br>             load must be undetectable on suppressive therapy, if indicated.<br><br>               -  Note: Known positive test for hepatitis B virus surface antigen (HBV sAg)<br>                  indicating acute or chronic infection would make the patient ineligible unless<br>                  the viral load becomes undetectable on suppressive therapy. Patients who are<br>                  immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible<br>                  (e.g. patients immunized against hepatitis B)<br><br>          -  For patients with a history of hepatitis C virus (HCV) infection must have been<br>             treated and cured. For patients with HCV infection who are currently on treatment,<br>             they are eligible if they have an undetectable HCV viral load<br><br>               -  Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA)<br>                  indicating acute or chronic infection would make the patient ineligible unless<br>                  the viral load becomes undetectable on suppressive therapy<br><br>          -  The patient or a legally authorized representative must provide study-specific<br>             informed consent prior to study entry and, for patients treated in the United States<br>             (U.S.), authorization permitting release of personal health information<br><br>        Exclusion Criteria:<br><br>          """,NULL,"""Distant Metastasis (DM) (De-intensification study);Metastasis-Free Survival (MFS) (Intensification study)""","""Overall Survival;Time to Prostate Specific Antigen (PSA) failure;MFS (De-intensification study);MFS including positron emission tomography (PET) imaging;Locoregional failure (LRF);Distant Metastasis (DM) including PET imaging;Prostate cancer-specific mortality;Sexual and hormonal function related quality of life;Fatigue;Cognition;Distant Metastasis (Intensification study);Locoregional progression""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05050162,"""26 September 2023""","""NCI-2021-08925;NRG-HN009;NRG-HN009;U10CA180868;NRG-HN009""","""Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer""","""Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)""","""https://clinicaltrials.gov/ct2/show/NCT05050162""",""" ""","""Paul M Harari""",NULL,"""""","""""","""NRG Oncology""",""" ""","""Paul M Harari""",NULL,"""""","""""","""NRG Oncology""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2/Phase 3""","""9/9/2021""","""October 27, 2021""","""464""","""Recruiting""","""NRG Oncology""","""National Cancer Institute (NCI)""","""Please refer to primary and secondary sponsors""","""United States;Canada;United States""","""Advanced Head and Neck Squamous Cell Carcinoma;Advanced Hypopharyngeal Squamous Cell Carcinoma;Advanced Laryngeal Squamous Cell Carcinoma;Advanced Oropharyngeal Squamous Cell Carcinoma;Squamous Cell Carcinoma of Unknown Primary""","""Drug: Cisplatin;Drug: Cisplatin;Other: Quality-of-Life Assessment;Other: Questionnaire Administration;Radiation: Radiation Therapy""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Pathologically (histologically or cytologically) proven diagnosis of SCCHN of the<br>             oropharynx, larynx, hypopharynx, or p16-positive unknown primary prior to<br>             registration; specimen from cervical lymph nodes with a well-defined primary site<br>             documented clinically or radiologically is acceptable; in patients with carcinoma of<br>             unknown primary this will be sufficient for pathologic confirmation without a<br>             clinically or radiographically defined primary site<br><br>               -  For patients with oropharyngeal cancer (OPC)/cancer of unknown primary (CUP):<br><br>        P16 status based on local site immunohistochemical tissue staining is required. A cell<br>        block obtained from a fine needle aspiration (FNA) biopsy specimen may be used as the sole<br>        diagnostic tissue. Centers are encouraged to contact the pathology chair for clarification<br><br>          -  Note: Institutions must screen patients for p16 status by immunohistochemistry (IHC)<br>             in order to be eligible for the trial using a Clinical Laboratory Improvement<br>             Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process<br>             similar to the United States (U.S.) CLIA certification, such as the provincial<br>             accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in<br>             Canada, the College of American Pathologists (CAP), or an equivalent accreditation in<br>             other countries, is acceptable.<br><br>               -  The p16 results must be reported on the pathology report being submitted. The p16<br>                  positivity is defined as > 70% of tumor cells showing strong nuclear and/or<br>                  cytoplasmic immunostaining with p16 antibody.<br><br>               -  For patients with laryngeal and hypopharyngeal primaries: Analysis of p16 status<br>                  is NOT required<br><br>                    -  Patients must have clinically or radiographically evident measurable disease<br>                       at the primary site or at nodal stations. Simple tonsillectomy or local<br>                       excision of the primary without removal of nodal disease is permitted, as is<br>                       excision removing gross nodal disease but with intact primary site. Limited<br>                       neck dissections retrieving =< 4 nodes are permitted and considered as<br>                       non-therapeutic nodal excisions<br><br>                    -  Clinical stage (American Joint Committee on Cancer [AJCC], 8th ed.),<br>                       including no distant metastases based on the following diagnostic workup:<br><br>               -  History/physical examination within 60 days prior to registration<br><br>               -  One of the following imaging studies is required within 60 days prior to<br>                  registration:<br><br>          -  Computed tomography (CT) scan of neck (diagnostic quality with contrast, unless<br>             contraindicated) OR<br><br>          -  Magnetic resonance imaging (MRI) of the neck (diagnostic quality with contrast, unless<br>             contraindicated) OR<br><br>          -  Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT of the neck; the CT<br>             component must be of diagnostic quality with contrast, unless contraindicated.<br><br>               -  Note: A diagnostic quality CT or MRI with contrast or FDG-PET/CT scan of neck<br>                  performed for the purposes of radiation planning may serve as both staging and<br>                  planning tools<br><br>                    -  One of the following imaging studies is required within 60 days prior to<br>                       registration:<br><br>          -  FDG-PET/CT of the chest; FDG-PET/CT scan is strongly preferred and highly recommended<br>             to be used for eligibility OR<br><br>          -  Chest CT<br><br>               -  Exam with laryngopharyngoscopy (mirror or in office direct procedure acceptable)<br>                  within 70 days prior to registration;<br><br>          -  Eligibility by patient cohort;<br><br>               -  Non-OPC/p16-negative OPC Cohort; Tumor Site: Larynx/Hypopharynx; Clinical Staging<br>                  (AJCC, 8th ed.): T3-4 N0 or T1-4 N1-3 T2 N0 (hypopharynx only)<br><br>               -  Tumor Site: p16-negative OPC; Clinical Staging (AJCC, 8th ed.): T2N1, T1-4 N2-3,<br>                  or T3-4 N0-1<br><br>          -  p16-positive OPC/CUP Cohort;<br><br>               -  Tumor Site: OPC; Smoking Status: =< 10 pack-years; Clinical Staging (AJCC, 8th<br>                  ed.): T1-3 N2-3 or T4 N0-3<br><br>               -  Tumor Site: OPC; Smoking Status: > 10 pack-years; Clinical Staging (AJCC, 8th<br>                  ed.): T1N2-3, T2N1-3 or T3-4 N0-3<br><br>               -  Tumor Site: CUP; Smoking Status: Any; Clinical Staging (AJCC, 8th ed.): T0 N2-3<br><br>        Note: Cigar and pipe tobacco consumption is not included in calculating the lifetime<br>        pack-years. Marijuana consumption is likewise not considered in this calculation. There is<br>        also no clear scientific evidence regarding the role of chewing tobacco-containing products<br>        in oropharyngeal cancer, although this is possibly more concerning given the proximity of<br>        the oral cavity and oropharynx. In any case, investigators should not count use of<br>        non-cigarette tobacco products in the pack-years calculation.<br><br>          -  Age >= 18<br><br>          -  Zubrod (Eastern Cooperative Oncology Group [ECOG]) performance status of 0-1 within 14<br>             days prior to registration<br><br>          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 30 days prior to<br>             registration)<br><br>          -  Platelets >= 75,000 cells/mm^3 (within 30 days prior to registration)<br><br>          -  Hemoglobin >= 8.0 g/dL (within 30 days prior to registration)<br><br>               -  Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >=<br>                  8.0 g/dL is acceptable)<br><br>          -  Calculated creatinine clearance (CrCl) >= 50 mL/min by the Cockcroft-Gault formula<br>             (within 30 days prior to registration)<br><br>          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 30 days<br>             prior to registration) (not applicable to patients with known Gilbert's syndrome)<br><br>          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x<br>             institutional ULN (within 30 days prior to registration)<br><br>          -  Known human immunodeficiency virus (HIV) infected patients on effective<br>             anti-retroviral therapy with undetectable viral load within 6 months and CD4 T Cell<br>             count > 200 cells/mm^3 are eligible for this trial. Testing is not required for entry<br>             into protocol<br><br>          -  Patients with a prior or concurrent malignancy whose natural history or treatment does<br>             not have the potential to interfere with the safety or efficacy assessment of the<br>             investigational regimen are eligible for this trial<br><br>          -  Negative urine or serum pregnancy test (in persons of childbearing potential) within<br>             14 days prior to registration. Childbearing potential is defined as any person who has<br>             experienced menarche and who has not undergone surgical sterilization (hysterectomy or<br>             bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically<br>             as 12 months o""",NULL,"""Incidence of acute toxicity (Phase II);Overall Survival (OS) (Phase III);Incidence of acute toxicity (Phase III)""","""Locoregional Failure Rates;Progression-free survival (PFS);Incidence of acute toxicity;Incidence of late toxicity;Hearing loss""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05050500,"""26 September 2023""","""DAFLO;DAFLO-CH""","""The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction""","""The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction""","""https://clinicaltrials.gov/ct2/show/NCT05050500""",""" ; ; ""","""Weisheng Liu, MD;Mengmei Li, MD;Weisheng Liu, MD""",NULL,""";sjogen@163.com;773524311@qq.com""",""";0086053284961672;0086053284961819""","""Qingdao Central Hospital;""",""" ; ; ""","""Weisheng Liu, MD;Mengmei Li, MD;Weisheng Liu, MD""",NULL,""";sjogen@163.com;773524311@qq.com""",""";0086053284961672;0086053284961819""","""Qingdao Central Hospital;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). ""","""Phase 4""","""9/9/2021""","""May 8, 2023""","""300""","""Recruiting""","""Qingdao Central Hospital""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Myocardial Infarction;Diabete Type 2;Glucose Intolerance""","""Drug: Dapagliflozin 10mg/Tab;Drug: Placebo""","""40 Years""","""80 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Diagnosed with acute MI, either STEMI or NSTEMI, according to the fourth universal<br>             definition of MI (Thygesen et al. 2019), disease onset within 7 days.<br><br>          2. Previously diagnosed with type2 diabetes mellitus, newly diagnosed type2 diabetes<br>             according to ADA criteria or glucose intolerance.<br><br>          3. Capable of giving signed informed consent, which includes compliance with the<br>             requirements and restrictions listed in the informed consent form and the protocol.<br><br>        Exclusion Criteria:<br><br>          1. Patients diagnosed with Type 1 Diabetes Mellitus.<br><br>          2. Patients with renal dysfunction. (GFR<90mmol/L).<br><br>          3. Patients who have recently undergone immunosuppressive therapy.<br><br>          4. Patients with a history of recurrent urinary tract infections.<br><br>          5. Patients who are known to be allergic to SGLT-2 inhibitors.<br><br>          6. Patients who are hemodynamically unstable.<br><br>          7. Chronic symptomatic heart failure within the last year and known reduced ejection<br>             fraction (LVEF=40 %), documented before the current MI hospitalization.<br><br>          8. Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the<br>             trial.<br><br>          9. Any other non cardiovascular diseases, such as active malignancy requiring treatment<br>             at the time of screening or with a life expectancy of fewer than two years based on<br>             the investigator´s clinical judgment.<br><br>         10. Currently on treatment with a sodium-glucose co-transporter 2 inhibitor<br>             (SGLT2-inhibitor).<br>      """,NULL,"""MACE events;Left ventricular ejection fraction,left ventricle end-systolic volume (LVESV), and left ventricular end-diastolic volume;Post-infarction angina;The rate of heart failure occurrence""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05077124,"""26 September 2023""","""O05""","""Safe and Timely Antithrombotic Removal (STAR) Registry""","""Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting""","""https://clinicaltrials.gov/ct2/show/NCT05077124""",""" ; ; ""","""Michael Schmoeckel, Prof, MD;Robert Storey, Prof, BSc;Cindy Rechner, PhD""",NULL,""";;star@cytosorbents.com""",""";;+49 30 654 99 145""","""LMU Klinikum Großhadern;University of Sheffield;""",""" ; ; ""","""Michael Schmoeckel, Prof, MD;Robert Storey, Prof, BSc;Cindy Rechner, PhD""",NULL,""";;star@cytosorbents.com""",""";;+49 30 654 99 145""","""LMU Klinikum Großhadern;University of Sheffield;""","""Observational""","""""","""""","""9/9/2021""","""September 30, 2021""","""500""","""Recruiting""","""CytoSorbents, Inc""",NULL,"""Please refer to primary and secondary sponsors""","""Austria;Belgium;Germany;Sweden;United Kingdom;Austria;Belgium;Germany;Sweden;United Kingdom""","""Hemorrhage, Surgical;Hemorrhage Postoperative;Blood Loss, Surgical;Blood Loss, Postoperative""","""Device: CytoSorb""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  CytoSorb utilization for antithrombotic removal<br><br>          -  Informed consent for prospective registry participation<br><br>        Exclusion Criteria:<br><br>        • Use of CytoSorb for purpose other than antithrombotic removal<br>      """,NULL,"""Bleeding complications including requirements for transfusions and other blood products""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05130580,"""26 September 2023""","""NCI-2020-11520;2019-1176;R01CA203984;2019-1176""","""Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction""","""Evaluation of a Patient-Specific Decision Aid System for Shared Decision-Making About Breast Reconstruction""","""https://clinicaltrials.gov/ct2/show/NCT05130580""",""" ""","""Gregory Reece""",NULL,"""""","""""","""M.D. Anderson Cancer Center""",""" ""","""Gregory Reece""",NULL,"""""","""""","""M.D. Anderson Cancer Center""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). ""","""N/A""","""9/9/2021""","""October 13, 2020""","""35""","""Active, not recruiting""","""M.D. Anderson Cancer Center""","""National Institutes of Health (NIH);National Cancer Institute (NCI)""","""Please refer to primary and secondary sponsors""","""United States""","""Breast Carcinoma""","""Other: Enhanced Consultation;Other: Standard of Care Consultation;Procedure: Conventional Imaging;Other: Educational Intervention;Other: Questionnaire Administration""","""21 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  MD Anderson patients, age 21 or older<br><br>          -  Planning to undergo either a unilateral or bilateral total, skin-sparing or<br>             nipple-sparing mastectomy; or, planning to undergo a unilateral or bilateral modified<br>             radical mastectomy<br><br>          -  Considering immediate breast reconstruction at MD Anderson<br><br>          -  Likely to be a suitable candidate for implant-based reconstruction and/or<br>             abdominal-tissue based reconstruction as determined by an MD Anderson Plastic Surgery<br>             faculty member<br><br>          -  Ambulatory and able to stand unassisted for two minutes (3D imaging system<br>             requirement)<br><br>          -  Ability to understand and read English without a translator<br><br>        Exclusion Criteria:<br><br>          -  Has had a prior consultation with a plastic surgeon to discuss breast reconstruction<br><br>          -  History of breast surgery (i.e., breast reduction, mastopexy, segmental mastectomy,<br>             augmentation, reconstruction, but not including biopsy)<br><br>          -  Planning to have a delayed breast reconstruction<br><br>          -  Adjuvant radiation of the breast is indicated at the time of enrollment<br><br>          -  Diagnosis consistent with psychosis (such as schizophrenia, schizoaffective disorder,<br>             major depressive disorder [MDD] with psychotic features or steroid induced psychosis)<br>             in the chart<br><br>          -  Diagnosis consistent with cognitive impairment such as dementia, cognitive changes<br>             with stroke or radiation therapy in the chart<br><br>          -  Documented personality disorder<br><br>          -  Presence of non-medical tattoo on the breast<br>      """,NULL,"""Length of consultation visit;Participant's decisional conflict score-Questionnaires""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04549688,"""26 September 2023""","""AS-plus-SiV-01""","""Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer""","""Active Surveillance Plus (AS+): Local Tumor Control With High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer""","""https://clinicaltrials.gov/ct2/show/NCT04549688""",""" ; ; ""","""Sven Löffeler;Sven Löffeler, MD, PhD;Sven Löffeler""",NULL,""";sven.loffeler@siv.no;sven.loffeler@siv.no""",""";+47-33342000;+4733342000""","""The Hospital of Vestfold;""",""" ; ; ""","""Sven Löffeler;Sven Löffeler, MD, PhD;Sven Löffeler""",NULL,""";sven.loffeler@siv.no;sven.loffeler@siv.no""",""";+47-33342000;+4733342000""","""The Hospital of Vestfold;""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/9/2020""","""September 1, 2020""","""250""","""Recruiting""","""The Hospital of Vestfold""",NULL,"""Please refer to primary and secondary sponsors""","""Norway""","""Prostate Cancer""","""Procedure: high-intensity focused ultrasound, HIFU""","""18 Years""","""80 Years""","""Male""","""<br>        Inclusion Criteria:<br><br>          -  Age 55-80 years<br><br>          -  Life expectancy >10 years<br><br>          -  Gleason-score:<br><br>               -  patients <75 years: Gleason score < 8<br><br>               -  patients 75-80 years: Gleason <9<br><br>          -  TNM-stage: clinical/ radiological stage <T2c (localized), rN0 and rM0<br><br>          -  PSA < 15<br><br>          -  PSA > 15 should be counseled with caution (does not apply to patients >75 years)<br><br>          -  Risk group: d'Amico intermediary risk group, open for high risk patients age >75 years<br><br>        Exclusion Criteria:<br><br>          -  Previous treatment<br><br>          -  Previous treatment of the primary cancer within the prostate<br><br>          -  Previous hormone treatment for prostate cancer within 6 months before trial<br><br>          -  Previous radiation to pelvis<br><br>          -  Acute urinary tract infection<br><br>          -  For patients <75 years: >5% chance of lymph node metastases calculated by the updated<br>             prostate cancer staging nomogram (Partin tables) (30)<br><br>          -  Radiological imaging:<br><br>          -  PI-RADS score <3, clinical significant cancer is equivocal<br><br>          -  Extracapsular extension or seminal vesicle invasion<br><br>          -  Lymph node or bone metastasis<br><br>          -  > 2 MRI detected tumors validated by systematic or MRI-guided biopsies<br><br>          -  Contraindications for MRI<br>      """,NULL,"""Number of patients without clinically significant prostate cancer;Measurement of functional results;Number of patients who need repeated focal treatment;Number of patients eligible for continuous AS+;Disease-free survival;Treatment-free survival;Overall survival;Metastasis-free survival;Number of patients who need radical (surgery or radiation), or palliative treatment (hormone therapy)""","""Number of patients where MRI predicted tumor recurrence/ tumor absence;Patient Reported Outcomes Measures""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04550962,"""26 September 2023""","""OBS16688""","""Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)""","""PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting""","""https://clinicaltrials.gov/ct2/show/NCT04550962""",""" ; ""","""Clinical Sciences & Operations;Trial Transparency email recommended (Toll free number for US & Canada)""",NULL,""";Contact-Us@sanofi.com""",""";800-633-1610""","""Sanofi;""",""" ; ""","""Clinical Sciences & Operations;Trial Transparency email recommended (Toll free number for US & Canada)""",NULL,""";Contact-Us@sanofi.com""",""";800-633-1610""","""Sanofi;""","""Observational [Patient Registry]""","""""","""""","""9/9/2020""","""November 2, 2020""","""800""","""Recruiting""","""Sanofi""","""Regeneron Pharmaceuticals""","""Please refer to primary and secondary sponsors""","""Argentina;Chile;Colombia;Israel;Kuwait;Lebanon;Mexico;Qatar;Russian Federation;Saudi Arabia;Singapore;United Arab Emirates;Argentina;Chile;Colombia;Israel;Kuwait;Lebanon;Mexico;Qatar;Russian Federation;Saudi Arabia;Singapore;United Arab Emirates;Greece""","""Asthma""","""Drug: Dupilumab SAR231893""","""12 Years""","""N/A""","""All""","""<br>        - Male or female, 12 years or older Initiating treatment with Dupixent for asthma according<br>        to the country-specific prescribing information Willing and able to comply with the<br>        required clinic visits, study procedures and assessments.<br><br>        Provided signed informed consent<br><br>        - Most important exclusion criteria for potential participants Patients who have a<br>        contraindication to Dupixent according to the country-specific prescribing information<br>        Treatment with Dupixent within 6 months before the baseline visit. Note: for patients who<br>        have been treated previously with DUPIXENT a washout period of 6 months is required before<br>        Visit 1.<br><br>        Any condition that, in the opinion of the Investigator, may interfere with patient's<br>        ability to participate in the study, such as short life expectancy, substance abuse, severe<br>        cognitive impairment, or other comorbidities that can predictably prevent the patient from<br>        adequately completing the schedule of visits and assessments Patients currently<br>        participating in any interventional clinical trial which modifies patient care.<br><br>        The above information is not intended to contain all considerations relevant to a patient's<br>        potential participation in a clinical trial.<br>      """,NULL,"""Baseline Characteristics: Socio-demographics;Baseline Characteristics: Medical history;Baseline Characteristics: Disease characteristics;Baseline Characteristics: Concomitant treatments for asthma""","""Dupixent and other asthma treatment use patterns;Lung function;Annualized exacerbation rate;Patient reported outcomes;Healthcare Resource Utilization;Number of participants with adverse events (AE) and serious adverse events (SAE)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04551885,"""26 September 2023""","""FT516-102""","""FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors""","""A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors""","""https://clinicaltrials.gov/ct2/show/NCT04551885""",""" ""","""Fate Trial Disclosure""",NULL,"""""","""""","""Fate Therapeutics""",""" ""","""Fate Trial Disclosure""",NULL,"""""","""""","""Fate Therapeutics""","""Interventional""","""Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/9/2020""","""September 7, 2020""","""12""","""Terminated""","""Fate Therapeutics""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Solid Tumor, Adult""","""Drug: FT516;Drug: Avelumab;Drug: Cyclophosphamide;Drug: Fludarabine;Drug: IL-2""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Locally advanced or metastatic solid tumor malignancies that have relapsed or<br>             progressed after at least one line of therapy and where the following anti-PD-L1 are<br>             approved: avelumab, atezolizumab or durvalumab<br><br>          -  Capable of giving signed informed consent<br><br>          -  Aged = 18 years old<br><br>          -  Willingness to comply with study procedures and duration<br><br>          -  Measurable disease per iRECIST<br><br>          -  Contraceptive use for women and men as defined in the protocol<br><br>        Exclusion Criteria:<br><br>          -  Pregnant or breast-feeding women<br><br>          -  ECOG performance status = 2<br><br>          -  Evidence of insufficient organ function<br><br>          -  Clinically significant cardiovascular disease<br><br>          -  Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is<br>             shorter or any investigational therapy within 28 days prior to Day 1<br><br>          -  Known active central nervous system (CNS) involvement by malignancy<br><br>          -  Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or<br>             neurodegenerative disease or receipt of medications for these conditions<br><br>          -  Currently receiving or likely to require immunosuppressive therapy<br><br>          -  Known active infections with Hepatitis B, Hepatitis C or HIV<br><br>          -  Live vaccine within 6 weeks prior to start of lympho-conditioning<br><br>          -  Known allergy to albumin (human) or DMSO<br>      """,NULL,"""Incidence of Dose-Limiting Toxicities (DLTs) Within Each Dose Level Cohort;Severity of DLTs Within Each Dose Level Cohort""","""Number of Participants with =1 Adverse Events (AE);Investigator-Assessed Duration of Response (DOR);Disease Control Rate (DCR);Progression Free Survival (PFS);Overall Survival (OS);Determination of PK of FT516 in peripheral blood""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04566445,"""26 September 2023""","""GT005-03""","""HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005""","""HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration""","""https://clinicaltrials.gov/ct2/show/NCT04566445""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 2""","""9/9/2020""","""September 28, 2020""","""255""","""Terminated""","""Gyroscope Therapeutics Limited""","""Novartis Pharmaceuticals""","""Please refer to primary and secondary sponsors""","""United States;Australia;France;Germany;Poland;Spain;United Kingdom;Australia;France;Germany;Poland;Spain;United Kingdom;United States""","""Dry Age-related Macular Degeneration""","""Drug: GT005: Medium Dose;Drug: GT005: High Dose""","""55 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Able and willing to give written informed consent<br><br>          2. Age =55 years<br><br>          3. a. In Stage 1: Have a clinical diagnosis of GA secondary to AMD in the study eye, as<br>             determined by the Investigator, and a diagnosis of AMD in the contralateral eye; b. In<br>             Stage 2: Have a clinical diagnosis of GA secondary to AMD in the study eye, as<br>             determined by the Investigator, that is non-foveal, as determined by the central<br>             reading centre, or has a CFI rare variant genotype and meets inclusion criteria 3a,<br>             and a diagnosis of AMD in the contralateral eye (except if monocular)<br><br>          4. GA lesion(s) within an acceptable size on FAF, in the study eye<br><br>          5. The GA lesion in the study eye must reside completely within the FAF image<br><br>          6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye<br><br>          7. Have a BCVA of =24 letters (6/95 or 20/320 Snellen acuity equivalent), using ETDRS<br>             charts, in the study eye<br><br>          8. a. In Stage 1: Meet one of the pre-specified AMD genetic subgroup criteria; b. In<br>             Stage 2: Genotyping is not required for study eligibility<br><br>          9. Able to attend all study visits and complete the study procedures<br><br>         10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks<br>             prior to randomisation (not required for postmenopausal women) or provide<br>             documentation of being surgically sterilised<br><br>        Exclusion Criteria:<br><br>          1. a. In Stage 1: Carriers of excluded genetic variants; b. In Stage 2: Subjects are<br>             excluded if they have a clinical diagnosis of Stargardt Disease or other retinal<br>             dystrophies<br><br>          2. Have a history, or evidence, of CNV in the study eye<br><br>          3. Presence of moderate/severe or worse non-proliferative, diabetic retinopathy in the<br>             study eye<br><br>          4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the<br>             study eye<br><br>          5. History of intraocular surgery in the study eye within 12 weeks prior to Visit 1<br><br>          6. Have clinically significant cataract that may require surgery during the study period<br>             in the study eye<br><br>          7. Presence of moderate to severe glaucomatous optic neuropathy, uncontrolled intraocular<br>             pressure (IOP), despite use of two or more topical agents; or a history of<br>             glaucoma-filtering or valve surgery<br><br>          8. Axial myopia of greater than -8 diopters in the study eye<br><br>          9. Have received any investigational product for the treatment of GA within the past 6<br>             months or 5 half-lives (whichever is longer), other than nutritional supplements such<br>             as the age-related eye disease study (AREDS) formula<br><br>         10. Have received a gene or cell therapy at any time.<br><br>         11. Have a contraindication to the protocol specified corticosteroid regimen<br><br>         12. Are unwilling to use two forms of contraception (one of which being a barrier method)<br>             for 90 days post-dosing, if relevant<br><br>         13. Active malignancy within the past 12 months, except for appropriately treated<br>             carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with<br>             a stable prostate-specific antigen (PSA) = 12 months<br><br>         14. Have any other significant ocular or non-ocular medical or psychiatric condition<br>             which, in the opinion of the Investigator, may either put the subject at risk or may<br>             influence the results of the study<br>      """,NULL,"""Progression of geographic atrophy""","""Progression of geographic atrophy;Evaluation of the safety and tolerability of GT005;Evaluation of the effect of GT005 on retinal anatomical measures;Evaluation of the effect of GT005 on functional measures;Evaluation of the effect of GT005 on functional measures;Evaluation of the effect of GT005 on visual function;Evaluation of the effect of GT005 on visual function;Evaluation of the effect of GT005 on patient-reported outcomes""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04085445,"""26 September 2023""","""S2460""","""An All-Comers Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients""","""Agent DCB Registry""","""https://clinicaltrials.gov/ct2/show/NCT04085445""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Observational [Patient Registry]""","""""","""""","""9/9/2019""","""November 13, 2019""","""500""","""Active, not recruiting""","""Boston Scientific Corporation""",NULL,"""Please refer to primary and secondary sponsors""","""Hong Kong;Singapore;Taiwan;Hong Kong;Singapore;Taiwan""","""Chinese Patients Treated With Agent DCB""","""Device: AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Chinese subject at least 18 years of age(or meet age requirements per local law).<br><br>          -  Subject (or legal guardian) who understands the study requirements and the treatment<br>             procedures and provides written informed consent before any study-specific tests or<br>             procedures are performed.<br><br>          -  Subject who has ischemic symptoms or evidence of myocardial ischemia and is clinically<br>             indicated for PCI and will be treated with Agent DCB.<br><br>          -  Subject is willing to comply with all protocol-required follow-up evaluation.<br><br>          -  In women with childbearing potential a negative pregnancy test is mandatory.<br><br>          -  Subject with no known intolerance to paclitaxel and no contraindications to<br>             antiplatelet regimen.<br><br>        Exclusion Criteria:<br><br>        - Exclusion criteria are not required in the Agent DCB registry study as it is an all<br>        comers study.<br>      """,NULL,"""Number of Participants with 12 months post index procedure""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04085523,"""26 September 2023""","""TCC-201""","""A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia""","""ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period""","""https://clinicaltrials.gov/ct2/show/NCT04085523""",""" ""","""Silas Gylvin, MD""",NULL,"""""","""""","""Ascendis Pharma""",""" ""","""Silas Gylvin, MD""",NULL,"""""","""""","""Ascendis Pharma""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 2""","""9/9/2019""","""June 24, 2020""","""57""","""Active, not recruiting""","""Ascendis Pharma A/S""",NULL,"""Please refer to primary and secondary sponsors""","""New Zealand;United States;Australia;Austria;Denmark;Germany;Ireland;New Zealand;Portugal;Australia;Austria;Denmark;Germany;Ireland;Portugal;United States""","""Achondroplasia""","""Drug: TransCon CNP;Drug: Placebo for TransCon CNP;Drug: sWfI Placebo for TransCon CNP""","""2 Years""","""10 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Clinical diagnosis of ACH with genetic confirmation<br><br>          2. Age between 2 to 10 years old (inclusive) at Screening Visit<br><br>          3. Prepubertal (Stage 1 breasts for girls or testicular volume < 4ml for boys) at<br>             Screening Visit<br><br>          4. Able to stand without assistance<br><br>          5. Caregiver willing and able to administer subcutaneous injections of study drug<br><br>        Exclusion Criteria:<br><br>          1. Clinically significant findings at Screening that:<br><br>               -  are expected to require surgical intervention during participation in the trial<br>                  or<br><br>               -  are musculoskeletal in nature, such as Salter-Harris fractures and severe hip<br>                  pain or<br><br>               -  otherwise are considered by investigator or Medical Monitor/Medical Expert to<br>                  make a participant unfit to receive study drug or undergo trial related<br>                  procedures<br><br>          2. Have received treatment (>3 months) of human growth hormone (hGH) or other medications<br>             known to affect stature or body proportionality at any time<br><br>          3. Have received any dose of medications intended to affect stature or body<br>             proportionality within the previous 6 months of Screening Visit<br><br>          4. Have received any study drug or device intended to affect stature or body<br>             proportionality at any time<br><br>          5. History or presence of injury or disease of the growth plate(s), other than<br>             Achondroplasia, that affects growth potential of long bones<br>      """,NULL,"""Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability);Annualized height velocity (centimeters/year) at 52 weeks""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04086524,"""26 September 2023""","""3600-105;12345""","""A Patch Free Treatment for Young Children With Amblyopia""","""A Patch Free Treatment for Young Children With Amblyopia""","""https://clinicaltrials.gov/ct2/show/NCT04086524""",""" ""","""Ben Thompson, PhD""",NULL,"""""","""""","""University of Waterloo""",""" ""","""Ben Thompson, PhD""",NULL,"""""","""""","""University of Waterloo""","""Interventional""","""Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ""","""N/A""","""9/9/2019""","""January 13, 2020""","""34""","""Active, not recruiting""","""University of Waterloo""","""Retina Foundation of the Southwest;McGill University;Queensland University of Technology""","""Please refer to primary and secondary sponsors""","""United States;Australia;United States""","""Amblyopia;Binocular Vision Disorder""","""Other: Binocular cartoon treatment at home;Other: Patching;Other: Binocular cartoon treatment in office""","""36 Months""","""83 Months""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Aged 3-5.9 years old (36-83 months at the time of registration)<br><br>          -  Confirmed diagnosis of amblyopia<br><br>          -  Best-corrected visual acuity of 20/32 - 20/100 in the amblyopic eye<br><br>          -  Best-corrected visual acuity of 20/16 - 20/40 in fellow eye for ages 3-4, and<br>             20/16-20/32 for ages 5-5.9<br><br>          -  Interocular difference in visual acuity of 3 lines or greater<br><br>          -  If anisometropic, anisometropia (=1.00D)<br><br>          -  Wearing glasses for 8+ weeks + no change in VA w/ glasses for 4-6 weeks<br><br>          -  Must be able to experience simultaneous perception when viewing the binocular<br>             treatment stimuli with an appropriate interocular contrast offset<br><br>          -  Doctor and parent must be willing to forego patching/drops for 4 week study period<br><br>        Exclusion Criteria:<br><br>          -  strabismus<br><br>          -  Diagnosed eye disease or visual disorder other than amblyopia or anisometropia<br><br>          -  >8 weeks premature<br><br>          -  Diagnosed or suspected developmental delay (eg. learning disability, autism, Down<br>             syndrome)<br><br>          -  Diagnosed systemic disease (eg. diabetes, lupus, albinism)<br>      """,NULL,"""Visual acuity""","""Visual acuity;Motor function;Stereopsis;Treatment adherence;Treatment adherence;Stereopsis;Motor function;Interocular suppression;Interocular suppression;Interocular contrast balance;Interocular contrast balance""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02999022,"""26 September 2023""","""LiFT001""","""Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)""","""Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial""","""https://clinicaltrials.gov/ct2/show/NCT02999022""",""" ; ""","""Diane Nam, MSc,MD,FRCSC;Pujitha Rao""",NULL,""";lift@sunnybrook.ca""",""";416-480-5627""","""Sunnybrook Health Sciences Centre;""",""" ; ""","""Diane Nam, MSc,MD,FRCSC;Pujitha Rao""",NULL,""";lift@sunnybrook.ca""",""";416-480-5627""","""Sunnybrook Health Sciences Centre;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 2""","""9/9/2016""","""July 21, 2017""","""160""","""Recruiting""","""Sunnybrook Health Sciences Centre""","""Canadian Institutes of Health Research (CIHR)""","""Please refer to primary and secondary sponsors""","""Canada""","""Fractures""","""Drug: Lithium Carbonate;Drug: Lactose Placebo""","""18 Years""","""55 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Age 18-55 years.<br><br>          2. ASA (American Society of Anesthesiologists) = 2 class (healthy) prior to injury.<br><br>          3. Diaphyseal fracture of the humerus, femur or combined tibia/fibula (OTA diaphyseal<br>             subclass 2A or B), and clavicle (OTA diaphyseal subclass B1 or B2), with or without<br>             nerve injury.<br><br>          4. Fracture that is primarily closed or open fracture that has complete wound coverage.<br><br>          5. Randomization =14 days from injury or surgery (for surgical patients).<br><br>          6. Fractures treated surgically or nonsurgically by endochondral/secondary bone healing.<br><br>          7. For surgical patients, surgery must be within 14 days of injury.<br><br>        Exclusion Criteria:<br><br>          1. Currently pregnant or breastfeeding.<br><br>          2. Any past or current malignancy that, in the opinion of an investigator, is not<br>             medically controlled.<br><br>          3. Metabolic bone disease based on clinical history that, in the opinion of an<br>             investigator, is not medically controlled.<br><br>          4. Autoimmune disease that, in the opinion of an investigator, is not medically<br>             controlled.<br><br>          5. Hypothyroidism based on clinical history that, in the opinion of an investigator, is<br>             not medically controlled.<br><br>          6. Renal impairment based on clinical history.<br><br>          7. Past allergy or adverse reaction to Lithium.<br><br>          8. Lactose intolerance.<br><br>          9. Fractures surgically treated with absolute stability/primary bone healing.<br><br>         10. Isolated tibia or isolated fibula fracture.<br><br>         11. Currently taking Lithium or anti-psychotic or anti-seizure medication for the<br>             treatment of these conditions or at the discretion of an investigator.<br><br>         12. Inability to comply with study protocol, in the opinion of the investigator(s).<br><br>         13. Participation in another interventional clinical trial, at the discretion of the<br>             principal investigator.<br><br>         14. Use of concomitant ultrasound or other bone stimulation device.<br>      """,NULL,"""radiographic healing of fracture""","""radiographic union of fracture;visual analogue pain score;physical function;NSAID use;re-operation (after initial fracture management);adverse events""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06041425,"""26 September 2023""","""2023-SR-093""","""The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE""","""The Effects of Single Dose Oxycodone Versus Sufentanil on Pain and Inflammatory Response After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: a Randomized Controlled Study""","""https://clinicaltrials.gov/ct2/show/NCT06041425""",""" ; ; ""","""Yu CHEN, MD;Wentao WU, MD;Wentao WU, MD""",NULL,""";doctorwuwentao@163.com;doctorwuwentao@163.com""",""";15251836687 ext +86;(+86)15251836687""","""The First Affiliated Hospital with Nanjing Medical University;""",""" ; ; ""","""Yu CHEN, MD;Wentao WU, MD;Wentao WU, MD""",NULL,""";doctorwuwentao@163.com;doctorwuwentao@163.com""",""";15251836687 ext +86;(+86)15251836687""","""The First Affiliated Hospital with Nanjing Medical University;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 4""","""9/8/2023""","""August 7, 2023""","""40""","""Recruiting""","""The First Affiliated Hospital with Nanjing Medical University""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Hepatocellular Carcinoma;Transcatheter Arterial Chemoembolization;Pain;Inflammation""","""Drug: Oxycodone;Drug: Sufentanil""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Age =18 years;<br><br>          -  Presence of histologically confirmed or clinically diagnosed hepatocellular carcinoma<br>             (fulfilling the criteria for lesions with typical imaging);<br><br>          -  Presence of Child-Pugh class A or B disease;<br><br>          -  Absence of benefit from a treatment of established efficacy such as resection and<br>             local ablation;<br><br>          -  ECOG:0-2.<br><br>        Exclusion Criteria:<br><br>          -  Extrahepatic metastasis and/or microvascular invasion;<br><br>          -  Severe liver and kidney dysfunction;<br><br>          -  Uncontrolled or significant cardiovascular disease; Autoimmune hepatitis; Long term<br>             use of opioids, steroid hormones, and non steroidal anti-inflammatory drugs; Abnormal<br>             elevation of C-reactive protein (CRP); Increased white blood cells (>11000/mm3); Study<br>             Drugs allergy; Patients who were treated within 4 weeks after COVID-19 infection was<br>             diagnosed.<br>      """,NULL,"""Intraoperative pain intensity during TACE.;Pain intensity at 1hour after the end of TACE.;Pain intensity at 6hours after the end of TACE.;Pain intensity at 12hours after the end of TACE.;Pain intensity at 24hours after the end of TACE.""","""The WBC count;Neutrophil percentage;Level of CRP;Level of IL-6;Nausea and vomiting scale""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06037980,"""26 September 2023""","""PURITY""","""CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence""","""A Phase II/III Randomized Clinical Trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study""","""https://clinicaltrials.gov/ct2/show/NCT06037980""",""" ; ; ""","""Monica Niger, MD;Monica Niger, MD;Monica Niger, MD""",NULL,""";;monica.niger@istitutotumori.mi.it""",""";;02 2390 2919""","""Fondazione IRCCS Istituto Nazionale dei Tumori di Milano;02 2390 2919;""",""" ; ; ""","""Monica Niger, MD;Monica Niger, MD;Monica Niger, MD""",NULL,""";;monica.niger@istitutotumori.mi.it""",""";;02 2390 2919""","""Fondazione IRCCS Istituto Nazionale dei Tumori di Milano;02 2390 2919;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2/Phase 3""","""9/8/2023""","""September 2023""","""300""","""Not yet recruiting""","""Gruppo Oncologico del Nord-Ovest""",NULL,"""Please refer to primary and secondary sponsors""","""Italy""","""Biliary Tract Cancer;Cholangiocarcinoma""","""Drug: Gemcitabine;Drug: Nab paclitaxel;Drug: Cisplatin;Procedure: Curative Surgery;Drug: Capecitabine""","""18 Years""","""75 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Patient able and willing to provide written informed consent and to comply with the<br>             study protocol and with the planned surgical procedures.<br><br>          2. Female and male patients =18 years and <75 years.<br><br>          3. Histologically or cytologically confirmed non metastatic resectable carcinoma of<br>             biliary tract (BTC), including gallbladder carcinoma (GBC), intrahepatic,<br>             periperihilar or distal Cholangiocarcinoma (CCA). Mixed tumor entities with<br>             hepatocellular carcinoma and ampullary cancers are excluded.<br><br>          4. Availability of a tumoral sample<br><br>          5. ECOG performance status of 0-1.<br><br>          6. No prior tumor resection for BTC.<br><br>          7. Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax and PET<br>             scan.<br><br>          8. Technically resectable BTC as per local Multidisciplinary Team (MDT) assessment,<br>             including a core team with at least one medical oncologist, one surgeon, one<br>             radiologist, one endoscopist/gastroenterologist and one pathologist, all with<br>             expertise > 3 years on biliary tract cancer and hepatobiliary oncology.<br><br>          9. High risk for recurrence defined as the presence of at least one of the following risk<br>             features, as evaluated at baseline (pre-surgery):<br><br>               1. For cholangiocarcinoma:<br><br>                    -  Suspected or definite locoregional lymph node involvement (at least one of<br>                       the following):<br><br>                         -  positive FNA cytology (obtained by EUS).<br><br>                         -  positive locoregional lymph nodes at PET-CT.<br><br>                         -  suspected positive locoregional lymph nodes at imaging (CT or MRI scan)<br>                            according to local MDT discussion (eg. short axis > 1.5 cm, contrast<br>                            enhancement uptake, round shape, restriction at DWI).<br><br>                    -  Macrovascular invasion at preoperative CT scan.<br><br>                    -  Expected R1 resection due to proximity to major intrahepatic vascular and<br>                       biliary structures.<br><br>                    -  For iCCA, presence of satellitosis or multifocal disease or radiological<br>                       suspicion of tumoral diaphragmatic adhesion.<br><br>                    -  For iCCA, size of the liver lesion >5 cm.<br><br>                    -  For eCCA, size of the primary lesion > 3cm.<br><br>                    -  Ca19.9 >100 U/mL.<br><br>               2. For GBC:<br><br>                    -  Incidentally Detected Gallbladder Carcinoma (IGBC) after simple<br>                       cholecystectomy with indication for radical second surgery (>pT2) or newly<br>                       diagnosed GBC.<br><br>         10. Estimated life expectancy > 3 months.<br><br>         11. Adequate baseline hematologic function characterized by the following at screening:<br><br>               1. ANC = 1.5 × 109/L<br><br>               2. platelets = 100 × 109/L<br><br>               3. hemoglobin = 9 g/dl. Note: prior transfusions for patients with low hemoglobin<br>                  are allowed.<br><br>         12. Adequate liver function characterized by the following at screening:<br><br>               1. Serum total bilirubin = 1.5 × ULN and < 2 mg/dL. Note: Subjects with Serum total<br>                  bilirubin = 1.5 × ULN and conjugated bilirubin = ULN or < 40% of total bilirubin<br>                  are allowed.<br><br>               2. Serum transaminases (AST and/or ALT) < 3 x ULN.<br><br>         13. Adequate renal function, i.e. serum creatinine = 1.5 x institutional ULN and<br>             calculated by Cockroft-Gault formula or directly measured creatinine clearance = 50<br>             mL/min<br><br>         14. Adequate coagulation functions as defined by International Normalized Ratio (INR) =<br>             1.5, and a partial thromboplastin time (PTT) = 5 seconds above the ULN (unless<br>             receiving anticoagulation therapy).<br><br>         15. No presence of complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency with<br>             DPYD gene testing mandatory at screening as per national guidelines<br><br>         16. Females of childbearing potential must agree to remain abstinent (refrain from sexual<br>             intercourse) or use highly effective contraceptive methods, as defined in APPENDIX V<br>             of the full protocol, during the treatment period and for at least 7 months after the<br>             last administration of study treatments.<br><br>         17. Males must agree to remain abstinent (refrain from sexual intercourse) or use highly<br>             effective contraceptive methods, as defined in APPENDIX V of the full protocol.<br><br>         18. Negative serum pregnancy test within 7 days of starting study treatment in<br>             pre-menopausal women and women <1 year after the onset of menopause.<br><br>         19. A participant must agree not to donate eggs/sperm for future use for the purposes of<br>             assisted reproduction during the study and for a period of 7 months after receiving<br>             the last dose of study treatment. Female and male participants should consider<br>             preservation of eggs/sperm prior to study treatment as anti-cancer treatments may<br>             impair fertility.<br><br>        Exclusion Criteria:<br><br>          1. Known allergy or hypersensitivity to any of the study drugs.<br><br>          2. Any known additional malignancy that is progressing or requires active treatment, or<br>             history of other malignancy within 2 years of study entry except for curatively<br>             treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, and<br>             prostate cancer.<br><br>          3. Locally unresectable tumor according to local MDT (including radiological evidence<br>             suggesting inability to resect with curative intent whilst maintaining adequate<br>             vascular inflow and outflow, and sufficient future liver remnant).<br><br>          4. Evidence of distant metastases at any site.<br><br>          5. Tumors requiring multi-step surgical procedures such as two-stage hepatectomy or<br>             Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS)<br>             due to liver volumetry-based assessment of anticipated inadequate future liver<br>             remnant.<br><br>          6. Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a<br>             history of hepatic decompensation in the year before enrolment.<br><br>          7. Know active uncontrolled hepatitis B or hepatitis C. Patients with a past or resolved<br>             HBV infection are eligible. Patients with chronic disease controlled by antiviral<br>             therapy or requiring prophylactic treatment are eligible.<br><br>          8. Chronic or current active infectious disease requiring systemic antibiotics or<br>             antifungal treatment within 2 weeks prior to enrollment.<br><br>          9. Known uncontrolled HIV infection. HIV-positive patients are eligible if their CD4+<br>             cell count amounts to 300 cells per µL or more; HIV viral load must be undetectable<br>             per standard of care assay, and they must be compliant with antiretroviral treatment.<br><br>         10. Pregnant or breast-feeding patient, or patient is planning to become pregnant within 7<br>             months after the end of treatment.<br><br>         11. Any other """,NULL,"""12-month progression-free survival (PFS) rate;median PFS""","""Median event free survival;Median relapse free survival;Median Overall survival;R0 resection rate;R0+R1 resection rate;Quality of life EORTC QLQ-C30 scores;Quality of life BIL21 scores;Overall response rate;Resectability rate of primary tumor;Toxicity rates;Perioperative morbidity and mortality""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05994755,"""26 September 2023""","""v1.0 22042023""","""Association Between Cardiac ARRHYTHMIAs and Glycemic Variability in Patient With Type 2 Diabetes Monitored Through FREEstyle Libre and Bluetooth Technology.""","""Association Between Cardiac ARRHYTHMIAs and Glycemic Variability in Patient With Type 2 Diabetes Monitored Through FREEstyle Libre and Bluetooth Technology. (ARRHYTHMIA FREE)""","""https://clinicaltrials.gov/ct2/show/NCT05994755""",""" ""","""Antonio Rapacciuolo, Prof.""",NULL,"""antonio.rapacciuolo@unina.it""","""081 1962 2964""","""""",""" ""","""Antonio Rapacciuolo, Prof.""",NULL,"""antonio.rapacciuolo@unina.it""","""081 1962 2964""","""""","""Observational [Patient Registry]""","""""","""""","""9/8/2023""","""October 30, 2023""","""58""","""Not yet recruiting""","""Antonio Rapacciuolo""",NULL,"""Please refer to primary and secondary sponsors""","""Italy""","""Diabetes;Arrhythmias;Atrial Fibrillation;Heart Failure""",NULL,"""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Patient already wearing CIEDs (Implantable Cardiac Electronic Device) with Bluetooth<br>             technology<br><br>          2. Diabetes Type II, no insulin-treated<br><br>          3. Over 18 years of age<br><br>          4. Patient in Sinus Rhythm at the time of the enrollment<br><br>          5. Ability to provide informed consent for registry participation and be willing and able<br>             to comply with the protocol described evaluations<br><br>        Exclusion Criteria:<br><br>          1. Subject who is, or is expected to be inaccessible for follow-up<br><br>          2. pregnancy<br><br>          3. Patients with persistent and longstanding persistent AF<br>      """,NULL,"""association between hypoglycemia, glycemic variability and cardiac arrhythmias""","""association between hypoglycemia, glycemic variability and heart failure""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05994807,"""26 September 2023""","""DCE806103""","""A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants""","""A Phase 1, Single-Center, Open-Label, 2-Cohort, Fixed-Sequence, Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants""","""https://clinicaltrials.gov/ct2/show/NCT05994807""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Interventional""","""Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label). ""","""Phase 1""","""9/8/2023""","""August 8, 2023""","""32""","""Active, not recruiting""","""DICE Therapeutics, Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Healthy Volunteers""","""Drug: DC-806;Drug: Itraconazole;Drug: Carbamazepine""","""18 Years""","""55 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Sex : male or female; females must be of non-childbearing potential, or<br>             postmenopausal.<br><br>          2. Age : 18 to 55 years, inclusive, at screening.<br><br>          3. Body mass index (BMI) : 18.0 to 32.0 kg/m^2, inclusive, at screening.<br><br>          4. Weight : =50 kg, inclusive, at screening.<br><br>          5. Status : healthy participants. Healthy status as defined by the absence of evidence of<br>             any clinically significant, in the opinion of the investigator, active, or chronic<br>             disease.<br><br>          6. Male participants and female participants of childbearing potential must agree to use<br>             protocol specified methods of contraception and comply with pregnancy precautions as<br>             described in the protocol.<br><br>          7. All prescribed medication must have been stopped at least 14 days prior to admission<br>             to the clinical site.<br><br>          8. All over-the-counter medication, vitamin preparations and other food supplements, or<br>             herbal medications (e.g., St. John's wort) must have been stopped at least 7 days (or<br>             5 half-lives for certain medications, whichever is longer) prior to admission to the<br>             clinical site. Occasional use of acetaminophen/paracetamol (e.g., up to 2 grams per<br>             day) is permitted during this period and throughout the study.<br><br>          9. Ability and willingness to abstain from alcohol-, caffeine-, and<br>             methylxanthine-containing beverages or food (e.g., coffee, tea, cola, chocolate,<br>             energy drinks) from 48 hours (2 days) prior to admission to the clinical site and<br>             during confinement at the clinical site.<br><br>         10. Willingness to abstain from any strenuous physical exercise from 96 hours (4 days)<br>             prior to admission and during confinement at the clinical site.<br><br>         11. Good physical and mental health on the basis of medical history, physical examination,<br>             clinical laboratory assessments, 12-lead electrocardiogram (ECG), Columbia-Suicide<br>             Severity Rating Scale (C-SSRS) (Cohort 2 only) and vital signs, as judged by the<br>             Investigator.<br><br>         12. Willing and able to sign the informed consent form (ICF).<br><br>        Exclusion Criteria:<br><br>          1. Employee of ICON or the Sponsor.<br><br>          2. History of relevant drug and/or food allergies, in the opinion of the Investigator.<br><br>          3. Females who are currently breastfeeding.<br><br>          4. Smoking more than 5 cigarettes, 1 cigar, or 1 pipe daily within 3 months prior to<br>             screening.<br><br>          5. Unwilling or unable to abstain from tobacco products within the 48 hours (2 days)<br>             prior to admission and during confinement at the clinical site.<br><br>          6. History of alcohol abuse or drug addiction (including soft drugs like cannabis<br>             products) within 1 year prior to screening.<br><br>          7. Positive drug and/or alcohol screen (opiates, methadone, cocaine, amphetamines<br>             [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic<br>             antidepressants, and alcohol) at screening or admission to the clinical site.<br><br>          8. History within the previous 12 months of alcohol consumption exceeding 2 standard<br>             drinks per day on average. Alcohol consumption will be prohibited 48 hours prior to<br>             admission to the clinical facility and until discharge in the study period.<br><br>          9. Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV) antibodies,<br>             or human immunodeficiency virus (HIV) 1 and 2 antibodies.<br><br>         10. Consumption of any nutrients known to modulate cytochrome P450 (CYP450) enzymes<br>             activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville<br>             [blood] orange products) within 14 days prior to the first administration of study<br>             drug and during the study (including washout period/clinic furlough until after<br>             discharge in the last study period).<br><br>         11. Participation in a drug study within 30 days prior to study drug administration in the<br>             current study. Participation in 4 or more other drug studies in the 12 months prior to<br>             study drug administration in the current study.<br><br>         12. History of donation of more than 450 mL of blood within 60 days prior to dosing in the<br>             clinical site or planned donation before 30 days has elapsed since intake of study<br>             drug.<br><br>         13. Plasma or platelet donation within 7 days of dosing and through follow-up.<br><br>         14. Significant and/or acute illness within 5 days prior to study drug administration that<br>             may impact safety assessments, in the opinion of the Investigator.<br><br>         15. Unsuitable veins for infusion or blood sampling as determined by the Investigator or<br>             study staff.<br><br>         16. Any other condition or prior therapy that, in the Investigator's opinion, would<br>             confound or interfere with the evaluation of safety, tolerability, or pharmacokinetics<br>             (PK) of the study drug, interfere with study compliance, or preclude informed consent.<br><br>             Cohort 2 Only:<br><br>         17. Individuals who have Asian ancestry (including those who have one or more Asian<br>             grandparents).<br><br>         18. Presence of active suicidal ideation or positive suicide behavior using the<br>             Baseline/Screening version of the C-SSRS and with either of the following criteria:<br><br>               -  History of a suicide attempt within the 5 years prior to the Screening Visit.<br>                  Participants with a history of a suicide attempt more than 5 years ago should be<br>                  evaluated by a mental healthcare professional (e.g., locally licensed<br>                  psychiatrist, psychologist, or master's level therapist) before enrolling into<br>                  the study.<br><br>               -  Suicidal ideation in the past month prior to the Screening Visit as indicated by<br>                  a positive response (Yes) to either Question 4 or 5 of the Baseline/Screening<br>                  version of the C-SSRS.<br><br>         19. History of epilepsy.<br><br>         20. Leukopenia (white blood cell count <lower limit of normal [LLN]), neutropenia<br>             (neutrophil count <LLN), or thrombocytopenia (platelet count <LLN), at screening or<br>             admission (Day -1).<br>      """,NULL,"""Cohort 1: Maximum Observed Plasma Concentrations (Cmax) of DC-806;Cohort 2: Cmax of DC-806;Cohort 1: Area Under the Plasma Concentration-time Curve Up to Time t (AUC0-t) of DC-806;Cohort 2: AUC0-t of DC-806;Cohort 1: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of DC-806;Cohort 2: AUC0-inf of DC-806""","""Cohorts 1 and 2: Number of Participants who Experience an Adverse Event""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05994820,"""26 September 2023""","""IRB00023512""","""Chatbot-based Intervention to Promote Vaccine Acceptance in Varansi, India""","""Implementing and Evaluating a Chatbot-based Intervention to Promote Vaccine Acceptance in Varansi, India""","""https://clinicaltrials.gov/ct2/show/NCT05994820""",""" ; ; ""","""Rajiv N Rimal, PhD;Rajiv N Rimal, PhD;Satyanarayan Mohanty, MA""",NULL,""";rimal@jhu.edu;satya@dcor.com""",""";4104916139;+91 99375-04610""","""Johns Hopkins University;""",""" ; ; ""","""Rajiv N Rimal, PhD;Rajiv N Rimal, PhD;Satyanarayan Mohanty, MA""",NULL,""";rimal@jhu.edu;satya@dcor.com""",""";4104916139;+91 99375-04610""","""Johns Hopkins University;""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). ""","""N/A""","""9/8/2023""","""September 2023""","""1950""","""Not yet recruiting""","""Johns Hopkins Bloomberg School of Public Health""",NULL,"""Please refer to primary and secondary sponsors""","""India""","""Vaccine Hesitancy""","""Behavioral: Happy Baby Programme -Vaccine Campaign;Behavioral: Happy Baby Programme- Vaccine ++ Campaign""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Speak Hindi;<br><br>          -  Reside in selected UUH neighborhood of Varanasi, India;<br><br>          -  Identify as a caregiver of a young child (<2) OR be at least 5 months pregnant and due<br>             to giver birth during the study period;<br><br>          -  Child is registered with local community health workers and included on patient<br>             rosters for vaccination clinics (also known as Village Health Sanitation and Nutrition<br>             Days (VHSNDs));<br><br>          -  Have regular access to a phone with WhatsApp.<br><br>        Exclusion Criteria:<br><br>          -  Only one caregiver is eligible per household<br><br>          -  Not meeting inclusion criteria.<br>      """,NULL,"""Post Intervention Vaccine Intentions;Post Intervention Vaccine Attitudes;Post Intervention Vaccine Hesitancy""","""Parental Awareness of Vaccine Services""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05994859,"""26 September 2023""","""MIIR-15""","""SIRT for Potentially Resectable HCC""","""Y-90 Selective Internal Radiation Therapy for Potentially Resectable Hepatocellular Carcinoma: a Prospective, Single Arm Trial""","""https://clinicaltrials.gov/ct2/show/NCT05994859""",""" ; ""","""Mingyue Cai, Dr.;Kangshun Zhu, Dr.""",NULL,"""cai020@yeah.net;zhksh010@126.com""","""+86-20-34156205;+86-20-34156205""","""""",""" ; ""","""Mingyue Cai, Dr.;Kangshun Zhu, Dr.""",NULL,"""cai020@yeah.net;zhksh010@126.com""","""+86-20-34156205;+86-20-34156205""","""""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/8/2023""","""August 10, 2023""","""35""","""Recruiting""","""Second Affiliated Hospital of Guangzhou Medical University""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Hepatocellular Carcinoma""","""Procedure: SIRT""","""18 Years""","""75 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  HCC with diagnosis confirmed pathologically or clinically<br><br>          -  No pervious treatment for HCC<br><br>          -  At least one measurable intrahepatic target lesion<br><br>          -  Potentially resectable HCC: tumor(s) confined to the left/right hemiliver,<br>             with/without invasion to the unilateral branch of the portal vein and/or hepatic vein<br><br>          -  Disease amenable to SIRT (after evaluation)<br><br>          -  Child-Pugh Class A or without cirrhosis<br><br>          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1<br><br>          -  Patients with active hepatitis B are allowed, but they need to receive antiviral<br>             treatment to achieve a HBV DNA<10^3 IU/mL<br><br>          -  Patients with hepatitis C need to finish the anti-HCV treatment<br><br>          -  Adequate organ and bone marrow function; the blood biochemical examination: platelet<br>             count =75×10^9/L, white blood cell count >3.0×10^9/L, absolute value of neutrophils<br>             >1.5×10^9/L, hemoglobin =85 g/L, ASL and AST=5×ULN, creatinine=1.5×ULN, INR<1.5 or<br>             PT/APTT normal range<br><br>          -  Life expectancy of at least 6 months<br><br>        Exclusion Criteria:<br><br>          -  Tumor involving main portal vein, bilateral branches of portal vein, or vena cava<br><br>          -  tumor extention beyond one lobe of the liver<br><br>          -  Bilobar tumor distribution<br><br>          -  Extrahepatic metastasis<br><br>          -  Decompensated liver function, including ascites, bleeding from esophageal and gastric<br>             varices, and/or hepatic encephalopathy<br><br>          -  Organ (heart, kidney) dysfunction<br><br>          -  HBsAg and anti-HCV antibody positive concurrently<br><br>          -  History of malignancy other than HCC<br><br>          -  Uncontrolled infection<br><br>          -  History of HIV<br><br>          -  History of organ and cell transplantation<br><br>          -  Patients with bleeding tendency<br>      """,NULL,"""Success rate of conversion to resection""","""Objective response rate (ORR);Disease control rate (DCR);Progression-free survival (PFS);Time to progression (TTP);Duration of response (DOR);Overall survival (OS);Adverse Events (AEs)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05994976,"""26 September 2023""","""INNO-5034""","""Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers""","""Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers for Molecular Characterization of Inflammatory Skin Diseases""","""https://clinicaltrials.gov/ct2/show/NCT05994976""",""" ; ; ""","""Robert Bissonnette, MD;Julie Bedoucha, MSc;Julie Bedoucha, MSc""",NULL,""";jbedoucha@innovaderm.com;jbedoucha@innovaderm.com""",""";514-521-4285;514-521-4285""","""Innovaderm Research Inc.;""",""" ; ; ""","""Robert Bissonnette, MD;Julie Bedoucha, MSc;Julie Bedoucha, MSc""",NULL,""";jbedoucha@innovaderm.com;jbedoucha@innovaderm.com""",""";514-521-4285;514-521-4285""","""Innovaderm Research Inc.;""","""Observational""","""""","""""","""9/8/2023""","""October 2023""","""500""","""Not yet recruiting""","""Innovaderm Research Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""Canada""","""Acne;Atopic Dermatitis;Chronic Hand Eczema;Hidradenitis Suppurativa;Plaque Psoriasis;Palmoplantar Pustulosis""","""Procedure: Blood samples collection;Procedure: Oral samples collection;Procedure: Hair samples collection;Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping);Procedure: Skin surface material samples;Procedure: Drainage fluid samples collection;Procedure: Stool samples collection""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>        All subjects:<br><br>          1. Subject is willing to participate and is capable of giving informed consent. Note:<br>             Consent must be obtained prior to any study-related procedures.<br><br>          2. Subject must be willing to comply with all study procedures and must be available for<br>             the duration of the study.<br><br>             Healthy volunteers:<br><br>          3. Male or female subject aged 18 years or older, at the time of consent.<br><br>          4. Subject is in good general health, according to the investigator's judgment.<br><br>             Subjects with Acne:<br><br>          5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.<br><br>             Subjects with AD:<br><br>          6. Male or female subject aged 18 years or older, at the time of consent.<br><br>          7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and<br>             Rajka criteria.<br><br>             Subjects with CHE:<br><br>          8. Male or female subject aged 18 years or older, at the time of consent.<br><br>          9. Subject has at least a 6-month history of CHE before Screening (information obtained<br>             from medical chart or subject's physician, or directly from the subject).<br><br>             Subjects with HS:<br><br>         10. Male or female subject aged 18 years or older, at the time of consent.<br><br>         11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of =<br>             6 months before screening as determined by the investigator through subject interview<br>             and/or review of the medical history.<br><br>             Subjects with PPP:<br><br>         12. Male or female subject aged 18 years or older at the time of consent.<br><br>         13. Subject has at least a 6-month history of PPP as defined by the presence of pustules<br>             on palms and/or soles, but without evidence of infection on palms and soles<br>             (information obtained from medical chart or subject's physician, or directly from the<br>             subject).<br><br>             Subjects with psoriasis:<br><br>         14. Male or female subject aged 18 years or older, at the time of consent.<br><br>        Exclusion Criteria:<br><br>        All subjects:<br><br>          1. Subject is a female who is pregnant or who is planning to become pregnant during the<br>             study.<br><br>          2. Subject has a history of skin disease or presence of skin condition that, in the<br>             opinion of the investigator, would interfere with the study assessments.<br>      """,NULL,"""Exploratory biomarker and gene expression analyses.;Untargeted biomarker approach with gene expression profile of skin samples""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05995275,"""26 September 2023""","""mRNA-1769-P101""","""A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From =18 Years of Age to <50 Years of Age""","""A Randomised, Placebo-Controlled, Dose-Ranging, Observer-Blind Phase 1/2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of mRNA-1769 in Healthy Participants""","""https://clinicaltrials.gov/ct2/show/NCT05995275""",""" ""","""Moderna Clinical Trials Support Center""",NULL,"""clinicaltrials@modernatx.com""","""1-877-777-7187""","""""",""" ""","""Moderna Clinical Trials Support Center""",NULL,"""clinicaltrials@modernatx.com""","""1-877-777-7187""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 1/Phase 2""","""9/8/2023""","""August 15, 2023""","""350""","""Recruiting""","""ModernaTX, Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""United Kingdom""","""Smallpox;Mpox""","""Biological: mRNA-1769;Other: Placebo""","""18 Years""","""49 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Has a body mass index (BMI) between =18 kilogram per square meter (kg/m^2) to =39<br>             kg/m^2.<br><br>          -  For female participants of childbearing potential: must have a negative highly<br>             sensitive pregnancy test with 28 days before the first dose of study drug, uses<br>             approved contraception during the study intervention period and for at least 3 months<br>             after the last dose of study drug, and not currently breastfeeding.<br><br>        Exclusion Criteria:<br><br>          -  History of smallpox vaccination, vaccination with any poxvirus-based vaccine, history<br>             of of/or recent exposure to Mpox (MPX) (defined as close contact with a confirmed case<br>             of MPX within the past 14 days).<br><br>          -  Participant should not have any significant, progressive, unstable, or uncontrolled<br>             clinical condition, including any condition that may affect participant safety,<br>             assessment of safety endpoints, assessment of immune response, or adherence to study<br>             procedures per Investigator judgement.<br><br>          -  Participant is undergoing investigations for a potential chronic medical disorder.<br><br>          -  Bleeding disorder considered a contraindication to IM injection or phlebotomy.<br><br>          -  Dermatologic conditions that could affect local solicited AR assessments.<br><br>          -  History of anaphylactic reaction or allergic reactions that required medical<br>             intervention following any vaccine.<br><br>          -  Known or suspected allergy to any component of mRNA-1769.<br><br>          -  History of malignancy within previous 10 years (excluding non-melanoma skin cancer).<br><br>          -  Participant has any medical, psychiatric, or occupational condition, including<br>             reported history of drug or alcohol abuse, that, in the opinion of the Investigator,<br>             might pose additional risk due to participation in the study or could interfere with<br>             the interpretation of study results.<br><br>          -  Participant has received systemic immunosuppressants or immune-modifying drugs for >14<br>             days in total within 6 months prior to Screening (for corticosteroids, =10 mg/day of<br>             prednisone or equivalent) or is anticipating the need for immunosuppressive treatment<br>             at any time during participation in the study. Topical tacrolimus is allowed if not<br>             used within 14 days prior to the day of enrolment. Participants may be rescheduled for<br>             enrolment if they no longer meet this criterion within the Screening Period. Inhaled,<br>             nasal, and topical steroids are allowed.<br><br>          -  Receipt or planned receipt of: Any vaccine(s), authorised or approved by local health<br>             agency, including mRNA vaccine, =28 days prior to the first injection through 28 days<br>             after the last dose of investigational (IMP).<br><br>          -  Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months<br>             prior to the first injection up to the end of the study.<br><br>          -  Participated in an interventional study/received an investigational product within 28<br>             days prior to the Screening Period or plans to do so while enroled in this study.<br><br>        Note: Other inclusion and exclusion criteria may apply.<br>      """,NULL,"""Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) Through 7 Days After Each Investigational Medicinal Product (IMP);Number of Unsolicited Adverse Events (AEs) Through 7 Days After Each IMP;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with AEs Leading to Study and/or Treatment Discontinuation""","""Geometric Mean Titer (GMT) of Neutralising Antibody (nAb) against Mpox Virus (MPXV) by Plaque reduction neutralisation test (PRNT);Percentage of Participants With Seroconversion Based on Neutralising Antibody Responses Against MPXV;Geometric Mean Concentration of Binding Antibodies (bAbs) Against MPXV Antigens by Meso Scale Discovery (MSD) Assay;Percentage of Participants With Seroconversion Based on Binding Antibodies (bAb) Responses against MPXV;Geometric Mean Titer of Neutralising Antibody Against Vaccinia Virus (VACV) by Plaque Reduction Neutralisation Test (PRNT);Percentage of Participants With Seroconversion Based on Neutralising Antibody Responses Against Vaccinia Virus;Geometric Mean Concentration of Binding Antibodies Against Vaccinia Virus Antigens by Meso Scale Discovery Assay;Percentage of Participants With Seroconversion Based on Binding Antibodies Responses Against Vaccinia Virus""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05995431,"""26 September 2023""","""PRIYANKAPERIO2023""","""Impact of Bruxism in the Outcome of Subgingival Instrumentation for the Management of Stage 2 and Stage 3 Periodontitis.""","""Impact of Bruxism in the Outcome of Subgingival Instrumentation for the Management of Stage 2 and Stage 3 Periodontitis: A Comparative Interventional Study.""","""https://clinicaltrials.gov/ct2/show/NCT05995431""",""" ; ""","""Priyanka Chandela, BDS;RAJINDER KR SHARMA, MDS""",NULL,""";rksharmamds@yahoo.in""",""";9416358222""","""PT BD SHARMA UHSR, HARYANA;""",""" ; ""","""Priyanka Chandela, BDS;RAJINDER KR SHARMA, MDS""",NULL,""";rksharmamds@yahoo.in""",""";9416358222""","""PT BD SHARMA UHSR, HARYANA;""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ""","""N/A""","""9/8/2023""","""September 2023""","""58""","""Not yet recruiting""","""Postgraduate Institute of Dental Sciences Rohtak""",NULL,"""Please refer to primary and secondary sponsors""","""India""","""Periodontitis;Bruxism""","""Procedure: scaling and root planing;Procedure: Subgingival instrumentation""","""30 Years""","""50 Years""","""All""","""<br>        Inclusion Criteria:<br><br>        TEST GROUP<br><br>          -  Systemically healthy patients<br><br>          -  Patient having stage 2 or stage 3 periodontitis with bruxism Age between 30-50 years<br><br>          -  Minimum 20 teeth present in oral cavity<br><br>        CONTROL GROUP<br><br>          -  Systemically healthy patients<br><br>          -  Patient having stage 2 or stage 3 periodontitis without bruxism<br><br>          -  Age between 30-50 years<br><br>          -  Minimum 20 teeth present in oral cavity<br><br>        Exclusion Criteria:<br><br>          -  History of systemic disease such as diabetes or autoimmune disease<br><br>          -  History of drugs having the potential impact on periodontal status like phenytoin,<br>             cyclosporin, calcium-channel blockers or antidepressant drugs<br><br>          -  Pregnant or lactating females<br>      """,NULL,"""Clinical Attachment Level (CAL);Bleeding on probing (BOP);Pocket Probing Depth (PPD)""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05995769,"""26 September 2023""","""REB23-0666""","""Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder""","""Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial""","""https://clinicaltrials.gov/ct2/show/NCT05995769""",""" ; ""","""Leah Mayo, PhD;Kaitlin O'Grady""",NULL,""";pactlab@ucalgary.ca""",""";587-893-0257""","""University of Calgary;""",""" ; ""","""Leah Mayo, PhD;Kaitlin O'Grady""",NULL,""";pactlab@ucalgary.ca""",""";587-893-0257""","""University of Calgary;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 2""","""9/8/2023""","""October 2023""","""128""","""Not yet recruiting""","""University of Calgary""","""Johns Hopkins University;University of Maryland;Canadian Institutes of Health Research (CIHR);Bloom Psychedelic Therapy and Research Institute""","""Please refer to primary and secondary sponsors""","""Canada""","""Alcohol Use Disorder;Alcoholism""","""Drug: Psilocybin""","""22 Years""","""65 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Meets DSM-5 AUD criteria of at least moderate severity<br><br>          -  At least 5 heavy drinking days in past 30 days<br><br>          -  At least 18 (females) or 24 (males) drinks per week in past 30 days<br><br>          -  Desire to decrease alcohol consumption<br><br>          -  Limited lifetime hallucinogen use (less than 10 times total, none in past 6 months)<br><br>        Exclusion Criteria:<br><br>          -  Severe or moderate substance use disorder other than alcohol or nicotine in past 6<br>             months<br><br>          -  Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis<br><br>          -  Active suicidal ideation or serious attempt within past 3 years<br><br>          -  Currently pregnant, nursing, or trying to become pregnant<br><br>          -  Any notable abnormality on ECG, physical exam, or routine medical blood laboratory<br>             test<br>      """,NULL,"""Heavy drinking""","""Abstinence;Biomarkers of alcohol consumption;Alcohol cue reactivity;Cognitive flexibility;Depression;Anxiety;Quality of life;Glutamate levels;GABA levels;Resting state functional connectivity""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05996328,"""26 September 2023""","""2025""","""CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)""","""CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)""","""https://clinicaltrials.gov/ct2/show/NCT05996328""",""" ; ; ""","""Scott L. Hummel, MD;Yuan Huang;Scott L Hummel, MD""",NULL,""";Yuan.Huang1@va.gov;Scott.Hummel@va.gov""",""";(203) 737-7966;""","""VA Ann Arbor Healthcare System, Ann Arbor, MI;""",""" ; ; ""","""Scott L. Hummel, MD;Yuan Huang;Scott L Hummel, MD""",NULL,""";Yuan.Huang1@va.gov;Scott.Hummel@va.gov""",""";(203) 737-7966;""","""VA Ann Arbor Healthcare System, Ann Arbor, MI;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Investigator, Outcomes Assessor). ""","""N/A""","""9/8/2023""","""April 1, 2024""","""1400""","""Not yet recruiting""","""VA Office of Research and Development""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Heart Failure""","""Other: Home-delivered meals and short-term dietary counseling;Other: Study -defined standard of care""","""60 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  aged 60 years<br><br>          -  Veterans enrolled in a VHA facility<br><br>          -  Hospitalized ( 24 hours) with new HF or worsening chronic HF<br><br>          -  Dentition, swallowing function, etc. sufficient to safely consume food and liquid of<br>             standard composition and texture (i.e., no pureed food, no thickened liquids needed)<br><br>          -  Able and willing to provide informed consent and perform study activities<br><br>        Exclusion Criteria:<br><br>          -  Food allergies or intolerances that cannot be accommodated by study diet<br><br>          -  On dialysis or estimated glomerular filtration rate <30 at randomization<br><br>          -  Serum potassium (non-hemolyzed) >6.0 mmol/L during index hospitalization<br><br>          -  Heart transplant or active transplant listing<br><br>          -  Left ventricular assist device present or anticipated <6 months<br><br>          -  Malignancy or other non-cardiac condition limiting life expectancy to <12 months<br><br>          -  Planned admission to a skilled nursing facility following hospital discharge, or<br>             discharge to other location/situation where Veteran does not have control over diet<br><br>          -  Lack of space to store food for a week or equipment to prepare food<br><br>          -  Severe cognitive impairment (SLUMS score <20, or <19 if less than high school<br>             education completed)<br><br>          -  Severe food insecurity (5 or 6 points on the USDA 6-item Food Insecurity Screen)<br><br>          -  Body mass index >50 kg/m2<br><br>          -  Other medical, psychiatric, behavioral, or logistical condition which, in the clinical<br>             judgement of the site investigator, makes it unlikely the patient can effectively<br>             participate in or complete the study<br>      """,NULL,"""Number of pairwise comparisons with wins of Clinical Benefit, evaluated a hierarchical composite of days alive out of hospital and =5-point difference in the change of health-related quality of life""","""DAOH at 6 months post-discharge""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05998161,"""26 September 2023""","""reviga RCT 2023""","""Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout""","""Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout - a Randomized Controlled Trial""","""https://clinicaltrials.gov/ct2/show/NCT05998161""",""" ; ; ""","""Kamila Jauch-Chara, MD;Gitta A. Jacob, PhD;Gitta A. Jacob, PhD""",NULL,""";gitta.jacob@gaia-group.com;gitta.jacob@gaia-group.com""",""";+49.40.349930-374;""","""Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Psychosomatik und Psychotherapie, Zentrum für Integrative Psychiatrie, Michaelistraße 1, 24105 Kiel;""",""" ; ; ""","""Kamila Jauch-Chara, MD;Gitta A. Jacob, PhD;Gitta A. Jacob, PhD""",NULL,""";gitta.jacob@gaia-group.com;gitta.jacob@gaia-group.com""",""";+49.40.349930-374;""","""Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Psychosomatik und Psychotherapie, Zentrum für Integrative Psychiatrie, Michaelistraße 1, 24105 Kiel;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/8/2023""","""September 4, 2023""","""290""","""Recruiting""","""Gaia AG""","""Universitätsklinikum Schleswig-Holstein, Campus Kiel;Hannover Medical School""","""Please refer to primary and secondary sponsors""","""Germany""","""Stress;Burnout""","""Behavioral: reviga""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  age >= 18<br><br>          -  living in Germany<br><br>          -  employed (minimum of 20h/week)<br><br>          -  increased stress level (>21 on the PSS-10)<br><br>          -  stable treatment (psychotherapy, medication, no treatment) for at least 30 days at the<br>             time of inclusion<br><br>          -  consent to participation<br><br>        Exclusion Criteria:<br><br>          -  plans to change treatment (psychotherapy, medication, ...) in the upcoming three<br>             months at the time of inclusion<br>      """,NULL,"""Stress symptoms""","""Anxiety symptoms;Functioning;Burnout symptoms;Health-related quality of life;Sick days;Stress symptoms""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06009939,"""26 September 2023""","""2023-01""","""Microvascular Sex and Age-related Day-to-day Variability in Healthy Subjects""","""Microvascular Sex and Age-related Day-to-day Variability in Healthy Subjects""","""https://clinicaltrials.gov/ct2/show/NCT06009939""",""" ""","""Fredrik Iredahl""",NULL,"""""","""""","""Linköping University, Department of Health, Medicine and Caring Sciences""",""" ""","""Fredrik Iredahl""",NULL,"""""","""""","""Linköping University, Department of Health, Medicine and Caring Sciences""","""Observational""","""""","""""","""9/8/2023""","""March 1, 2023""","""48""","""Completed""","""Vårdcentralen Åby""","""Department of Biomedical Engineering (IMT);Department of Health, Medicine and Caring Sciences (HMV);Linkoeping University""","""Please refer to primary and secondary sponsors""","""Sweden""","""Healthy Subjects""","""Other: Occlusion of the circulation in the arm and foot""","""20 Years""","""60 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Men and women between 20-30 years old and 50-60 years old<br><br>        Exclusion Criteria:<br><br>          -  Regular use of medication (except for anti-conception medication)<br><br>          -  Hypertension<br><br>          -  Skin- or cardiovascular disease<br>      """,NULL,"""Speed-resolved perfusion;Red blood cell tissue fraction;Oxygen saturation;Vessel diameter""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06027684,"""26 September 2023""","""317639;NHS002026""","""Intensive Care Decision-making, Survival and Dying Well""","""Intensive Care Decision-making, Survival and Dying Well: How do the Experiences of Intensive Care Patients and Their End-of-life Wishes Affect Their Willingness to Accept Intensive Care Treatment at Different Chances of Survival?""","""https://clinicaltrials.gov/ct2/show/NCT06027684""",""" ; ""","""Thomas M Donaldson, MB/BChir;Thomas M Donaldson, MB/BChir""",NULL,""";thomas.donaldson-2@postgrad.manchester.ac.uk""",""";07737298024""","""University of Manchester;""",""" ; ""","""Thomas M Donaldson, MB/BChir;Thomas M Donaldson, MB/BChir""",NULL,""";thomas.donaldson-2@postgrad.manchester.ac.uk""",""";07737298024""","""University of Manchester;""","""Observational""","""""","""""","""9/8/2023""","""September 30, 2023""","""50""","""Not yet recruiting""","""University of Manchester""","""Royal College of Anaesthetists""","""Please refer to primary and secondary sponsors""",NULL,"""Critical Illness""",NULL,"""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  The principle inclusion criteria are being 18 years or older and having previously<br>             been a patient on an intensive care/critical care unit in the past.<br><br>          -  Being willing to talk about experiences of intensive care treatment, end-of-life<br>             wishes, and the context (chances of survival/functional decline) which would make<br>             intensive care treatments acceptable and being willing to either meet in person or<br>             have access to a computer, tablet or mobile phone with video and a stable internet<br>             connection (for a Zoom conversation) are also inclusion criteria.<br><br>        Exclusion Criteria:<br><br>          -  The exclusion criteria are being under the age of 18, having had a planned admission<br>             to an intensive care/critical care unit (e.g. after an elective operation), being<br>             unable to consent to participate in the research and having a significant language<br>             barrier (as there is no available funding to pay for translation).<br>      """,NULL,"""The chance of survival that would make participants willing to go through critical care treatment again.""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT06052293,"""26 September 2023""","""ANG003-22-101""","""Phase 1 Study to Assess Safety and Efficacy of ANG003""","""A Phase 1 Open-Label, Multicenter Study to Assess the Safety and Efficacy of ANG003 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis""","""https://clinicaltrials.gov/ct2/show/NCT06052293""",""" ; ; ""","""Meghana Sathe, MD;Maria Basco, MD, MPH;Samya Nasr, MD""",NULL,""";maria.basco@ssistrategy.com;snasr@med.umich.edu""",""";630.863.1761;734-764-4123""","""University of Texas;""",""" ; ; ""","""Meghana Sathe, MD;Maria Basco, MD, MPH;Samya Nasr, MD""",NULL,""";maria.basco@ssistrategy.com;snasr@med.umich.edu""",""";630.863.1761;734-764-4123""","""University of Texas;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/8/2023""","""August 25, 2023""","""60""","""Recruiting""","""Anagram Therapeutics, Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Exocrine Pancreatic Insufficiency""","""Drug: ANG003""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Male and female subjects 18 years of age or older.<br><br>          2. Confirmed diagnosis of CF defined as: a) CF signs and symptoms AND b) Two CF-causing<br>             mutations on genetic testing or sweat chloride >60 mEq/L.<br><br>          3. Documented history of fecal elastase <100 µg/g stool.<br><br>          4. EPI clinically controlled with minimal clinical symptoms and on a stable dose of PERT<br>             for 90 days before screening as determined by the Investigator.<br><br>          5. Adequate nutritional status measured by body mass index =20kg/m2 for adult subjects.<br><br>        Exclusion Criteria:<br><br>          1. Subjects with diabetes mellitus who are unable to refrain from short-acting and<br>             rapid-acting insulin on Days 1 and 5 for a daily total of 6 hours.<br><br>          2. Involuntary loss of =10% of usual body weight within last 6 months or involuntary loss<br>             of >5% of body weight within 1 month.<br><br>          3. Requires use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study<br>             duration.<br><br>          4. CF pulmonary exacerbation within 30 days prior to the Baseline SACT Period (Visit 2).<br><br>          5. Subjects who cannot discontinue omega-3 supplements >500 mg of DHA and EPA daily.<br><br>          6. Subjects unable to tolerate missing a dose of PERT.<br>      """,NULL,"""Adverse Events (AE), Serious Adverse Events (SAE), and AEs Leading to Study Discontinuation;Malabsorption Symptoms""","""Fat Absorption;Protein Absorption;Carbohydrate Absorption""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05560607,"""26 September 2023""","""D9230C00003""","""Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease""","""An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease""","""https://clinicaltrials.gov/ct2/show/NCT05560607""",""" ""","""AstraZeneca Clinical Study Information Center""",NULL,"""information.center@astrazeneca.com""","""1-877-240-9479""","""""",""" ""","""AstraZeneca Clinical Study Information Center""",NULL,"""information.center@astrazeneca.com""","""1-877-240-9479""","""""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ""","""Phase 1""","""9/8/2022""","""August 12, 2022""","""20""","""Recruiting""","""AstraZeneca""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Non-alcoholic Fatty Liver Disease;Fatty Liver, Nonalcoholic;NAFLD;Nonalcoholic Fatty Liver Disease;Nonalcoholic Steatohepatitis;NASH""","""Drug: AZD7503 Intervention""","""18 Years""","""70 Years""","""All""","""<br>        Inclusion Criteria # Part A<br><br>          1. Participant must be = 18 to = 70 years of age at the time of signing the informed<br>             consent.<br><br>          2. Participants with suspected or confirmed NAFLD or NASH including laboratory values<br>             with any of the following deviations at screening<br><br>               1. ALT > ULN,<br><br>               2. Imaging demonstrating hepatic steatosis including controlled attenuation<br>                  parameter (CAP) >290 dB/m, OR Liver stiffness of >7.1 kPa as measured by<br>                  Fibroscan.<br><br>          3. Body mass index (BMI) =20 kg/m2.<br><br>          4. Male and /or female of non-child bearing potential.<br><br>             Inclusion Criteria # Part B<br><br>          5. Histologic evidence of NAFLD or NASH with a NAS =3 following baseline liver biopsy.<br><br>        Exclusion Criteria:<br><br>          1. History or presence of hepatic disease (with the exception of hepatic steatosis, NASH)<br>             or evidence of other known forms of known chronic liver<br><br>          2. History of liver transplant, evidence of cirrhosis, or current placement on a liver<br>             transplant<br><br>          3. Positive results for HIV antigen and hepatitis B surface antigen If a participant has<br>             a positive result at the screening visit for hepatitis C antibody, the investigator<br>             will document that the participant has hepatitis C RNA below the limit of detection<br>             and has not received curative treatment in the last 3 years.<br><br>          4. History of alcohol abuse or excessive intake of alcohol as judged by the investigator.<br><br>          5. Uncontrolled blood pressure, defined as any of the following during pre-screening<br>             and/or Day -1 (mean of 3 measurements):<br><br>               1. Systolic blood pressure >160 mmHg.<br><br>               2. Diastolic blood pressure >100 mmHg.<br><br>          6. Any clinically important abnormalities in rhythm, conduction or morphology of the<br>             resting ECG.<br><br>          7. Any clinically important abnormalities in clinical chemistry, hematology, or<br>             urinalysis results,<br><br>          8. Known or suspected history of drug abuse as judged by the investigator.<br><br>          9. Positive screen for drugs of abuse at screening or admission to the study site prior<br>             to the administration of the study intervention.<br><br>         10. Changes to any concomitant medication (initiation, dose change, or cessation) within<br>             one month prior to the screening visit.<br><br>         11. Any laboratory values with following deviations at screening (one re-test allowed):<br><br>               1. (a) ALT >3X ULN<br><br>               2. (b) AST >3X ULN<br><br>               3. (c) TBL >ULN or INR =1.3<br><br>               4. (d) ALP >1.5X ULN<br><br>               5. (e) eGFR <60 mL/min/1.73 m2 (calculated using CKD Epidemiology Collaboration<br><br>               6. [CKD-EPI] formula) and applying the standard correction factor for African<br><br>               7. American to the (CKD-EPI) by multiplying the GFR estimate by 1.159 and<br><br>               8. confirmed.<br><br>               9. (f) Platelets <150 × 109/L<br>      """,NULL,"""Number of participants with Adverse Events (AEs).""","""Change in HSD17B13 mRNA Expression;Number of participants with positive anti-drug antibodies to AZD7503;Area under plasma concentration time-curve from zero to infinity (AUCinf) of AZD7503;Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast) of AZD7503;Maximum observed plasma (peak) drug concentration (Cmax) of AZD7503;Time to reach peak or maximum observed concentration or responsefollowing drug administration (tmax) of AZD7503;Half-life associated with terminal slope (?z) of a semi logarithmic concentration time curve (t½?z) of AZD7503;Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD7503;Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD7503;Apparent volume of distribution at steady state following extravascular administration based on terminal phase(Vz/F) of AZD7503;Time of last observed (quantifiable) concentration (tlast) of AZD7503;Lowest observed drug concentration (Ctrough) before next dose of AZD7503;Apparent volume of distribution at steady state following extravascular administration (Vss/F) of AZD7503;Accumulation ratio for AUC of AZD7503.;Accumulation ratio for Cmax (Rac Cmax) of AZD7503;Partial area under plasma concentration-time-curve from time 0 to time t (AUC(0-t)) of AZD7503""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05523700,"""26 September 2023""","""22-000895""","""Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)""","""Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)""","""https://clinicaltrials.gov/ct2/show/NCT05523700""",""" ; ""","""Tiffany Lai, MD;Jenny Lester, MPH""",NULL,""";jlester@mednet.ucla.edu""",""";310-794-9727""","""University of California, Los Angeles;""",""" ; ""","""Tiffany Lai, MD;Jenny Lester, MPH""",NULL,""";jlester@mednet.ucla.edu""",""";310-794-9727""","""University of California, Los Angeles;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). ""","""N/A""","""9/8/2022""","""October 1, 2023""","""200""","""Not yet recruiting""","""Jonsson Comprehensive Cancer Center""","""University of California, Davis;University of California, Irvine;University of California, San Francisco;University of California, San Diego""","""Please refer to primary and secondary sponsors""",NULL,"""Ovarian Cancer""","""Other: Mobile Application""","""18 Years""","""90 Years""","""Female""","""<br>        Inclusion Criteria:<br><br>          1. Female =18 years of age at Screening Visit.<br><br>          2. Diagnosed with ovarian cancer, fallopian tube, or primary peritoneal cancer<br><br>          3. Undergoing active treatment at some point during the study period including<br>             chemotherapy, immunotherapy, targeted agent or hormonal therapy. If active treatment<br>             has not yet started at time of screening, active treatment must be anticipated to<br>             begin within 30 days of enrollment.<br><br>          4. Written informed consent (and assent when applicable) obtained from subject or<br>             subject's legal representative and ability for subject to comply with the requirements<br>             of the study.<br><br>          5. Access to IOS or Android-based smart phone<br><br>        Exclusion Criteria:<br><br>          1. Unwilling or unable to adhere to the protocol<br><br>          2. Unwilling or unable to adhere to the informed consent<br><br>          3. Age <18yo<br><br>          4. Concurrent non-gynecologic cancer diagnosis requiring active treatment at enrollment<br><br>          5. Presence of a condition or abnormality that in the opinion of the Investigator would<br>             compromise the safety of the patient or the quality of the data.<br>      """,NULL,"""Assessment of the NFOSI-18 Function/Well-being subscale score between study groups""","""Comparison of patient-reported outcome measures (FOSI);Comparison of medication adherence (Adherence Index);Comparison of patient activation scores (PAM-13);Comparison of adverse events (including medication side-effects);Rate of comparison of healthcare utilization;Determine progression free survival rate;Determine Over-all survival (OS) rate""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05506891,"""26 September 2023""","""AS-PDS""","""Efficacy and Safety of Astragalus for Non-motor Symptoms of a-Synucleinopathy""","""Efficacy and Safety of Astragalus for Non-Motor Symptoms of a-Synucleinopathy:an Open-Label Self-Controlled Before-and-After Study""","""https://clinicaltrials.gov/ct2/show/NCT05506891""",""" ; ""","""Xiaodong Pan;Xiaodong Pan""",NULL,"""pxd77316@163.com;xieheyb@163.com""","""0591-86218341;059186218341""","""""",""" ; ""","""Xiaodong Pan;Xiaodong Pan""",NULL,"""pxd77316@163.com;xieheyb@163.com""","""0591-86218341;059186218341""","""""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2""","""9/8/2022""","""October 1, 2023""","""40""","""Recruiting""","""Fujian Medical University Union Hospital""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Parkinsonism""","""Behavioral: Physical therapy group;Drug: Astragalus""","""30 Years""","""85 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Participants with a clinical diagnosis of PD, MSA and DLB, with orthostatic<br>             hypotension.<br><br>          -  Participants with cognitive disorder.<br><br>          -  Adults signed informed consents.<br><br>        Exclusion Criteria:<br><br>          -  Patients with history of astragalus allergy.<br><br>          -  Patients with secondary Parkinsonism that cannot be excluded.<br><br>          -  Patients with diseases that may cause other types of hypotension or similar<br>             symptoms/signs because of hypotension<br><br>          -  Patients with other medical conditions requiring treatments that may affect blood<br>             pressure.<br><br>          -  Patients with other neurological disorders.<br><br>          -  Patients with serious comorbidities and immune diseases.<br><br>          -  Uncooperative patients.<br><br>          -  Pregnant or lactating women.<br>      """,NULL,"""Change from baseline mean arterial pressure after 3 minutes of upright posture versus decubitus position (mmHg) at 3 months.""","""OH Questionnaire score;Change from baseline Rate of change in ?HR/?SBP at 3months.;Change from baseline HRV (ms) at 3months.;Change from baseline decumbent and orthostatic digit span (DDS) difference at 3months.;Change from baseline decumbent and orthostatic character conversion (CDS) difference at 3months.;Change from baseline MoCA scores at 3 months.;Change from baseline CDR scores at 3 months.;Change from baseline RAVLT scores at 3 months.;Change from baseline HAS scores at 3 months.;Change from baseline HDS scores at 3 months.;Change from baseline NPI scores at 3 months.;Change from the baseline plasma a-synuclein levels (ng/ml) at 3 months.;Change from baseline Vic at 3 months.;Change from baseline ODI at 3 months.;Change from baseline PAF (Hz) at 3 months.""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05511467,"""26 September 2023""","""00116626""","""Learning in Stroke""","""Neural Circuitries of Motor Learning as a Target to Modulate Sensorimotor Recovery After Stroke""","""https://clinicaltrials.gov/ct2/show/NCT05511467""",""" ; ""","""Kirstin-Friederike Heise, PhD;Kirstin-Friederike Heise, PhD""",NULL,"""heisek@musc.edu;heisek@musc.edu""","""(843)792-3435;843-792-3435""","""""",""" ; ""","""Kirstin-Friederike Heise, PhD;Kirstin-Friederike Heise, PhD""",NULL,"""heisek@musc.edu;heisek@musc.edu""","""(843)792-3435;843-792-3435""","""""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label). ""","""N/A""","""9/8/2022""","""September 1, 2022""","""48""","""Recruiting""","""Medical University of South Carolina""","""National Institutes of Health (NIH)""","""Please refer to primary and secondary sponsors""","""United States""","""Stroke;Sensorimotor Impairment""","""Behavioral: Visuomotor learning task""","""18 Years""","""N/A""","""All""","""<br>        INCLUSION CRITERIA<br><br>        For all participants:<br><br>          -  adult volunteers (age =18 years)<br><br>          -  right-hand dominance as defined by the Edinburgh Handedness Inventory<br><br>        Stroke-specific inclusion criteria:<br><br>          -  ischemic or hemorrhagic lesion<br><br>          -  subcortical or cortical tissue involvement<br><br>          -  chronic phase (>6 months) after their index lesion<br><br>          -  voluntary whole-hand grip force (MRC, Medical Research Council scale for muscle force<br>             =2)<br><br>          -  repeated release (standardized as a reduction of 50% of maximum voluntary contraction<br>             measured with a dynamometer)<br><br>        EXCLUSION CRITERIA<br><br>        For all participants:<br><br>          -  Presence of any MRI risk factors<br><br>          -  substance use disorder<br><br>          -  psychotic disorders<br><br>        Stroke-group specific exclusion criteria:<br><br>          -  Primary intracerebral hematoma<br><br>          -  subarachnoid hemorrhage<br><br>          -  bi-hemispheric or cerebellar strokes<br><br>          -  other concomitant neurological disorders affecting upper extremity motor function<br><br>          -  documented history of dementia before or after stroke<br><br>          -  severe aphasia, particularly of receptive nature (NIHSS Language subsection =2),<br>             affecting their ability to understand the purpose of the study and give informed<br>             consent<br><br>          -  uncontrolled hypertension despite treatment<br><br>          -  intake of tricyclic anti-depressants or neuroleptic medication.<br>      """,NULL,"""Learning rate as indexed by change in the precision of visuomotor grip force adjustment;2. Change in blood-oxygen-level-dependent (BOLD) signal derived multi-voxel brain activation""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05516797,"""26 September 2023""","""A22-076""","""IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)""","""Continuous Glucose Monitoring Versus Blood Glucose Monitoring to Optimize Glycemic Outcomes in People With Type 2 Diabetes Following the Virta Treatment Program (IGNITE: Impact of Glucose moNitoring and nutrItion on Time in rangE Study)""","""https://clinicaltrials.gov/ct2/show/NCT05516797""",""" ""","""Holly Willis, PhD""",NULL,"""""","""""","""HealthPartners Institute dba International Diabetes Center""",""" ""","""Holly Willis, PhD""",NULL,"""""","""""","""HealthPartners Institute dba International Diabetes Center""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/8/2022""","""September 22, 2022""","""150""","""Active, not recruiting""","""HealthPartners Institute""","""Virta Health;Abbott Diabetes Care""","""Please refer to primary and secondary sponsors""","""United States""","""Type 2 Diabetes""","""Device: Continuous Glucose Monitoring (CGM)""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Age > 18 years<br><br>          2. U.S. residence with plans to remain in the U.S. for study duration (for shipping<br>             purposes)<br><br>          3. Diagnosis of T2D<br><br>          4. HbA1c between 7.5-11.5% documented within 60 days prior to consent<br><br>          5. Stable diabetes medication regimen and lifestyle patterns (eating and activity) within<br>             approximately 90 days prior to consent<br><br>          6. Using at least one glucose-lowering medication (oral or injectable) for diabetes<br>             management at the time of consent; if using insulin, this may include up to a total of<br>             three or fewer insulin injections per day (e.g., once or twice daily basal insulin,<br>             once or twice daily basal insulin plus one prandial insulin dose, once or twice daily<br>             pre-mix insulin, or another combination etc.)<br><br>          7. English language comprehension<br><br>          8. Confirmed download of FreeStyle Libre 2 app on personal smartphone with access to WiFi<br><br>          9. Willing and able to record study data using smartphone, tablet, and/or computer<br><br>         10. Willing to wear and use study-provided CGM devices for up to 7 months<br><br>         11. Willing to perform fingersticks to test blood glucose<br><br>         12. Willing to perform fingersticks to test blood ketones twice daily<br><br>         13. Eligible to initiate and intention to participate in the dietary changes required as<br>             part of the Virta Treatment for at least 7 months<br><br>        Exclusion Criteria:<br><br>          1. Type 1 diabetes<br><br>          2. Currently using an insulin pump or multiple daily injection insulin therapy with >3<br>             insulin injections per day or using bolus injections to cover every meal<br><br>          3. Currently following a self-reported, very low-carbohydrate eating pattern<br><br>          4. Currently using a personal CGM or plans to use a personal CGM during the study period<br><br>          5. Advanced-stage renal, cardiac, hepatic, or other chronic disease<br><br>          6. History of ketoacidosis<br><br>          7. Pregnant, lactating, or planned pregnancy<br><br>          8. Allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin<br><br>          9. Participation in another interventional trial at the time of enrollment or during the<br>             study period<br><br>         10. Participant is unsuitable for participation due to any cause as determined by<br>             Investigators<br>      """,NULL,"""Difference in change in 14-day CGM-derived TIR""","""Difference in 90-day mean blood ketone levels;Difference in change in the CGM-derived metric, Time above range > 180 mg/dL, from Baseline to 3-month Post-Dietary Change period;Difference in percent of participants reaching CGM-derived consensus targets;Difference in Change in HbA1c""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05518409,"""26 September 2023""","""IIT20220213B-R1""","""Immunohistochemical Study of Neurodegenerative Diseases""","""Immunohistochemical Study of Peripheral Blood Mononuclear Cells in Sporadic Alzheimer's Disease and Dementia With Lewy Body""","""https://clinicaltrials.gov/ct2/show/NCT05518409""",""" ; ; ""","""Li YouMing;Hu ShaoHua;Hu ShaoHua""",NULL,""";dorhushaohua@zju.edu.cn;dorhushaohua@zju.edu.cn""",""";086-13957162903;13957162903""","""Zhejiang University;""",""" ; ; ""","""Li YouMing;Hu ShaoHua;Hu ShaoHua""",NULL,""";dorhushaohua@zju.edu.cn;dorhushaohua@zju.edu.cn""",""";086-13957162903;13957162903""","""Zhejiang University;""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ""","""N/A""","""9/8/2022""","""April 1, 2022""","""100""","""Recruiting""","""First Affiliated Hospital of Zhejiang University""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Alzheimer Disease;Lewy Body Disease;Neurodegenerative Diseases""","""Biological: Detection of cytof in peripheral PBMC;Drug: Donepezil for patients with AD and DLB""","""55 Years""","""100 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. AD inclusion criteria:<br><br>             a.Clinical diagnosis of Alzheimer's Disease<br><br>          2. DLB inclusion criteria:<br><br>               1. Clinical diagnosis of Dementia with Lewy bodies<br><br>        Exclusion Criteria:<br><br>          1. Infectious diseases<br><br>          2. autoimmune disease<br><br>          3. heart failure<br><br>          4. chronic obstructive pulmonary disease (COPD)<br><br>          5. cancer<br><br>          6. renal failure<br><br>          7. recently major surgery<br><br>          8. alcohol and / or drug abuse<br><br>          9. disturbance of consciousness<br><br>         10. clinical diagnosis of major depression disorder<br><br>         11. clinical diagnosis of Anxiety disorder<br>      """,NULL,"""Immunerepertorie;immunological Elastic-Net (iEN) model""","""Mini-mental State Examination(MMSE)""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05496348,"""26 September 2023""","""P23-430""","""Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis""","""Early therapeUtic RespOnse and Predictivity of Long-term Effectiveness of Upadacitinib in Ulcerative Colitis (EUROPE)""","""https://clinicaltrials.gov/ct2/show/NCT05496348""",""" ; ""","""ABBVIE INC.;ABBVIE CALL CENTER""",NULL,""";abbvieclinicaltrials@abbvie.com""",""";844-663-3742""","""AbbVie;""",""" ; ""","""ABBVIE INC.;ABBVIE CALL CENTER""",NULL,""";abbvieclinicaltrials@abbvie.com""",""";844-663-3742""","""AbbVie;""","""Observational""","""""","""""","""9/8/2022""","""October 20, 2022""","""400""","""Recruiting""","""AbbVie""",NULL,"""Please refer to primary and secondary sponsors""","""Austria;Germany;Austria;Germany""","""Ulcerative Colitis""",NULL,"""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Participants with an endoscopically confirmed diagnosis of active moderate to severe<br>             Ulcerative colitis (UC).<br><br>          -  Participants initiating Upadacitinib (UPA) at the investigator's discretion as part of<br>             their routine clinical care; the decision to administer UPA must be made prior to and<br>             independent of documentation for the study and according to the approved local label.<br><br>          -  Participants able to understand and communicate with the investigator and comply with<br>             the requirements of the study.<br><br>          -  Participants willing to continue with study documentation after cessation of UPA.<br><br>        Exclusion Criteria:<br><br>          -  Participants with any contraindication to Upadacitinib (UPA).<br><br>          -  Participants previously exposed to a Janus kinase (JAK) inhibitor.<br>      """,NULL,"""Percentage of participants achieving symptomatic remission per partial adapted Mayo score among those who achieved clinical response and/or intestinal ultrasound (IUS) response at week 8 of upadacitinib (UPA) induction""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05496738,"""26 September 2023""","""C4521001""","""A Preliminary Study to Evaluate PF-07264660 in Healthy Participants""","""A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07264660 IN HEALTHY PARTICIPANTS""","""https://clinicaltrials.gov/ct2/show/NCT05496738""",""" ""","""Pfizer CT.gov Call Center""",NULL,"""""","""""","""Pfizer""",""" ""","""Pfizer CT.gov Call Center""",NULL,"""""","""""","""Pfizer""","""Interventional""","""Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). ""","""Phase 1""","""9/8/2022""","""August 16, 2022""","""59""","""Active, not recruiting""","""Pfizer""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Healthy""","""Drug: PF-07264660 intravenous single ascending dose;Drug: PF-07264660 subcutaneous multiple ascending dose;Other: Intravenous placebo;Other: subcutaneous placebo""","""18 Years""","""65 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Healthy volunteer male and female participants between 18 to 65 years of age<br><br>          -  Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight >50 kg (110 lb)<br><br>        Exclusion Criteria:<br><br>          -  Evidence or history of clinically significant hematological, renal, endocrine,<br>             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or<br>             allergic disease (including drug allergies, but excluding untreated, asymptomatic,<br>             seasonal allergies at the time of dosing).<br><br>          -  Evidence of active, latent, or inadequately treated infection with Mycobacterium<br>             tuberculosis<br><br>          -  Participants with acute or chronic infections or infection history<br><br>          -  History of human immunodeficiency virus (HIV); Infection with hepatitis B or hepatitis<br>             C viruses according to protocol specific testing algorithm<br><br>          -  History of febrile illness within 5 days prior to the first dose of investigational<br>             product.<br><br>          -  Recent exposure to live or attenuated vaccines within 28 days of the screening visit.<br><br>          -  Failure to comply with coronavirus disease 2019 (COVID-19) vaccination requirements as<br>             per site protocols.<br><br>          -  Have any malignancies or have a history of malignancies with the exception of<br>             adequately treated or excised non-metastatic basal cell or squamous cell cancer of the<br>             skin, or cervical carcinoma in situ.<br><br>          -  History of any lymphoproliferative disorder such as Epstein-Barr Virus (EBV) related<br>             lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms<br>             suggestive of current lymphatic or lymphoid tissue disease.<br><br>          -  Undergone significant trauma or major surgery within 1 month of the first dose of<br>             study drug<br><br>          -  Previous administration with an investigational product (drug or vaccine) within 30<br>             days (or as determined by the local requirement) or 5 half-lives preceding the first<br>             dose of study intervention used in this study (whichever is longer)<br><br>          -  Screening supine blood pressure (BP) =140 mm Hg (systolic) or =90 mm Hg (diastolic),<br>             following at least 5 minutes of supine rest<br><br>          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level =1.5 × Upper<br>             limit of normal (ULN);<br><br>          -  Total bilirubin level =1.5 × ULN; participants with a history of Gilbert's syndrome<br>             may have direct bilirubin measured and would be eligible for this study provided the<br>             direct bilirubin level is =ULN.<br><br>          -  estimated glomerular filtration rate (eGFR) =75 mL/min/1.73 m2 based on chronic kidney<br>             disease epidemiology (CKD-EPI) equation<br><br>          -  History of alcohol abuse or binge drinking and/or any other illicit drug use or<br>             dependence within 6 months of Screening<br><br>          -  Participants with more than 5 cigarettes per day or =10 pack years<br><br>          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more<br>             within 60 days prior to dosing<br>      """,NULL,"""Number of participants with treatment emergent treatment related adverse events (AE's);Number of participants with treatment emergent treatment-related serious adverse events (SAE's);Number of participants with change from baseline in blood pressure;Number of participants with change from baseline in pulse rate;Number of participants with change from baseline in temperature;Number of participants with change from baseline in clinical laboratory values;Number of participants with change from baseline in heart rate;Number of participants with change from baseline in QT interval;Number of participants with change from baseline in corrected QT interval;Number of participants with change from baseline in PR interval;Number of participants with change from baseline in QRS interval""","""Number of participants with change from baseline in area under the concentration versus time curve from time zero to the last quantifiable time point (AUClast) of single ascending doses of PF-07264660;Number of participants with change from baseline in maximum plasma concentration (Cmax) of PF-07264660 after a single dose;Number of participants with change from baseline in maximum plasma concentration (Cmax) of PF-07264660 after multiple doses;Number of participants with change from baseline in time to maximum plasma concentration (Tmax) of PF-07264660 after a single dose;Number of participants with change from baseline in time to maximum plasma concentration (Tmax) of PF-07264660 after multiple doses;Number of participants with change from baseline in terminal elimination half-life (t½) of PF-07264660 after a single dose;Number of participants with change from baseline in terminal elimination half-life (t½) of PF-07264660 after multiple doses;Number of participants with change from baseline in area under the serum concentration time profile from time 0 extrapolated to infinite time (AUCinf) of single ascending doses of PF-07264660;Number of participants with change from baseline in area under the concentration time profile from time zero to time tau (t), the dosing interval (AUCtau) of multiple ascending doses of PF-07264660;Number of participants with change from baseline in incidence and titers of anti-drug antibodies against PF-07264660;Number of participants with change from baseline in incidence and titers of neutralizing antibodies against PF-07264660""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05498402,"""26 September 2023""","""CPR-6""","""Effect of IAM With an I-gel® on Ventilation Parameters in Simulated Pediatric OHCA""","""Effect of Intermediate Airway Management Using an I-gel® on Ventilation Parameters in Simulated Pediatric Out-of-Hospital Cardiac Arrest: Protocol for a Randomized Crossover Trial""","""https://clinicaltrials.gov/ct2/show/NCT05498402""",""" ""","""Loric Stuby""",NULL,"""""","""""","""Genève TEAM Ambulances""",""" ""","""Loric Stuby""",NULL,"""""","""""","""Genève TEAM Ambulances""","""Interventional""","""Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ""","""N/A""","""9/8/2022""","""January 30, 2023""","""34""","""Completed""","""Geneve TEAM Ambulances""","""ESAMB - College of Higher Education in Ambulance Care;Ambulances de la Ville de Sion;University Hospital, Geneva""","""Please refer to primary and secondary sponsors""","""Switzerland""","""Pediatric ALL;Cardiac Arrest;Cardiopulmonary Arrest;Resuscitation;Pediatric Emergency Medicine""","""Device: i-gel ® device;Device: bag-valve-mask ventilation""","""N/A""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Being a registered EMT, or paramedic<br><br>        Exclusion Criteria:<br><br>          -  Member of the study team<br>      """,NULL,"""Alveolar ventilation per minute""","""The proportion, and number of ventilations below, within and over the target volume;The time to the first efficient ventilation;The time to the first compression;The chest compression fraction;The chest compression rate;The proportion of chest compressions below, within and over the target rate;The compression depth;The proportion of chest compressions below and within the target depth;The proportion of complete chest recoil;The time to first epinephrine injection;The proportion of scenarios in which epinephrine is administered within 5 minutes""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05499962,"""26 September 2023""","""21-USHE-104""","""SNS and PrEP Initiation and Adherence in Black SMM""","""PrEP Initiation and Adherence Among Black SMM: A Social Network-Level Intervention""","""https://clinicaltrials.gov/ct2/show/NCT05499962""",""" ; ; ""","""DeMarc A Hickson, PhD;DeMarc A Hickson, PhD;Dianne Murphy""",NULL,""";dhickson@uhupil.org;dmurphy@uhupil.org""",""";678.613.9827;202-446-1100""","""Executive Director;""",""" ; ; ""","""DeMarc A Hickson, PhD;DeMarc A Hickson, PhD;Dianne Murphy""",NULL,""";dhickson@uhupil.org;dmurphy@uhupil.org""",""";678.613.9827;202-446-1100""","""Executive Director;""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). ""","""N/A""","""9/8/2022""","""March 1, 2022""","""30""","""Recruiting""","""Us Helping Us, People Into Living, Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""HIV""","""Behavioral: Social Networking Strategies""","""18 Years""","""N/A""","""Male""","""<br>        Inclusion Criteria:<br><br>          -  Age of 18 years or above<br><br>          -  Black or African American race<br><br>          -  Cisgender male identity<br><br>          -  Gay, bisexual or a male who has sex with other males<br><br>          -  Residence in the greater Washington, DC area (includes District of Columbia, Prince<br>             George's County, MD and Montgomery County, MD)<br><br>          -  Current PrEP use<br><br>          -  Confirmed HIV-negative status.<br><br>        Exclusion Criteria:<br><br>          -  Being younger than 18 years of age ;<br><br>          -  Cisgender or transgender female identity<br><br>          -  Males having sex with women exclusively<br><br>          -  Being unable to speak or read English<br><br>          -  Reside outside of the defined greater Washington, DC area<br><br>          -  Being unable or unwilling to provide written informed consent<br><br>          -  Being unable to comply with the requirements of the protocol (e.g. persons with mental<br>             health conditions, persons who are intoxicated or incoherent for other reasons)<br><br>          -  Being a member of other vulnerable populations: pregnant women, children or wards of<br>             the state.<br>      """,NULL,"""Feasibility of Intervention as measured by Weiner et al., 2017.;Acceptability of Intervention as measured by Weiner et al., 2017.""","""Recruited Network Members;Network members on PrEP;Comfortability of the Intervention as measured by an adaptation of Weiner et al., 2017.""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05500170,"""26 September 2023""","""FP00006694""","""Benefits of Nicotinamide Riboside Upon Cognition and Sleep""","""The Benefits of Nicotinamide Riboside Upon Cognition and Sleep in Older Veterans""","""https://clinicaltrials.gov/ct2/show/NCT05500170""",""" ""","""Carleara Weiss, PhD, MS, RN""",NULL,"""carleara@buffalo.edu""","""7168282006""","""""",""" ""","""Carleara Weiss, PhD, MS, RN""",NULL,"""carleara@buffalo.edu""","""7168282006""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Participant). ""","""N/A""","""9/8/2022""","""April 4, 2023""","""50""","""Recruiting""","""State University of New York at Buffalo""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Cognitive Impairment;Sleep Quality""","""Dietary Supplement: Nicotinamide riboside;Dietary Supplement: Placebo""","""65 Years""","""85 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Sleep Quality. Pittsburgh Sleep Quality Index (PSQI) global score >5<br><br>        Exclusion Criteria:<br><br>          -  Dementia. Veteran Affairs - St. Louis University Mental Status questionnaire<br>             (VA-SLUMS) score <20<br>      """,NULL,"""Sleep Quality Assessment""","""Cognitive function""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05502978,"""26 September 2023""","""110289""","""Education Using WhatsApp and Face-to-Face Meetings on IYCF for the Nutritional Status of Infants""","""Effect of Education Using WhatsApp and Face-to-Face Meetings Concerning Infant and Young Child Feeding in the COVID-19 Pandemic on the Nutritional Status of Infants: Protocol for a Prospective Interventional Study""","""https://clinicaltrials.gov/ct2/show/NCT05502978""",""" ""","""Siti Helmyati, ph.D""",NULL,"""""","""""","""Gadjah Mada University""",""" ""","""Siti Helmyati, ph.D""",NULL,"""""","""""","""Gadjah Mada University""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ""","""N/A""","""9/8/2022""","""October 7, 2022""","""126""","""Completed""","""Gadjah Mada University""",NULL,"""Please refer to primary and secondary sponsors""","""Indonesia""","""Nutritional Stunting""","""Behavioral: Blended education of Infant and Young Child Feeding""","""20 Years""","""35 Years""","""Female""","""<br>        Inclusion Criteria:<br><br>          -  Pregnant women who are currently pregnant for the first or second time<br><br>          -  Mother does not have chronic disease such as asthma, hypertension and coronary heart<br>             disease<br><br>          -  Planning to stay minimal for a year in the research area<br><br>          -  Having smartphone with access to internet and whatsApp messaging application<br><br>        Exclusion Criteria:<br><br>          -  Participants who have multiple pregnancies<br><br>          -  After the baby was born has a congenital disease/congenital disorders<br><br>          -  Participants unwilling to continue with the study<br>      """,NULL,"""Infant Nutritional status;Infant and young child feeding practice (early initiation of breastfeeding practice);Infant and young child feeding practice (Exclusive breastfeeding practice);Infant and young child feeding practice (complementary feeding practice);Infant and young child feeding practice (continued breastfeeding >6 month practice)""","""Changes in knowledge breastfeeding;Changes in attitude breastfeeding;Changes in self-efficacy breastfeeding;Changes in knowledge complementary feeding;Changes in self-efficacy complementary feeding;Changes in knowledge of cadre;Changes in practice counselling of cadre""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05503849,"""26 September 2023""","""2022390B00""","""Born In Guangzhou Intervention Study""","""Born In Guangzhou Intervention Study""","""https://clinicaltrials.gov/ct2/show/NCT05503849""",""" ; ""","""Xiu Qiu;Xiu Qiu""",NULL,""";xiu.qiu@bigcs.org""",""";86-020-38367160""","""Guangzhou Women and Children's Medical Center;""",""" ; ""","""Xiu Qiu;Xiu Qiu""",NULL,""";xiu.qiu@bigcs.org""",""";86-020-38367160""","""Guangzhou Women and Children's Medical Center;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Care Provider, Outcomes Assessor). ""","""N/A""","""9/8/2022""","""September 2023""","""1160""","""Not yet recruiting""","""Guangzhou Women and Children's Medical Center""",NULL,"""Please refer to primary and secondary sponsors""","""China""","""Pregnancy Outcomes;Child Development;Pregnancy Complications""","""Behavioral: Lifestyle modification""","""18 Years""","""50 Years""","""Female""","""<br>        Inclusion Criteria:<br><br>          -  Pregnant women attending prenatal care at Guangzhou Women and Children's Medical<br>             Center (GWCMC) <20 weeks' gestation<br><br>          -  Pregnant women plan to deliver at GWCMC<br><br>          -  Pregnant women intend to reside in Guangzhou for at least 3 years<br><br>        Exclusion Criteria:<br><br>          -  Multiple pregnancies<br><br>          -  Existing medical conditions (uncontrolled diabetes, hypertension or thyroid disease;<br>             other serious cardiovascular diseases, respiratory or systematic disorders)<br><br>          -  Use of drugs (aspirin, metformin, low molecular weight heparin)<br><br>          -  Women with reading and/or writing difficulties<br><br>          -  Women with serious mental disorders<br><br>          -  Women with eating disorders<br>      """,NULL,"""Maternal gestational weight change;Newborn size;Neonatal skinfold thickness (at birth);Maternal blood lipid profile postpartum (3 years);Maternal blood glucose profile postpartum (3 years);Maternal blood insulin profile postpartum (3 years);Child blood lipid profile (3 years);Child blood glucose profile (3 years);Child blood insulin profile (3 years);Child growth parameters (3 years);Incidence of pregnancy complications""","""Child skinfold thickness (6 months);Child skinfold thickness (1 year);Child skinfold thickness (3 years);Child skinfold thickness (6 years);Child growth parameters (6 months);Child growth parameters (1 year);Child growth parameters (6 years);Child blood lipid profile (6 years);Child blood sugar profile (6 years);Child blood insulin profile (6 years);Neurological development of child (1 year);Neurological development of child (3 years);Maternal hand grip strength during pregnancy;Maternal hand grip strength after delivery;Maternal body composition postpartum;Maternal blood lipid profile postpartum (6 years);Maternal blood sugar profile postpartum (6 years);Maternal blood insulin profile postpartum (6 years)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05045677,"""26 September 2023""","""047-2021""","""Digital Dialectical Behavioral Therapy (d-DBT) Skills for Acute Suicidality in Psychiatric Inpatients""","""Digital Dialectical Behavioral Therapy (d-DBT) Skills for Treatment of Acute Suicidality in Psychiatric Inpatients: Randomized Feasibility Trial""","""https://clinicaltrials.gov/ct2/show/NCT05045677""",""" ""","""Ishrat Husain, MD (Res)""",NULL,"""""","""""","""Centre for Addiction and Mental Health""",""" ""","""Ishrat Husain, MD (Res)""",NULL,"""""","""""","""Centre for Addiction and Mental Health""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Care Provider, Investigator, Outcomes Assessor). ""","""N/A""","""9/8/2021""","""April 1, 2022""","""42""","""Completed""","""Centre for Addiction and Mental Health""","""The Physicians' Services Incorporated Foundation""","""Please refer to primary and secondary sponsors""","""Canada""","""Suicidal Ideation""","""Other: digital DBT skills intervention;Other: Standard Care""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. patients with any DSM-5 diagnosis aged 18 years and above;<br><br>          2. admitted to CAMH with suicidality and a baseline BSI score of > 6;<br><br>          3. capable and willing to give informed consent;<br><br>          4. anticipated length of admission is greater than 5 days;<br><br>          5. deemed suitable by the primary team to take part in a psychotherapeutic intervention<br>             as part of standard care<br><br>        Capacity to consent will be evaluated by the research staff performing the informed consent<br>        process. It will be assessed as the participant's ability to understand and appreciate the<br>        risks and benefits of taking part in the proposed study.<br><br>        Exclusion Criteria:<br><br>          1. presence of psychiatric symptoms that interfere with the ability to complete the d-DBT<br><br>          2. Concurrent treatment with ECT or MST<br>      """,NULL,"""Recruitment and retention rates;Client Satisfaction Questionnaire 8 (CSQ-8);User Experience Questionnaire (UXQ)""","""Columbia-Suicide Severity Rating Scale (C-SSRS);Clinical Global Impression (CGI);Brief Difficulties in Emotion Regulation Scale (DERS-16);Kessler psychological distress scale (K10)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05026177,"""26 September 2023""","""PTI-125-06""","""Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease""","""A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease""","""https://clinicaltrials.gov/ct2/show/NCT05026177""",""" ""","""Jim Kupiec, MD""",NULL,"""""","""""","""Cassava Sciences""",""" ""","""Jim Kupiec, MD""",NULL,"""""","""""","""Cassava Sciences""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 3""","""9/8/2021""","""November 18, 2021""","""1083""","""Active, not recruiting""","""Cassava Sciences, Inc.""","""Premier Research Group plc""","""Please refer to primary and secondary sponsors""","""United States;Canada;Korea, Republic of;Puerto Rico;Canada;Korea, Republic of;Puerto Rico;United States""","""Alzheimer Disease""","""Drug: Simufilam;Drug: Placebo""","""50 Years""","""87 Years""","""All""","""<br>        Key Inclusion Criteria:<br><br>          1. Meets National Institute on Aging and Alzheimer's Association Research Framework<br>             criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum.<br><br>          2. Evidence for AD pathophysiology, confirmed prior to or during screening.<br><br>          3. MMSE score = 16 and = 27 at screening.<br><br>          4. Clinical Dementia Rating - Global Score must be 0.5, 1 or 2.<br><br>          5. If receiving background AD medications, the dosing regimen must be stable for at least<br>             12 weeks prior to randomization. Chronic medications for conditions other than AD<br>             (such as depression) must be prescribed at a stable dose for at least 4 weeks prior to<br>             screening.<br><br>          6. The subject has not been a cigarette smoker or chewed tobacco for at least 3 years.<br><br>          7. Availability of a study partner.<br><br>          8. Individuals who have participated in a clinical study with an investigational drug<br>             targeting the underlying AD process may be permitted to participate in this study.<br><br>          9. Completed a COVID-19 vaccine primary series (fully vaccinated) at least 2 weeks<br>             prior to randomization or had an unambiguous COVID-19 infection diagnosed more than 3<br>             months before the start of the Screening Period.<br><br>        Key Exclusion Criteria:<br><br>          1. A neurologic condition other than AD that significantly contributes to the subject's<br>             dementia.<br><br>          2. Any current primary psychiatric diagnosis other than AD if it is likely to confound<br>             cognitive assessment or ability to comply with study procedures.<br><br>          3. Geriatric Depression Scale (15-item) score > 8 (Note - a subject with a score > 8 may<br>             continue in screening if, in the judgment of the Investigator, the elevated score is<br>             not attributed to a major depressive episode).<br><br>          4. Suicidal ideation during the past 3 months or suicidal behavior during the past 12<br>             months.<br><br>          5. Alcohol or substance use disorder within 2 years of screening.<br><br>          6. MRI presence of cerebral vascular or other significant pathology.<br><br>          7. History of transient ischemic attack or stroke within 12 months of screening.<br><br>          8. Seizure within 12 months of screening.<br><br>          9. Severe head trauma or head trauma considered likely to be contributing to the<br>             subject's cognitive impairment.<br><br>         10. Sleep apnea that is considered likely to be contributing to the subject's cognitive<br>             impairment.<br><br>         11. Insufficiently controlled diabetes mellitus or hypertension.<br><br>         12. Body mass index < 18.5 or > 37.5.<br><br>         13. History or diagnosis of clinically significant cardiac disease.<br><br>         14. Currently or previously prescribed/administered aducanumab, lecanemab, or any<br>             anti-amyloid monoclonal antibody, more than 2 doses.<br>      """,NULL,"""Change from baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12);Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)""","""Change from baseline in the integrated Alzheimer's Disease Rating Scale (iADRS);Change from baseline in the Neuropsychiatric Inventory (NPI);Change from baseline in the MMSE;Change from baseline in the Clinical Dementia Rating Sum of Boxes (CDR-SB);Change from baseline in the Zarit Burden Interview (ZBI);Changes from baseline in CSF neurogranin, neurofilament light chain, total tau, phospho-tau181 (P-tau181) and/or phospho-tau217 (P-tau217), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and Aß42;Changes from baseline in brain volume via MRI;Changes from baseline in amyloid and tau PET;Changes from baseline in plasma biomarkers P-tau181, P-tau217, and neurofilament light chain;Change from baseline in plasma biomarker SavaDx""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05030675,"""26 September 2023""","""NCI-2021-08494;2020-1117;2020-1117""","""Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents""","""Phase I Open-Label Study of Fostamatinib, a SYK Inhibitor, in Patients With Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents""","""https://clinicaltrials.gov/ct2/show/NCT05030675""",""" ; ""","""Guillermo M Bravo;Guillermo M. Bravo""",NULL,""";gmontalban1@mdanderson.org""",""";713-794-3604""","""M.D. Anderson Cancer Center""",""" ; ""","""Guillermo M Bravo;Guillermo M. Bravo""",NULL,""";gmontalban1@mdanderson.org""",""";713-794-3604""","""M.D. Anderson Cancer Center""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/8/2021""","""August 13, 2021""","""20""","""Recruiting""","""M.D. Anderson Cancer Center""","""National Cancer Institute (NCI)""","""Please refer to primary and secondary sponsors""","""United States""","""Refractory Chronic Myelomonocytic Leukemia;Refractory Myelodysplastic Syndrome""","""Drug: Fostamatinib""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Age >= 18 years as MDS is a very rare disease in the pediatric setting<br><br>          -  Diagnosis of MDS or CMML according to World Health Organization (WHO) and very low,<br>             low or intermediate risk by Revised International Prognostic Scoring System (IPSS-R)<br>             (with IPSS-R score of =< 3.5)<br><br>          -  Patients need to have not responded to prior therapy with hypomethylating agents<br>             (HMAs). These could include azacitidine, decitabine, SGI-110, ASTX727. Patients will<br>             need to have received at least 4 cycles of HMA. Patients with relapse or progression<br>             after any number of cycles of HMA by IWG 2006 criteria will also be candidates.<br>             Patients with MDS with isolated del(5q) must have received prior therapy with<br>             lenalidomide<br><br>          -  Cytopenias, in the form of anemia and thrombocytopenia, as follows:<br><br>               -  Hemoglobin < 10 g/dL OR<br><br>               -  Platelets < 75 x10^9/L OR<br><br>               -  Transfusion dependency, defined as the receipt of any red blood cell or platelet<br>                  transfusions within at least 28 days prior to the start of study treatment<br><br>          -  Patient (or patient's legally authorized representative) must have signed an informed<br>             consent document indicating that the patient understands the purpose of and procedures<br>             required for the study and is willing to participate in the study<br><br>          -  Total bilirubin < 2 x upper limit of normal (ULN)<br><br>          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN<br><br>          -  Serum creatinine clearance > 30 mL/min and no end/stage renal disease (using<br>             Cockcroft-Gault)<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2<br><br>          -  Hydroxyurea for control of leukocytosis is allowed at any time prior to or during<br>             study if considered to be in the best interest of the patient<br><br>          -  Both females of childbearing potential and males with female partners of childbearing<br>             potential must agree to use contraception during the study period and for at least one<br>             month after the last dose<br><br>        Exclusion Criteria:<br><br>          -  No prior therapy for MDS or CMML<br><br>          -  Uncontrolled infection not adequately responding to appropriate antibiotics<br><br>          -  Absolute neutrophil count (ANC) < 0.5 x 10^9 k/uL<br><br>          -  Uncontrolled or poorly controlled hypertension, defined as systolic blood pressure >=<br>             135 mmHg or diastolic blood pressure >= 85 mmHg, whether or not the subject is<br>             receiving anti-hypertensive treatment<br><br>          -  Female patients who are pregnant or lactating<br><br>          -  Patients with reproductive potential who are unwilling to following contraception<br>             requirements (including condom use for males with sexual partners, and for females:<br>             prescription oral contraceptives [birth control pills], contraceptive injections,<br>             intrauterine devices [IUD], double-barrier method [spermicidal jelly or foam with<br>             condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the<br>             study. Reproductive potential is defined as no previous surgical sterilization or<br>             females that are not post-menopausal for 12 months<br><br>          -  Female patients with reproductive potential who do not have a negative urine or blood<br>             beta-human chorionic gonadotropin (beta human chorionic gonadotropin [HCG]) pregnancy<br>             test at screening<br><br>          -  History of an active malignancy within the past 2 years prior to study entry, with the<br>             exception of: a. Adequately treated in situ carcinoma of the cervix uteri b.<br>             Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the<br>             skin or any other malignancy with a life expectancy of more than 2 years<br><br>          -  Patients receiving any other concurrent investigational agent or chemotherapy,<br>             radiotherapy, or immunotherapy (within 14 days of initiating study treatment)<br><br>          -  Evidence of graft versus host disease or prior allo-stem cell transplantation within 6<br>             months of Cycle 1 Day 1 or receiving immunosuppressants following a stem-cell<br>             procedure<br>      """,NULL,"""The PI doesnt wish to add any Outcome Measures this will be add at the time of results""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05004116,"""26 September 2023""","""21-156""","""A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer""","""Phase 1/2 Study of TPX-0005 (Repotrectinib) in Combination With Chemotherapy in Pediatric and Young Adult Subjects With Advanced or Metastatic Solid Tumors and Primary Central Nervous System Tumors""","""https://clinicaltrials.gov/ct2/show/NCT05004116""",""" ; ; ""","""Tara O'Donohue, MD;Tara O'Donohue, MD;Tara O'Donohue, MD""",NULL,""";odonohut@mskcc.org;""",""";1-833-675-5437;833-675-5437""","""Memorial Sloan Kettering Cancer Center;""",""" ; ; ""","""Tara O'Donohue, MD;Tara O'Donohue, MD;Tara O'Donohue, MD""",NULL,""";odonohut@mskcc.org;""",""";1-833-675-5437;833-675-5437""","""Memorial Sloan Kettering Cancer Center;""","""Interventional""","""Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1/Phase 2""","""9/8/2021""","""August 9, 2021""","""50""","""Recruiting""","""Memorial Sloan Kettering Cancer Center""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Advanced Cancer;Metastatic Solid Tumor""","""Drug: Repotrectinib;Drug: Irinotecan and temozolomide""","""1 Year""","""25 Years""","""All""","""<br>        Inclusion Criteria (ALL Patients) :<br><br>          -  Prior Therapy: Patients must have fully recovered from the acute toxic effects of all<br>             previous chemotherapy, immunotherapy, or radiotherapy prior to study enrollment.<br>             Patients must not have received the therapies indicated below for the specified time<br>             period prior to the first day of administration of protocol therapy on this study:<br><br>               -  Myelosuppressive chemotherapy: Last dose was given at least 21 days before the<br>                  start date for protocol therapy.<br><br>               -  Biologic (anti-neoplastic agent including retinoids): Last dose given at least 7<br>                  days prior to the start date for protocol therapy.<br><br>               -  Monoclonal antibodies: Last dose of any monoclonal antibodies must have received<br>                  at least 7 days or 3 half-lives, whichever is longer, prior to the start date for<br>                  protocol therapy.<br><br>               -  Other immunotherapy (ex: tumor vaccine): Patient is eligible after 42 days of<br>                  completion. Steroids are excluded from inclusion in immunotherapy.<br><br>               -  Radiation Therapy: Patients must not have received radiation for a minimum of two<br>                  weeks prior to first dose of the drug for small port. If extensive bone marrow<br>                  radiation, at least 42 days must have elapsed.<br><br>               -  Palliative radiotherapy on study is permitted for the treatment of painful bony<br>                  lesions providing the lesions were known at the time of study entry and the<br>                  Investigator clearly indicates that the need for palliative radiotherapy is not<br>                  indicative of disease progression. In view of the current lack of data about the<br>                  interaction of repotrectinib with radiotherapy, repotrectinib treatment should be<br>                  interrupted during palliative radiotherapy, stopping 1 day before palliative<br>                  radiotherapy and resuming treatment 1 day after completion of palliative<br>                  radiotherapy and recovery from any acute radiation toxicities to baseline.<br><br>               -  Hematopoietic Stem Cell Transplant (HSCT): Patients are eligible 12 weeks after<br>                  date of autologous hematopoietic stem cell infusion following myeloablative<br>                  therapy (timed from first day of this protocol therapy). Patients who have<br>                  received an autologous hematopoietic stem cell infusion to support non-<br>                  myeloablative therapy (such as ^131 I-MIBG) are eligible at any time as long as<br>                  they meet the other criteria for eligibility.<br><br>               -  ^131 I-MIBG therapy: A minimum of 6 weeks must have elapsed after ^131 I-MIBG<br>                  therapy prior to start of protocol therapy.<br><br>               -  Growth factors: Patients are eligible 14 days after last dose of long-acting<br>                  growth factor (ex: peg-GCSF) or 7 days after short acting growth factor.<br><br>               -  Any investigational agent or anticancer therapy other than chemotherapy and not<br>                  otherwise noted: Not within 2 weeks prior to planned start of TPX-0005<br>                  (Repotrectinib) or 5 half-lives, whichever is shorter. Full recovery of<br>                  clinically significant toxicities from that therapy must be evident.<br><br>               -  Any prior treatment with a tyrosine kinase inhibitor (TKI) of ALK/ROS/NTRK does<br>                  NOT exclude patient from study (Patients are eligible for study at least 7 days<br>                  or 5 half-lives, whichever is shorter, after last dose)<br><br>          -  Disease Status<br><br>               -  Patients must have relapsed or refractory disease despite standard therapy.<br><br>               -  Phase 1: Patients must have evaluable or measurable disease<br><br>               -  Phase 2: All patients must have measurable disease (per Appendices 1-3) at time<br>                  of enrollment<br><br>               -  Exception: Neuroblastoma patients are permitted to have evaluable disease only<br>                  (ex: bone disease only, evaluable by MIBG or FDG PET/CT)<br><br>               -  Exception: Patients with DIPG can have stable or progressive disease after<br>                  upfront radiation therapy.<br><br>          -  Biopsy Requirement<br><br>             °Archived tissue must be available for analysis, but no fresh biopsy is required<br>             (exception: patients with DIPG do not require archived tissue). If no archival tissue<br>             is available, waiver may be permitted by study PI (phase 1 only).<br><br>          -  Patients with Primary CNS Tumors:<br><br>               -  Patients with primary CNS tumor or CNS metastases must be neurologically stable<br>                  on a stable or decreasing dose of steroids for at least 14 days prior to<br>                  enrollment<br><br>               -  Archived tissue and histologic verification requirement are waived for patients<br>                  with diffuse intrinsic pontine glioma (DIPG)<br><br>          -  Performance Score: Patients must have a Lansky (< 16 years age) or Karnofsky (= 16<br>             years age) score of at least 50. Patients who are unable to walk because of paralysis<br>             or tumor pain, but who are up in a wheelchair, will be considered ambulatory for the<br>             purpose of assessing the performance score.<br><br>          -  No bone marrow involvement<br><br>               -  Absolute Neutrophil Count =1000/mm^3 (1 x 10^9/L)<br><br>               -  Platelet Count =100,000/mm ^3 (100 x 10^9/L); transfusions allowed<br><br>               -  Hemoglobin = 8.0 g/dL, transfusions are allowed<br><br>          -  Known bone marrow involvement (applicable for phase 2 only)<br><br>               -  Absolute Neutrophil Count =750/mm 3 (1.5 x 109/L)<br><br>               -  Platelet Count =50,000/mm^3 (100 x 10^9/L), transfusions allowed<br><br>               -  Hemoglobin = 8.0 g/dL, transfusions are allowed<br><br>          -  Serum Creatinine or Creatinine Clearance*Creatinine within normal limits for<br>             age/gender (see table below) or creatinine clearance or nuclear GFR = 60<br>             mL/min/1.73m^2<br><br>          -  Total Serum Bilirubin <2.5 x ULN for age/gender<br><br>          -  Liver Transaminases (AST/ALT) <2.5 x ULN for age/gender; < 5 x ULN for age/gender if<br>             liver metastasis is present<br><br>          -  Serum calcium, magnesium and potassium Normal for age/gender or = CTCAE Grade 1 with<br>             or without supplementation.<br><br>          -  Cardiac Function Echocardiogram with left ventricular shortening fraction >25% and QTc<br>             </= 470ms on screening electrocardiogram<br><br>          -  AST/ALT = aspartate aminotransferase/alanine aminotransferase, ULN = upper limit of<br>             normal<br><br>          -  Adequate Renal Function using the Schwartz formula for estimating GFR Schwartz et al.<br>             J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.<br><br>          -  Females of Childbearing potential: Must have negative serum pregnancy test during<br>             screening and be neither breastfeeding nor intending to become pregnant during study<br>             participation. Females of childbearing potential must agree to avoid pregnancy during<br>             the study and agree to the use of 2 effective contraceptive methods (hormonal and<br>             barrier method of birth control) prior to """,NULL,"""incidence of Dose Limiting Toxicity (DLTs) (phase I);Maximum tolerated dose (MTD) (phase I)""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05007470,"""26 September 2023""","""21-000674""","""Alcoholic Liver Disease and the Gut Microbiome""","""Alterations of the Brain-Gut-Microbiome Axis Modulates Sex Differences in Outcomes of Alcohol-Related Liver Disease""","""https://clinicaltrials.gov/ct2/show/NCT05007470""",""" ; ""","""William Katzka, BA;William Katzka, BA""",NULL,"""wkatzka@gmail.com;wkatzka@mednet.ucla.edu""","""6103891064;610-389-1064""","""""",""" ; ""","""William Katzka, BA;William Katzka, BA""",NULL,"""wkatzka@gmail.com;wkatzka@mednet.ucla.edu""","""6103891064;610-389-1064""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). ""","""N/A""","""9/8/2021""","""January 31, 2022""","""80""","""Recruiting""","""University of California, Los Angeles""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Alcohol Use Disorder;Alcoholic Liver Disease;Microbiome""","""Drug: VSL #3 112.5 Capsule;Other: Placebo""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Adult patients admitted to Santa Monica UCLA hospital or Ronald Reagan UCLA Hospital<br>             with a diagnosis of AUD and ALD will be screened and potentially recruited.<br><br>          -  ALD patients will be identified based on the recent American Association of the Study<br>             of Liver Disease (AASLD) guidelines: onset of jaundice within 8 weeks, 2) ongoing<br>             consumption of ethanol of >40 for women or >60 in men for 6 months or <60 days of<br>             abstinence before onset of jaundice, AST>50, AST:ALT>1.5 and both <400 IU/L, total<br>             bilirubin >3, or liver biopsy showing histologic features of ALD.<br><br>          -  AUD will be defined based on the current DSM-V definition<br><br>        Exclusion Criteria:<br><br>          -  To avoid any confounders to the gut microbiome analysis, patients will be excluded if<br>             they have been on antibiotics within 3 months or probiotics within 1 month of<br>             enrollment<br><br>          -  If patients have a history of inflammatory bowel disease, irritable bowel syndrome,<br>             gastrointestinal malignancy, or gastrointestinal surgery.<br><br>          -  If patients are started on antibiotics while in the study, they will be withdrawn from<br>             the study to avoid confounders of antibiotic use on microbiome analysis.<br><br>          -  To avoid any cofounders of advanced liver fibrosis on the microbiome analysis, we will<br>             also exclude patients with underlying cirrhosis and/or overt hepatic encephalopathy<br>             (West Haven criteria >3).<br><br>          -  Patients with acute pancreatitis or history of chronic pancreatitis will also be<br>             excluded. The diagnosis of acute pancreatitis and chronic pancreatitis will be<br>             ascertained from their history and physical.<br><br>          -  Cirrhosis will be determined by a review of their medical charts and Fib4 calculation.<br>             If their medical charts do not mention any history of cirrhosis and their Fib4 score<br>             is less than or equal to 1.35 then they will be deemed as being non-cirrhotic.<br>             Subjects will be provided their Fib4 score if it is greater than 1.35 and instructed<br>             to follow up with their primary care physician for further evaluation if warranted.<br>             Fib4 is based on their clinical blood work and age which will be abstracted from their<br>             chart and is validated at ruling out advanced liver fibrosis and cirrhosis.<br>      """,NULL,"""Sex differences within ALD""","""Microbiome changes due to sex differences within ALD;Alcohol consumption changes due to sex differences within ALD;Quality of life changes due to sex differences within ALD;Alcohol Craving changes due to sex differences within ALD""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04510558,"""26 September 2023""","""PROMESH TRIAL""","""Reducing the Incidence of Incisional Hernia After Stoma Closure Using a Prophylactic Mesh""","""Reducing the Incidence of Incisional Hernia After Stoma Closure Using a PROphylactic MESH: a Single-blinded Randomized Controlled Trial (PROMESH TRIAL).""","""https://clinicaltrials.gov/ct2/show/NCT04510558""",""" ; ; ""","""Nicolas Buchs, MD, PD;Jeremy Meyer, MD, MD-PhD;Nicolas Buchs, MD, PD""",NULL,""";jeremy.meyer@unige.ch;nicolas.c.buchs@hcuge.ch""",""";+41795533182;""","""University Hospitals of Geneva;""",""" ; ; ""","""Nicolas Buchs, MD, PD;Jeremy Meyer, MD, MD-PhD;Nicolas Buchs, MD, PD""",NULL,""";jeremy.meyer@unige.ch;nicolas.c.buchs@hcuge.ch""",""";+41795533182;""","""University Hospitals of Geneva;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant). ""","""N/A""","""9/8/2020""","""May 1, 2021""","""72""","""Recruiting""","""University Hospital, Geneva""",NULL,"""Please refer to primary and secondary sponsors""","""Switzerland""","""Incisional Hernia""","""Device: Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position;Procedure: Stoma closure without mesh""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Adult patient<br><br>          -  Ileostomy or colostomy performed during surgery for digestive cancer<br><br>          -  Planned elective closure of ileostomy or colostomy<br><br>          -  Informed written consent<br><br>        Exclusion Criteria:<br><br>          -  Allergy to the mesh<br><br>          -  Patients under corticosteroids or other immunosuppressive treatment<br><br>          -  Inability/refusal to follow the procedures of the study<br>      """,NULL,"""Incidence of incisional hernia at site of stoma at one year after closure""","""Incidence of surgical site infection (SSI) at site of stoma closure""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04077723,"""26 September 2023""","""2019-000416-28;BP41072""","""A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma""","""An Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma""","""https://clinicaltrials.gov/ct2/show/NCT04077723""",""" ; ""","""Clinical Trials;Reference Study ID Number: BP41072 https://forpatients.roche.com/""",NULL,""";global-roche-genentech-trials@gene.com""",""";888-662-6728 (U.S. and Canada)""","""Hoffmann-La Roche;""",""" ; ""","""Clinical Trials;Reference Study ID Number: BP41072 https://forpatients.roche.com/""",NULL,""";global-roche-genentech-trials@gene.com""",""";888-662-6728 (U.S. and Canada)""","""Hoffmann-La Roche;""","""Interventional""","""Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/8/2019""","""August 13, 2019""","""498""","""Recruiting""","""Hoffmann-La Roche""",NULL,"""Please refer to primary and secondary sponsors""","""United States;Australia;Belgium;Denmark;France;Italy;Spain;United Kingdom;Australia;Belgium;Denmark;France;Italy;Spain;United Kingdom;United States""","""Lymphoma, Non-Hodgkin""","""Drug: RO7227166;Drug: Obinutuzumab;Drug: Glofitamab;Drug: Tocilizumab""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Depending upon study part: a history or status of a histologically-confirmed<br>             hematological malignancy that is expected to express CD19 and CD20; relapse after or<br>             failure to respond to at least two prior treatment regimens; and no available<br>             treatment options that are expected to prolong survival<br><br>          -  Must have at least one measureable target lesion (>/= 1.5 cm) in its largest dimension<br>             by computed tomography scan<br><br>          -  Able and willing to provide a fresh biopsy from a safely accessible site, per<br>             Investigator's determination, providing the participant has more than one measurable<br>             target lesion<br><br>          -  Eastern Cooperative Oncology Group performance status of 0 or 1<br><br>          -  Life expectancy of >/= 12 weeks<br><br>          -  Adverse events from prior anti-cancer therapy must have resolved to Grade </= 1<br><br>          -  Adequate liver, haematological, and renal function<br><br>          -  Negative test results for acute or chronic hepatitis B virus infection<br><br>          -  Negative test results for hepatitis C virus and HIV<br><br>          -  The contraception and abstinence requirements are intended to prevent exposure of an<br>             embryo to the study treatment. The reliability of sexual abstinence for male and/or<br>             female enrollment eligibility needs to be evaluated in relation to the duration of the<br>             clinical study and the preferred and usual lifestyle of the participant. Periodic<br>             abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and<br>             withdrawal are not acceptable methods of preventing drug exposure<br><br>          -  Female participants: A female participant is eligible to participate if she is not<br>             pregnant and not breastfeeding, and if at least one of the following applies: women of<br>             non-childbearing potential (WONCBP); women of child bearing potential (WOCBP) who<br>             agree to remain abstinent or use two highly effective contraceptive methods with a<br>             failure rate of <1% per year during the treatment period and for at least 18 months<br>             after obinutuzumab or 3.5 months after the last dose of RO7227166, 2 months after last<br>             dose of glofitamab, or 3 months after the last dose of tocilizumab, whichever is<br>             longer. Examples of contraceptive methods with a failure rate of < 1% per year include<br>             bilateral tubal occlusion/ ligation, male sexual partner who is sterilized,<br>             established proper use of hormonal contraceptives that inhibit ovulation,<br>             hormone-releasing intrauterine devices and copper intrauterine devices. Hormonal<br>             contraceptive methods must be supplemented by a barrier method; have a negative<br>             pregnancy test (blood) within the 7 days prior to the first study treatment<br>             administration<br><br>          -  Male participants: During the treatment period and for at least 3 months after<br>             obinutuzumab, or 3.5 months after the last dose of RO7227166, 2 months after the last<br>             dose of glofitamab, or 2 months after the last dose of tocilizumab whichever is<br>             longer, agreement to: Remain abstinent or use contraceptive measures such as a condom<br>             plus an additional contraceptive method that together result in a failure rate of < 1%<br>             per year, with a partner who is a women of childbearing potential. With pregnant<br>             female partner, remain abstinent or use contraceptive measures such as a condom to<br>             avoid exposing the embryo; refrain from donating sperm during this same period<br><br>        Exclusion Criteria:<br><br>          -  Circulating lymphoma cells, defined by out of range (high) absolute lymphocyte count<br>             or the presence of abnormal cells in the peripheral blood differential signifying<br>             circulating lymphoma cells<br><br>          -  Participants with acute bacterial, viral, or fungal infection at baseline, confirmed<br>             by a positive blood culture within 72 hours prior to obinutuzumab infusion or by<br>             clinical judgment in the absence of a positive blood culture<br><br>          -  Participants with known active infection, or reactivation of a latent infection,<br>             whether bacterial, viral fungal, mycobacterial, or other pathogens (excluding fungal<br>             infections of nail beds) or any major episode of infection requiring hospitalization<br>             or treatment with IV antibiotics<br><br>          -  Pregnant or breast-feeding or intending to become pregnant during the study<br><br>          -  Prior treatment with systemic immunotherapeutic agents, including, but not limited to,<br>             radio-immunoconjugates, antibody-drug conjugates, immune/cytokines or monoclonal<br>             antibodies within 4 weeks or five half-lives of the drug, whichever is shorter, before<br>             obinutuzumab infusion on D-7<br><br>          -  History of treatment-emergent immune-related AEs associated with prior<br>             immunotherapeutic agents and auto-immune disease<br><br>          -  Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with<br>             any other investigational or approved anti-cancer agent within 4 weeks or 5 half-lives<br>             of the drug, whichever is shorter, prior to obinutuzumab infusion<br><br>          -  Prior solid organ transplantation<br><br>          -  Prior allogeneic stem cell transplant (SCT) and prior chimeric antigen receptor<br>             -T-cell therapy<br><br>          -  Autologous SCT within 100 days prior to obinutuzumab infusion<br><br>          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy<br>             and confirmed progressive multifocal leukoencephalopathy<br><br>          -  Current or past history of central nervous system (CNS) lymphoma and CNS disease<br><br>          -  Evidence of significant, uncontrolled concomitant diseases that could affect<br>             compliance with the protocol or interpretation of results, including diabetes<br>             mellitus, history of relevant pulmonary disorders and known autoimmune diseases<br><br>          -  Major surgery or significant traumatic injury < 28 days prior to the Gpt infusion or<br>             anticipation of the need for major surgery during study treatment<br><br>          -  Participants with another invasive malignancy in the last 2 years<br><br>          -  Significant cardiovascular disease<br><br>          -  Administration of a live, attenuated vaccine within 4 weeks before Gpt infusion or<br>             anticipation that such a live attenuated vaccine will be required during the study<br><br>          -  Received systemic immunosuppressive medications (including but not limited to<br>             cyclohosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis<br>             factor agents) within two weeks prior to Gpt, with the exception of corticosteroid<br>             treatment <=25 mg/day of prednisone or equivalent, however there must be documentation<br>             that the participant was on a stable dose of at least a 2-week duration prior to Gpt<br>             infusion. Inhaled and topical steriods are permitted<br>      """,NULL,"""Nature and frequency of dose-limiting toxicities (DLTs);Proportion of Participants with Adverse Event (AE);Overall Response Rate (ORR);Disease Control Rate (DCR);Duration of Response (DOR);Progression-free Survival (PFS);Overall Survival (OS);Complete Response (CR)""","""Total exposure (area under the concentration time curve [AUC]) of RO7227166 in combination with obinutuzumab and glofitamab;Maximum serum concentration (peak concentration, Cmax) of RO7227166 in combination with obinutuzumab and glofitamab;Minimum serum concentration (trough concentration, Cmin) of RO7227166 in combination with obinutuzumab and glofitamab;Clearance (CL) of RO7227166 in combination with obinutuzumab and glofitamab;Volume of distribution of steady state (Vss) and half-life (t1/2) of RO7227166 in combination with obinutuzumab and glofitamab;ORR;DCR;DOR;PFS;OS;Proportion of Participants with Adverse Event (AE);Total exposure (area under the concentration time curve [AUC]) of RO7227166 in combination with glofitamab;Maximum serum concentration (peak concentration, Cmax) of RO7227166 in combination with glofitamab;Minimum serum concentration (trough concentration, Cmin) of RO7227166 in combination with glofitamab;Clearance (CL) of RO7227166 in combination with glofitamab;Volume of distribution of steady state (Vss) and half-life (t1/2) of RO7227166 in combination with glofitamab Part I/II/III;T-cell and Natural killer (NK)-cell status in blood, using markers of T and NK-cell lineage, function and activation including, but not limited to, CD3, CD8, 41BB, and Ki67 expression;B-cell reduction in blood and tumor tissue;Change from Baseline in RO7227166 Anti-Drug Antibody (ADA) Titer;Time to First Complete Response (TFCR);Time to First Overall Response (TFOR);Duration of Complete Response (DOCR);Change from Baseline in Physical Function, Role Function, and Health-Related Quality of Life (HRQoL) Based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30);Change from Baseline in Physical Function, Role Function, and HRQoL According to the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Scale""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03629171,"""26 September 2023""","""NCI-2018-01589;2017-1055;2017-1055""","""Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia""","""Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML)""","""https://clinicaltrials.gov/ct2/show/NCT03629171""",""" ; ; ""","""Tapan M Kadia;Tapan Kadia;Tapan M. Kadia""",NULL,""";tkadia@mdanderson.org;tkadia@mdanderson.org""",""";713-563-3534;713-792-7305""","""M.D. Anderson Cancer Center;""",""" ; ; ""","""Tapan M Kadia;Tapan Kadia;Tapan M. Kadia""",NULL,""";tkadia@mdanderson.org;tkadia@mdanderson.org""",""";713-563-3534;713-792-7305""","""M.D. Anderson Cancer Center;""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2""","""9/8/2018""","""October 29, 2018""","""52""","""Recruiting""","""M.D. Anderson Cancer Center""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Recurrent Acute Myeloid Leukemia;Refractory Acute Myeloid Leukemia""","""Drug: Liposome-encapsulated Daunorubicin-Cytarabine;Drug: Venetoclax""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  For the lead in phase: Patients >= 18 years of age with a diagnosis of relapsed and/or<br>             refractory AML will be eligible. Patients who have had prior treatment with venetoclax<br>             will be allowed to participate in the lead in phase and cohort A<br><br>          -  For the dose expansion cohort A (relapsed/refractory [R/R] AML): Patients >= 18 years<br>             of age with a diagnosis of relapsed and/or refractory AML will be eligible<br><br>          -  For the dose expansion cohort B (de novo AML): Patients >= 18 years to 69 years of<br>             age; patients in this cohort must have received no prior therapy for AML<br><br>          -  Prior therapy with hydroxyurea, hematopoietic growth factors, or tretinoin (ATRA) (for<br>             emergency use for stabilization) is allowed with no washout. A cumulative dose of<br>             ara-C of up to 3 g for emergency stabilization in patients with rapidly proliferating<br>             disease is also allowed provided it was administered > 48 hrs prior to enrollment<br><br>          -  Bilirubin =< 2 mg/dL<br><br>          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper<br>             limit of normal (ULN) or < 5 x ULN if related to leukemic involvement<br><br>          -  Creatinine =< 1.5 x ULN<br><br>          -  Known cardiac ejection fraction of > or = 45% within the past 3 months<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 2<br><br>          -  A negative urine or serum pregnancy test is required within 1 week for all women of<br>             childbearing potential prior to enrolling on this trial. A woman of childbearing<br>             potential is defined as a woman who has not been naturally postmenopausal for at least<br>             12 consecutive months, or who had no previous surgical sterilization<br><br>          -  Patient must have the ability to understand the requirements of the study and signed<br>             informed consent. A signed informed consent by the patient or his legally authorized<br>             representative is required prior to their enrollment on the protocol<br><br>        Exclusion Criteria:<br><br>          -  Pregnant women are excluded from this study because the agents used in this study have<br>             the potential for teratogenic or abortifacient effects. Because there is a potential<br>             risk for adverse events in nursing infants secondary to treatment of the mother with<br>             the chemotherapy agents, breastfeeding should also be avoided<br><br>          -  Uncontrolled intercurrent illness including, but not limited to active uncontrolled<br>             infection, symptomatic congestive heart failure (New York Heart Association [NYHA]<br>             class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia,<br>             or psychiatric illness/social situations that would limit compliance with study<br>             requirements<br><br>          -  Patient with documented hypersensitivity to any of the components of the chemotherapy<br>             program<br><br>          -  Patients with acute promyelocytic leukemia (M3) or core-binding factor AML<br><br>          -  Patients with active central nervous system (CNS) leukemia are excluded since the<br>             antileukemia activity of the treatment components against CNS leukemia are not known<br><br>          -  Men and women of childbearing potential who do not practice contraception. Women of<br>             childbearing potential and men must agree to use contraception prior to study entry<br>             and for the duration of study participation<br><br>          -  Prior treatment with CPX-351 or venetoclax. Patients with prior treatment with<br>             venetoclax will be allowed in patients with relapsed/refractory (R/R) disease<br>             including those in the lead-in phase as well as those in cohort A<br>      """,NULL,"""Achievement of composite complete remission;Incidence of adverse events""","""Event-free survival;Overall survival;Biomarker changes""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03648450,"""26 September 2023""","""Propeller Asthma Study""","""Feasibility and Acceptability of the Propeller Monitoring System in Children With Persistent Asthma""","""Feasibility and Acceptability of the Propeller Monitoring System in Children With Persistent Asthma""","""https://clinicaltrials.gov/ct2/show/NCT03648450""",""" ""","""Glenn Flores, MD""",NULL,"""""","""""","""Connecticut Children's Medical Center""",""" ""","""Glenn Flores, MD""",NULL,"""""","""""","""Connecticut Children's Medical Center""","""Observational""","""""","""""","""9/8/2018""","""November 1, 2020""","""50""","""Completed""","""Connecticut Children's Medical Center""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Asthma""","""Other: Propeller EMD""","""10 Years""","""18 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Children in the ED or inpatient setting presenting with an asthma exacerbation between<br>             10-18 years old<br><br>          2. History of persistent asthma (defined as prescribed a controller medication)<br><br>          3. Both the child and primary caregiver/parent have access to a cell phone with an<br>             activated number<br><br>          4. Ability of child's parent/legal guardian to understand and the willingness to sign a<br>             written informed consent document.<br><br>        Exclusion Criteria:<br><br>          1. Child or parent has no access to a personal cell phone.<br><br>          2. The child has another chronic pulmonary condition (for example, cystic fibrosis)<br><br>          3. Having any chronic condition that could affect the child's ability to participate in<br>             the study (examples: cancer, autism, or cerebral palsy)<br><br>          4. The subject has an inhaler medication besides the following, given these are the<br>             current medications compatible with the Propeller EMD.<br><br>             i. Advair HFA ii. Flovent HFA iii. QVAR HFA v. Ventolin HFA vi. ProAir HFA<br>      """,NULL,"""Regular device use at three months""","""Acceptability of the Propeller EMD as determined by the electronic Medical Devices Assessment Toolkit (AMDAT);Asthma Control;Device use at one month""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03653598,"""26 September 2023""","""K16""","""BLITZ Atrial Fibrillation""","""BLITZ Atrial Fibrillation""","""https://clinicaltrials.gov/ct2/show/NCT03653598""",""" ""","""Michele M Gulizia, MD""",NULL,"""""","""""","""Heart Care Foundation""",""" ""","""Michele M Gulizia, MD""",NULL,"""""","""""","""Heart Care Foundation""","""Observational [Patient Registry]""","""""","""""","""9/8/2018""","""February 1, 2016""","""4125""","""Completed""","""Heart Care Foundation""",NULL,"""Please refer to primary and secondary sponsors""","""Italy""","""Atrial Fibrillation""","""Other: Atrial Fibrillation""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  All patients with AF, admitted to cardiology wards for an urgent or planned<br>             hospitalization.<br><br>          -  All patients admitted in a Day Hospital regimen for treatment of AF The diagnosis of<br>             AF must be confirmed by ECG.<br><br>          -  Signed Patient Inform Consent.<br><br>        Exclusion Criteria:<br><br>          -  The qualifying episode of AF was not documented with an ECG.<br><br>          -  Age <18 years.<br><br>          -  Patients with AF as a complication of an acute coronary syndrome (within 1 week from<br>             symptoms onset).<br><br>          -  Patients with AF associated with cardiothoracic surgery (within 1 week from surgery).<br><br>          -  Concomitant participation in other studies that can modify the diagnostic and/or<br>             therapeutic treatments.<br><br>          -  Patients already enrolled in BLITZ-AF<br>      """,NULL,"""Number of admissions of patients with AF;Rate or rhythm control strategy;Antithrombotic strategies""","""Admission to the ER for atrial flutter;Patients regularly followed up by the cardiology centers;Adherence to the 1A recommendations of current guidelines""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03250026,"""26 September 2023""","""459-17""","""Cooperation for Primary Care Patients on Sick Leave for CMD: Care Manager and Workplace Intervention - CO-WORK-CARE""","""Cooperation for Patients With Common Mental Disorders: Care Manager Function at the Primary Care Centre and Intervention at the Workplace - CO-WORK-CARE""","""https://clinicaltrials.gov/ct2/show/NCT03250026""",""" ""","""Cecilia Björkelund, prof""",NULL,"""""","""""","""Göteborg University""",""" ""","""Cecilia Björkelund, prof""",NULL,"""""","""""","""Göteborg University""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/8/2017""","""December 5, 2017""","""349""","""Active, not recruiting""","""Göteborg University""","""Vastra Gotaland Region""","""Please refer to primary and secondary sponsors""","""Sweden""","""Depressive Disorder;Anxiety Disorders""","""Behavioral: Workplace convergence dialogue;Behavioral: Care Manager""","""18 Years""","""67 Years""","""All""","""<br>        Inclusion Criteria:<br><br>        Patients attending primary care centers with care manager function<br><br>          -  aged >=18 to 67 years<br><br>          -  diagnosed with a new (< 1 month) depression diagnose (F32, F33), anxiety syndrome<br>             (F41, F48) or stress related adjustment disorder (F43)<br><br>          -  on sick-leave > 14 days<br><br>        Exclusion Criteria:<br><br>          -  Bipolar disorder<br><br>          -  psychosis<br><br>          -  addiction<br><br>          -  other serious mental disorder<br><br>          -  suicidal ideation or earlier suicide attempt<br><br>          -  cognitive impairment or not speaking/understanding Swedish<br>      """,NULL,"""Net and gross sick-leave days""","""Depressive symptoms;Anxiety symptoms;Quality-of-life questionnaire score;Work ability;Exhaustion""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02876302,"""26 September 2023""","""16-151""","""Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer""","""Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer""","""https://clinicaltrials.gov/ct2/show/NCT02876302""",""" ""","""Filipa Lynce, MD""",NULL,"""""","""""","""Dana-Farber Cancer Institute""",""" ""","""Filipa Lynce, MD""",NULL,"""""","""""","""Dana-Farber Cancer Institute""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2""","""9/8/2016""","""April 26, 2017""","""23""","""Active, not recruiting""","""Dana-Farber Cancer Institute""","""Incyte Corporation""","""Please refer to primary and secondary sponsors""","""United States""","""Inflammatory Breast Cancer (IBC)""","""Drug: Ruxolitinib;Drug: Paclitaxel;Drug: Doxorubicin;Drug: Cyclophosphamide""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Participants must have histologically confirmed invasive breast cancer. All histologic<br>             subtypes are eligible.<br><br>          -  Patients must have known ER, PR, and HER2 status defined as triple-negative breast<br>             cancer (TNBC), defined as:<br><br>             --ER and PR <10% by immunohistochemistry, and HER2-negative ( as per ASCO/CAP<br>             guidelines, defined as IHC 0 or 1+, or FISH ratio <2.0 or HER2 copy number <6.0).<br><br>          -  Patients must have the clinical diagnosis of inflammatory breast cancer, involving an<br>             intact breast.<br><br>          -  Age = 18 years. Because no dosing or adverse event data are currently available on the<br>             use of ruxolitinib in participants <18 years of age, children are excluded from this<br>             study.<br><br>          -  ECOG performance status 0 or 1.<br><br>          -  Participants must have normal organ and marrow function as defined below:<br><br>               -  Leukocytes = 3,000/mm3<br><br>               -  Absolute neutrophil count = 1,500/mm3<br><br>               -  Platelets = 100,000/mm3<br><br>               -  Bilirubin = 1.5 x institutional upper limit of normal (ULN)<br><br>               -  AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal<br><br>               -  Creatinine =1.5 x institutional upper limit of normal OR creatinine clearance ><br>                  60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal<br><br>          -  Patients with evidence of extensive nodal involvement are allowed. Extensive nodal<br>             involvement is defined as metastatic disease involving any nodal region outside of the<br>             involved breast.<br><br>          -  Patients with minimal metastatic disease involvement in bone or viscera are allowed.<br>             Minimal metastatic disease is defined as: evidence of metastatic involvement as<br>             demonstrated by imaging only, not amenable to biopsy confirmation.<br><br>          -  Both men and women are allowed.<br><br>          -  The effects of ruxolitinib on the developing human fetus are unknown. For this reason<br>             women of child-bearing potential and men must agree to use adequate contraception<br>             (hormonal or barrier method of birth control; abstinence) prior to study entry until<br>             completion of chemotherapy. Should a woman become pregnant or suspect she is pregnant<br>             while participating in this study, she should inform her treating physician<br>             immediately.<br><br>          -  Ability to understand and the willingness to sign a written informed consent document.<br><br>          -  LVEF > 50% calculated by echocardiogram (ECHO) or MUGA<br><br>          -  Patients may have bilateral breast cancer so long as one breast meets criteria for<br>             inflammatory breast cancer, and neither breast cancer has received prior therapy<br><br>        Exclusion Criteria:<br><br>          -  Participants may not be receiving any other investigational agents.<br><br>          -  Participants with known brain metastases should be excluded from this clinical trial<br>             because of their poor prognosis and because they often develop progressive neurologic<br>             dysfunction that would confound the evaluation of neurologic and other adverse events.<br><br>          -  History of allergic reactions attributed to compounds of similar chemical or biologic<br>             composition to ruxolitinib.<br><br>          -  Participants receiving any medications or substances that are potent inhibitors of<br>             CYP3A4, including grapefruit juice are ineligible. Participants receiving fluconazole<br>             are also ineligible. (Please refer to Appendix B for the full list of potent<br>             inhibitors and washout periods).<br><br>          -  Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once daily.<br><br>          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active<br>             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac<br>             arrhythmia, or psychiatric illness/social situations that would limit compliance with<br>             study requirements.<br><br>          -  Pregnant women are excluded from this study because paclitaxel, doxorubicin, and<br>             cyclophosphamide have the potential for teratogenic or abortifacient effects. Because<br>             there is an unknown but potential risk of adverse events in nursing infants secondary<br>             to treatment of the mother with these agents, breastfeeding should be discontinued if<br>             the mother is treated on study. These potential risks may also apply to other agents<br>             used in this study.<br><br>          -  Individuals with a history of a different malignancy are ineligible except for the<br>             following circumstances. Individuals with a history of other malignancies are eligible<br>             if they have been disease-free for at least 3 years and are deemed by the investigator<br>             to be at low risk for recurrence of that malignancy. Individuals with the following<br>             cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer<br>             in situ, and basal cell or squamous cell carcinoma of the skin.<br><br>          -  Known HIV-positive individuals on combination antiretroviral therapy are eligible so<br>             long as they meet all other criteria. Known HIV-positive individuals who are not on<br>             combination antiretroviral therapy are not eligible because these individuals are at<br>             increased risk of lethal infections when treated with marrow-suppressive therapy.<br>             Appropriate studies will be undertaken in participants receiving combination<br>             antiretroviral therapy when indicated.<br><br>          -  Clinically significant malabsorption syndrome.<br><br>          -  Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as<br>             anti-neoplastic therapy.<br><br>          -  Patients with prior radiation to the affected breast.<br>      """,NULL,"""Assess JAK Inhibition With Ruxolitinib On pStat3+ Expression""","""Determine Pathologic Complete Response rate (pCR) after preoperative therapy;Correlate effects on pSTAT3+ and STAT3 gene expression with pCR;Assess changes in pSTAT3 level and STAT3 gene expression following treatment;Asses difference in pCR rate following preoperative treatment;Determine efficacy defined as Disease-Free Survival (DFS);Determine efficacy defined as Time to Treatment Failure (TTF);Determine efficacy defined as Overall Survival (OS);Assess Residual Cancer Burden (RCB) differences after preoperative therapy;Describe changes in IL-6 plasma levels during treatment;Describe changes in CRP plasma levels during treatment;Assess distribution of CD44+/CD24- stem cell population in tumor pre- and post-exposure to ruxolotinib""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT00362843,"""26 September 2023""","""06-M-0214;060214""","""Protein Synthesis in the Brain of Patients With Fragile X Syndrome""","""PET Measurement of Regional Rates of Cerebral Protein Synthesis in Subjects With Fragile X Syndrome""","""https://clinicaltrials.gov/ct2/show/NCT00362843""",""" ""","""Robert B Innis, M.D.""",NULL,"""""","""""","""National Institute of Mental Health (NIMH)""",""" ""","""Robert B Innis, M.D.""",NULL,"""""","""""","""National Institute of Mental Health (NIMH)""","""Observational""","""""","""""","""9/8/2006""","""August 22, 2006""","""147""","""Completed""","""National Institute of Mental Health (NIMH)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Fragile X Syndrome;Healthy Volunteers""","""Drug: [15-O]water""","""18 Years""","""24 Years""","""Male""","""<br>        -  INCLUSION CRITERIA:<br><br>        Fragile X subjects:<br><br>        Male subjects, 18-24 years of age, with diagnosis of fragile X syndrome will be considered.<br>        Diagnosis will be confirmed by molecular genetic testing. Subjects with CGG repeat<br>        sequences greater than 200 and methylation of FMR1 will be included.<br><br>        Control:<br><br>        Male subjects, 18-24 years of age will be considered.<br><br>        EXCLUSION CRITERIA:<br><br>        Fragile X subjects:<br><br>        Fragile X subjects with a high level of repeat size or methylation mosaicism will be<br>        excluded. Fragile X subjects on psychotropic medications will be excluded from the study.<br>        Fragile X subjects who have received radiation doses for research purposes exceeding 4 rem<br>        (whole body effective dose) in the previous 12 months will be excluded. Fragile X subjects<br>        in whom MRI is contraindicated will be excluded. Subjects with metal objects in their<br>        bodies, such as pacemakers, aneurysm clips (metal clips on the wall of a large artery),<br>        metallic prostheses, cochlear implants, or shrapnel fragments will be excluded from the<br>        study. Welders and metal workers at risk for eye injury because of unsuspected tiny metal<br>        fragments there will also be excluded. Subjects in whom sedation is contraindicated will be<br>        excluded. Fragile X subjects on medications that interfere with blood coagulation will be<br>        excluded (see Appendix 1). In addition, fragile X subjects with respiratory illnesses or<br>        cardiovascular diseases will be excluded as there might be increased risk of complications<br>        with sedation/anesthesia.<br><br>        Control:<br><br>        Subjects with premutation alleles, i.e., repeat length between 55 and 200 will be excluded.<br>        Subjects with IQ less than 90 or subnormal language skills will be excluded. Subjects on<br>        psychotropic medication will be excluded from the study. Subjects who have received<br>        radiation doses for research purposes exceeding 3.5 rem (whole body effective dose) in the<br>        previous 12 months and subjects for whom MRI is contraindicated will be excluded. Subjects<br>        in whom sedation is contraindicated will be excluded from Part II. Subjects on medications<br>        that interfere with blood coagulation will be excluded (see Appendix 1). Subjects with any<br>        previous history of psychiatric or neurological disease, as assessed by the Structured<br>        Clinical Interview for DSM-IV (SCID), will be excluded. In addition, subjects with<br>        respiratory illnesses or cardiovascular diseases will be excluded from Part II as there<br>        might be increased risk of complications with sedation/anesthesia. Subjects positive for<br>        HIV will be excluded from the study. Subjects with positive results on the urine drug<br>        screen will be excluded.<br>      """,NULL,"""Regional rates of cerebral protein synthesis""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT00128973,"""26 September 2023""","""05-I-0213;050213""","""Evaluation of Patients With Immune Function Abnormalities""","""Screening and Baseline Assessment of Patients With Abnormalities of Immune Function""","""https://clinicaltrials.gov/ct2/show/NCT00128973""",""" ; ; ""","""Harry L Malech, M.D.;Patricia L Littel, R.N.;For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)""",NULL,""";plittel@mail.nih.gov;ccopr@nih.gov""",""";(301) 335-1744;800-411-1222""","""National Institute of Allergy and Infectious Diseases (NIAID);""",""" ; ; ""","""Harry L Malech, M.D.;Patricia L Littel, R.N.;For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)""",NULL,""";plittel@mail.nih.gov;ccopr@nih.gov""",""";(301) 335-1744;800-411-1222""","""National Institute of Allergy and Infectious Diseases (NIAID);""","""Observational""","""""","""""","""9/8/2005""","""September 19, 2005""","""2400""","""Recruiting""","""National Institute of Allergy and Infectious Diseases (NIAID)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Chronic Granulomatous Disease (CGD);X-Linked Severe Combined Immune Deficiency (XSCID);Leukocyte Adhesion Deficiency 1 (LAD);Graft Versus Host Disease (cGvHD)""",NULL,"""N/A""","""N/A""","""All""","""<br>        -  INCLUSION CRITERIA:<br><br>        Patients:<br><br>          -  Patients with abnormalities of immune function as manifested by recurrent or unusual<br>             infections, recurrent or chronic inflammation, or previous laboratory evidence of<br>             immune dysfunction are eligible for screening and baseline assessment under this<br>             protocol.<br><br>          -  Of particular focus of this study are patients with clinical features or medical<br>             history suggestive of Chronic Granulomatous Disease (CGD), X-linked Severe Combined<br>             Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD) or chronic Graft<br>             versus Host Disease (cGvHD).<br><br>          -  There will be no limit due to age, sex, race, or disability.<br><br>          -  All patients must have a primary physician outside of the NIH.<br><br>          -  Women of child-bearing potential, or who are pregnant or lactating, may be eligible<br>             and will only undergo tests and procedures, and/or receive medications for which data<br>             exists proven minimal risk to the fetus or child. Only diagnostic tests without<br>             radiographs will be performed.<br><br>          -  All patients will be required to have blood stored for future studies (such as but not<br>             limited to the modification of cells into iPS cells), and/or other medical conditions.<br><br>        Relatives of Patient:<br><br>          -  Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and<br>             first cousins to a patient.<br><br>          -  There is no limit due to age, sex, race or disability.<br><br>          -  Women of childbearing potential, or who are pregnant or lactating, may be eligible and<br>             will only undergo tests and procedures, and/or receive medications for which data<br>             exists proven minimal risk to the fetus or child. Pregnant females will undergo<br>             diagnostic tests without radiograph exposure.<br><br>          -  Must be willing to have blood stored for future studies and/or other research<br>             purposes.<br><br>        Healthy Volunteers must:<br><br>          -  Be a healthy adult of either sex and between age of 18 and 85 years old.<br><br>          -  Have a hemoglobin count of greater than or equal to 11.<br><br>          -  Weight greater than 110 pounds.<br><br>          -  Not have any heart, lung, or kidney disease, or bleeding disorders.<br><br>          -  Not have a history of viral hepatitis (B or C) since age 11.<br><br>          -  Not have a history of intravenous injection drug use.<br><br>          -  Not have a history of engaging in high-risk activities for exposure to the AIDS virus.<br><br>          -  Not be pregnant<br><br>          -  Be willing to have their blood samples stored for future research and modified iPS<br>             cells.<br><br>        Patient Participants in the FDG PET-CT and/or FDG PET-CT/MR-PET Scan Study Must:<br><br>        - Already be enrolled and eligible to participate on protocol #05-I-0213 Screening and<br>        Baseline Assessment of Patients with<br><br>        Abnormalities of Immune Function<br><br>        - Be at least 8 years old<br><br>        Must have clinical evidence for significant life-threatening infection that would be a<br>        standard of care medical indication for diagnostic CT scan where the FDG PET-CT/MR-PET scan<br>        would be performed in lieu of that indicated diagnostic CT; or have had a CT or MRI that<br>        did not adequately indicate the anatomic extent, location(s) or intensity of the infection<br><br>          -  Must be capable of overnight fasting and stopping of any intravenous glucose or other<br>             intravenous nutritional feeding for at least 12 hours before the FDG injection and<br>             through the period of time required for the FDG PET-CT/MR-PET scans, because glucose<br>             and insulin significantly inhibits uptake of FDG.<br><br>          -  Must be psychologically capable of remaining in the confined space of the PET-CT and<br>             MR-PET instruments. Patient will remain eligible for FDG PET-CT alone if the subject<br>             cannot tolerate the confines of the MR-PET instrument.<br><br>        Patient Participants in Lung MRI as a CT supplement in Infection Surveillance Sub Study<br>        Must:<br><br>          -  Have a primary immune deficiency and be enrolled under 05-I-0213.<br><br>          -  Be willing to sign a supplemental consent to undergo lung MRI.<br><br>          -  Be greater or equal to 12 years of age<br><br>          -  Need a medically indicated chest CT<br><br>          -  Be psychologically/physically capable of remaining in the confined space of the MRI<br>             machine for at least 30 minutes.<br><br>          -  Be able to lay flat.<br><br>          -  Be capable of following breath-holding instructions.<br><br>        EXCLUSION CRITERIA:<br><br>        Patients:<br><br>          -  The presence of certain types of acquired abnormalities of immunity solely due to HIV,<br>             chemotherapeutic agent(s), or an underlying malignancy could be grounds for possible<br>             exclusion for a patient.<br><br>          -  In the opinion of the investigator, the presence of such disease processes may<br>             interfere with the evaluation of a co-existing abnormality of immunity that is the<br>             subject of study under this protocol.<br><br>          -  Pregnant women will not be allowed to participate in any procedure that may be<br>             dangerous to the pregnancy or the fetus, such as risk of radiographic studies.<br><br>        Relatives of Patient:<br><br>          -  The presence of certain types of acquired abnormalities of immunity solely due to HIV,<br>             chemotherapeutic agent(s), or an underlying malignancy could be grounds for possible<br>             exclusion for a relative.<br><br>          -  In the opinion of the investigator, the presence of such disease processes may<br>             interfere with evaluation of a co-existing abnormality of immunity that is the subject<br>             of study under this protocol.<br><br>          -  Pregnant female relatives will not be allowed to participate in any procedure that may<br>             be dangerous to the pregnancy or the fetus.<br><br>        Healthy Volunteer not eligible if:<br><br>          -  Less than 18 years old or older than 85 years.<br><br>          -  Have viral hepatitis (B or C).<br><br>          -  Receiving chemotherapeutic agent(s) or have underlying malignancy.<br><br>          -  Pregnant.<br><br>          -  Have history of heart, lung, kidney disease, or bleeding disorders.<br><br>        Patient Participants in the FDG PET-CT and/or FDG PET-CT/MRPET Scan Study Must Not:<br><br>          -  Have cancer or have had radiation or chemotherapy to treat a cancer in the past 5<br>             years.<br><br>          -  Have diabetes or abnormal glucose tolerance.<br><br>          -  Weigh more than 299lbs (or 136kg) or cannot fit in the bore of the instruments.<br><br>          -  Are a women of childbearing potential, you must have a negative urine or blood<br>             pregnancy test within 1days prior to having the FDG<br><br>        PET-CT/MR-PET scans.<br><br>        - If you have aneurysm clips, metal fragments in the eye, certain types of metal implants<br>        or prostheses, a pacemaker or other permanently attached electronic devices that are not<br>        marked MRI compatible you may not be able to participate in the MR-PET portion of the study<br><br>        Patient Participants in Lung MRI as a CT supplement in I""",NULL,"""To establish the pattern and pace of change of disease (frequency, distribution, type and extent of infections, inflammatory lesions and abnormalities of immune function) during a period of up to one year baseline assessment.;To establish the extent of organ involvement (infection and/or inflammation) and organ damage or dysfunction resulting from the abnormality of immune function.;To determine genetic linkage and biochemical correlates of the patient s abnormality of immunity by study of first and second-degree related family members blood cells (buccal smears instead of blood for genetic studies in some individuals)...;To characterize the physiologic, biochemical or genetic basis of the abnormality of immunity.""","""To establish a baseline assessment of the pace and extent of the disease before entering a therapeutic clinical trial.;To determine a patient s eligibility for other studies.;To assess the patient s ability to safely tolerate specific aspects of other diagnostic or therapeutic research protocols.""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05948787,"""26 September 2023""","""INL US State Department;UNODC POPHL 2023""","""Assessing the Feasibility of Providing a Family Skills Intervention Strong Families for Families in the Philippines.""","""A Multi-site Randomized Controlled Trial: Testing the Feasibility and Effectiveness of the Strong Families Programme in the Philippines, Skills-based Prevention Intervention for Families With Children Ages 8-14 Years Old.""","""https://clinicaltrials.gov/ct2/show/NCT05948787""",""" ; ; ; ; ""","""Aala El Khani;Wadih Maalouf;Olivier Lermet;Aimee Rose Manda, PhD;Geraldine F Santos, PhD""",NULL,""";;;;""",""";;;;""","""United Nations Office on Drugs and Crime (UNODC);United Nations Office on Drugs and Crime (UNODC);United Nations Office on Drugs and Crime (UNODC);Polytechnique University of the Philippines;Polytechnique University of the Philippines""",""" ; ; ; ; ""","""Aala El Khani;Wadih Maalouf;Olivier Lermet;Aimee Rose Manda, PhD;Geraldine F Santos, PhD""",NULL,""";;;;""",""";;;;""","""United Nations Office on Drugs and Crime (UNODC);United Nations Office on Drugs and Crime (UNODC);United Nations Office on Drugs and Crime (UNODC);Polytechnique University of the Philippines;Polytechnique University of the Philippines""","""Interventional""","""Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: Double (Participant, Care Provider). ""","""N/A""","""9/7/2023""","""February 28, 2023""","""210""","""Enrolling by invitation""","""United Nations Office on Drugs and Crime (UNODC)""","""Polytechnique University of the Philippines;Anti-Drug Abuse Councils, LGUs in the Philippines""","""Please refer to primary and secondary sponsors""","""Philippines""","""Parenting Skills;Family Relationship""","""Behavioral: Psychosocial intervention""","""N/A""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Parent or caregivers that speak Filipino (Tagalog) with at least one child and up to<br>             two children under their care aged 8-14<br><br>          -  Willing to take part in the program<br><br>          -  Will be in town for the duration of the programme and research sessions<br><br>        Exclusion Criteria:<br><br>          -  Families that have taken part in family skills training in the past 24 months<br><br>          -  Families in which parent/caregiver live separately from children<br><br>          -  Families in which parents/caregivers/children identified to have drug dependence<br>      """,NULL,"""Improved parenting skills""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05961865,"""26 September 2023""","""6672""","""Change in Inflammatory State in Patients Undergoing Transcatheter Ablation of Atrial Fibrillation""","""Change in Inflammatory State in Patients Undergoing Transcatheter Ablation of Atrial Fibrillation""","""https://clinicaltrials.gov/ct2/show/NCT05961865""",""" ; ; ""","""Stefano Carugo, MD;Stefano Carugo, MD;Stefano Carugo, MD""",NULL,""";stefano.carugo@policlinico.mi.it;""",""";+390255033532;+39 0255033579""","""IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico;""",""" ; ; ""","""Stefano Carugo, MD;Stefano Carugo, MD;Stefano Carugo, MD""",NULL,""";stefano.carugo@policlinico.mi.it;""",""";+390255033532;+39 0255033579""","""IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico;""","""Observational""","""""","""""","""9/7/2023""","""July 11, 2023""","""180""","""Recruiting""","""Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico""","""University of Milan""","""Please refer to primary and secondary sponsors""","""Italy""","""Atrial Fibrillation;Marker of Inflammation;Inflammation;Arrhythmia""","""Diagnostic Test: Markers of inflammation and fibrosis""","""18 Years""","""85 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Paroxysmal or persistent AF;<br><br>          -  Patients undergoing ESC/ERAH(European Society of Cardiology/European Heart Rhythm<br>             Association) approved catheter ablation procedures;<br><br>          -  Aged between 18 and 85 years;<br><br>          -  Ability to provide informed consent for study participation.<br><br>        Exclusion Criteria:<br><br>          -  Age > 85 years or < 18 years;<br><br>          -  Presence of left auricular thrombosis on pre-procedural transesophageal<br>             echocardiogram;<br><br>          -  NYHA functional class IV;<br><br>          -  Left ventricular ejection fraction <30%;<br><br>          -  Myocardial infarction or unstable angina or recent coronary artery bypass graft (<6<br>             months);<br><br>          -  Significant co-morbidity, such as cancer, severe renal failure requiring dialysis,<br>             severe obstructive pulmonary disease, cirrhosis, with a life expectancy of less than<br>             12 months;<br><br>          -  Presence of contraindications to the procedure;<br><br>          -  Inability to provide informed consent for study participation.<br>      """,NULL,"""Prevalence of subjects with AF undergoing ablation who have a reduction of inflammatory burden following treatment.""","""Prevalence of subjects with AF undergoing ablation who show improvement in clinical terms and in the arrhythmia recurrence rate.;Relationship between the degree of inflammation and atrial fibrosis and the degree of atrial fibrosis detected by electroanatomical mapping.""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04994132,"""26 September 2023""","""NCI-2021-06711;ARST2031;ARST2031;U10CA180886;ARST2031""","""A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma""","""A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)""","""https://clinicaltrials.gov/ct2/show/NCT04994132""",""" ""","""Wendy Allen-Rhoades""",NULL,"""""","""""","""Children's Oncology Group""",""" ""","""Wendy Allen-Rhoades""",NULL,"""""","""""","""Children's Oncology Group""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 3""","""9/7/2021""","""September 13, 2021""","""118""","""Recruiting""","""Children's Oncology Group""","""National Cancer Institute (NCI)""","""Please refer to primary and secondary sponsors""","""United States;Australia;Canada;Puerto Rico;Saudi Arabia;Australia;Canada;Puerto Rico;Saudi Arabia;United States""","""Alveolar Rhabdomyosarcoma;Botryoid-Type Embryonal Rhabdomyosarcoma;Embryonal Rhabdomyosarcoma;Metastatic Embryonal Rhabdomyosarcoma;Metastatic Rhabdomyosarcoma;Solid Alveolar Rhabdomyosarcoma;Spindle Cell Rhabdomyosarcoma;Spindle Cell/Sclerosing Rhabdomyosarcoma""","""Procedure: Bone Scan;Procedure: Biospecimen Collection;Procedure: Bone Marrow Aspiration;Procedure: Bone Marrow Biopsy;Procedure: Computed Tomography;Drug: Cyclophosphamide;Biological: Dactinomycin;Procedure: Magnetic Resonance Imaging;Procedure: Positron Emission Tomography;Radiation: Radiation Therapy;Drug: Vincristine Sulfate;Drug: Vinorelbine Tartrate;Procedure: X-Ray Imaging""","""N/A""","""50 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Patients must be =< 50 years of age at the time of enrollment<br><br>          -  Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based<br>             upon institutional histopathologic classification are eligible to enroll on the study<br>             based upon stage, group, and age, as below. FOXO1 fusion status must be determined by<br>             week 4 (day 28) of therapy. RMS types included under embryonal RMS (ERMS) include<br>             those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as<br>             ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the<br>             2020 World Health Organization (WHO) Classification as ERMS (classic, dense and<br>             botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical<br>             spindle cell ERMS variant and the newly recognized sclerosing RMS variant).<br>             Classification of alveolar RMS (ARMS) in the 2020 WHO Classification is the same as in<br>             the ICR and includes classic and solid variants<br><br>               -  ERMS<br><br>                    -  Stage 4, group IV, >= 10 years of age<br><br>               -  ARMS<br><br>                    -  Stage 4, group IV Patients will be eligible to remain on protocol therapy<br>                       based upon stage, group, and age<br><br>          -  Bone marrow metastatic disease is based on morphologic evidence of RMS based on<br>             hematoxylin and eosin (H&E) stains. In the absence of morphologic evidence of marrow<br>             involvement on H&E, patients with bone marrow involvement detected ONLY by flow<br>             cytometry, reverse transcriptase (RT)-polymerase chain reaction (PCR), fluorescence in<br>             situ hybridization (FISH), or immunohistochemistry will NOT be considered to have<br>             clinical bone marrow involvement for the purposes of this study<br><br>          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70<br>             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (must be<br>             performed within 7 days prior to enrollment):<br><br>               -  Age; Maximum serum creatinine (mg/dL)<br><br>               -  1 month to < 6 months; 0.4 mg/dL (male); 0.4 mg/dL (female)<br><br>               -  6 months to < 1 year; 0.5 mg/dL (male); 0.5 mg/dL (female)<br><br>               -  1 to < 2 years; 0.6 mg/dL (male); 0.6 mg/dL (female)<br><br>               -  2 to < 6 years; 0.8 mg/dL (male); 0.8 mg/dL (female)<br><br>               -  6 to < 10 years; 1 mg/dL (male); 1 mg/dL (female)<br><br>               -  10 to < 13 years; 1.2 mg/dL (male); 1.2 mg/dL (female)<br><br>               -  13 to < 16 years; 1.5 mg/dL (male); 1.4 mg/dL (female)<br><br>               -  >= 16 years; 1.7 mg/dL (male); 1.4 mg/dL (female)<br><br>          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (must be performed within<br>             7 days prior to enrollment)<br><br>               -  If there is evidence of biliary obstruction by tumor, then total bilirubin must<br>                  be < 3 x ULN for age<br><br>          -  All patients and/or their parents or legal guardians must sign a written informed<br>             consent<br><br>          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute<br>             (NCI) requirements for human studies must be met<br><br>        Exclusion Criteria:<br><br>          -  Patients with evidence of uncontrolled infection are not eligible<br><br>          -  RMS that is considered a second malignancy and previous cancer(s) that were treated<br>             with chemotherapy and/or radiation. Surgical resection alone of previous cancer(s) is<br>             allowed<br><br>          -  Patients with central nervous system involvement of RMS as defined below:<br><br>               -  Malignant cells detected in cerebrospinal fluid<br><br>               -  Intra-parenchymal brain metastasis separate and distinct from primary tumor<br>                  (i.e., direct extension from parameningeal primary tumors is allowed).<br><br>               -  Diffuse leptomeningeal disease<br><br>          -  Patients who have received any chemotherapy (excluding steroids) and/or radiation<br>             therapy for RMS prior to enrollment.<br><br>               -  Note: the following exception:<br><br>                    -  Patients requiring emergency radiation therapy for RMS. These patients are<br>                       eligible, provided they are consented to ARST2031 prior to administration of<br>                       radiation<br><br>               -  Note: Patients who have received or are receiving chemotherapy or radiation for<br>                  non-malignant conditions (e.g. autoimmune diseases) are eligible. Patients must<br>                  discontinue chemotherapy for non-malignant conditions prior to starting protocol<br>                  therapy<br><br>          -  Vincristine and vinorelbine are sensitive substrates of CYP450 3A4 isozyme. Patients<br>             must not have received drugs that are moderate to strong CYP3A4 inhibitors and<br>             inducers within 7 days prior to study enrollment<br><br>          -  Female patients who are pregnant since fetal toxicities and teratogenic effects have<br>             been noted for several of the study drugs. A pregnancy test is required for female<br>             patients of childbearing potential<br><br>          -  Lactating females who plan to breastfeed their infants<br><br>          -  Sexually active patients of reproductive potential who have not agreed to use an<br>             effective contraceptive method for the duration of their study participation<br>      """,NULL,"""Event-free survival""","""Overall survival;Radiologic response rate;Incidence of adverse events;Feasibility and safety assessed by the adverse events, toxicities and treatment delays""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04968847,"""26 September 2023""","""CP-200-001""","""FemaSeed LOCAL Artificial Insemination Trial""","""LOCAL: Prospective Multi-Center LOCALized Directional Insemination Trial for Artificial Insemination""","""https://clinicaltrials.gov/ct2/show/NCT04968847""",""" ""","""Study Director""",NULL,"""FemaSeedSupport@femasys.com""","""700-500-3910""","""""",""" ""","""Study Director""",NULL,"""FemaSeedSupport@femasys.com""","""700-500-3910""","""""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/7/2021""","""July 15, 2021""","""214""","""Recruiting""","""Femasys Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Infertility;Male Factor""","""Device: FemaSeed Localized Directional Insemination""","""19 Years""","""40 Years""","""Female""","""<br>        Inclusion Criteria:<br><br>          1. Female, 19-40 years of age, with no tubal, uterine or ovarian infertility factor<br>             (including patent fallopian tubes with no evidence of hydrosalpinx)<br><br>          2. Couples who have documented male factor infertility, total motile sperm count of =1<br>             million and = 20 million post sperm preparation<br><br>          3. Agrees to receive medical treatment with methotrexate if diagnosed during the course<br>             of the study with an ectopic pregnancy and meets the clinical criteria for medical<br>             management (i.e., hemodynamically stable, unruptured mass and no absolute<br>             contraindications to methotrexate administration)<br><br>        Exclusion Criteria:<br><br>          1. Greater than three prior intrauterine insemination (IUI) cycles<br><br>          2. Current or recent (within the last 3 months) pelvic infection (cervix, endometrium, or<br>             fallopian tubes)<br><br>          3. Prior history of ectopic pregnancy or tubal surgery<br><br>          4. Known allergy/ sensitivity to methotrexate<br>      """,NULL,"""Confirmed pregnancy rate at approximately 3 weeks following FemaSeed procedure.;Primary Safety: Occurrence of ectopic pregnancy per cycle;Primary Safety: Occurrence of uterine perforation per cycle""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04968912,"""26 September 2023""","""2021-000665-32;80202135SJS2001;CR109062""","""A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)""","""A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)""","""https://clinicaltrials.gov/ct2/show/NCT04968912""",""" ""","""Janssen Research & Development, LLC Clinical Trial""",NULL,"""""","""""","""Janssen Research & Development, LLC""",""" ""","""Janssen Research & Development, LLC Clinical Trial""",NULL,"""""","""""","""Janssen Research & Development, LLC""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Double (Participant, Investigator). ""","""Phase 2""","""9/7/2021""","""September 21, 2021""","""163""","""Active, not recruiting""","""Janssen Research & Development, LLC""",NULL,"""Please refer to primary and secondary sponsors""","""United States;France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States""","""Sjogren's Syndrome""","""Other: Placebo;Drug: Nipocalimab;Drug: Standard of Care Treatment""","""18 Years""","""75 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016<br>             American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at<br>             the time of screening, and was diagnosed with pSS no less than 26 weeks prior to<br>             screening<br><br>          -  At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's<br>             syndrome-related antigen A [SSA])<br><br>          -  Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity<br>             Index (clinESSDAI) score greater than or equal to (>=) 6<br><br>          -  At least one abnormal laboratory marker of pSS-related inflammatory disease activity,<br>             and at least low activity in one or more specified European League Against Rheumatism<br>             Sjogren's Syndrome Disease Activity Index (ESSDAI) domains<br><br>          -  It is recommended that participants are up to date on all age-appropriate vaccinations<br>             prior to screening as per routine local medical guidelines. For study participants who<br>             received locally-approved (and including emergency use-authorized) coronavirus disease<br>             2019 (COVID-19) vaccines recently prior to study entry, applicable local vaccine<br>             labelling, guidelines, and standards-of-care for participants receiving<br>             immune-targeted therapy will be followed when determining an appropriate interval<br>             between vaccination and study enrollment<br><br>        Exclusion Criteria:<br><br>          -  Has any confirmed or suspected clinical immunodeficiency syndrome not related to<br>             treatment of his/her pSS or has a family history of congenital or hereditary<br>             immunodeficiency unless confirmed absent in the participant<br><br>          -  Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have<br>             required 3 or more courses of systemic glucocorticoids within the previous 12 months<br><br>          -  Has any unstable or progressive manifestation of pSS that is likely to warrant<br>             escalation in therapy beyond permitted background medications and/or has severely<br>             active pSS<br><br>          -  Has received oral cyclophosphamide within 3 months or intravenous (IV)<br>             cyclophosphamide within 6 months prior to first administration of study intervention<br><br>          -  Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic<br>             or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic<br>             lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the<br>             primary diagnosis or has clinical manifestations that, in the opinion of the<br>             investigator, or the sponsor or sponsor's representative, are likely to interfere with<br>             the investigator's ability to assess pSS manifestations<br>      """,NULL,"""Change from Baseline in Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24""","""Change from Baseline in European League Against Rheumatism (EULAR) Sjogren Syndrome Patient Reported Index (ESSPRI) Score at Week 24;Improvement of Greater than or Equal to (>=) 4 Points from Baseline in ESSDAI Score (Minimal Clinically Important Improvement) at Week 24;Improvement of >= 4 Points from Baseline in clinESSDAI Score (Minimal Clinically Important Improvement) at Week 24;ESSPRI Response at Week 24;Disease Response as Assessed by Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24;Improvement in Disease Activity Level by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24;Improvement from Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjogren's Syndrome (CRESS) Categories at Week 24;Percentage of Participants with Treatment-emergent Adverse Events (TEAEs);Percentage of Participants with Adverse Events of Special interests (AESIs);Percentage of Participants with Treatment-emergent Serious Adverse Events (SAEs);Percentage of Participants with TEAEs Leading to Treatment Discontinuation;Percentage of Participants with Clinically Significant Abnormalities in Vital Signs;Percentage of Participants with Clinically Significant Abnormalities in Laboratory Parameters;Serum Concentration of Nipocalimab Over Time;Number of Participants with Antibodies to Nipocalimab (Anti-drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs]);Number of Participants with Change from Baseline in Biomarkers;Number of Participants with Change from Baseline in Autoantibodies""","""JPRN-jRCT2031210484                               ""","""parent    ""","""EUCTR2021-000665-32-DE;EUCTR2021-000665-32-ES;EUCTR2021-000665-32-IT;EUCTR2021-000665-32-NL;EUCTR2021-000665-32-PL;EUCTR2021-000665-32-PT;JPRN-jRCT2031210484""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04975230,"""26 September 2023""","""1K99NR018886-01A1;STUDY20201829""","""Self-Management in Young Adults With Type 1 Diabetes""","""Sleep, Glycemia, and Self-Management in Young Adults With Type 1 Diabetes""","""https://clinicaltrials.gov/ct2/show/NCT04975230""",""" ""","""Stephanie Griggs, PhD""",NULL,"""""","""""","""Case Western Reserve University""",""" ""","""Stephanie Griggs, PhD""",NULL,"""""","""""","""Case Western Reserve University""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Participant). ""","""N/A""","""9/7/2021""","""April 29, 2022""","""44""","""Active, not recruiting""","""Case Western Reserve University""","""National Institute of Nursing Research (NINR);National Institutes of Health (NIH)""","""Please refer to primary and secondary sponsors""","""United States""","""Type 1 Diabetes""","""Behavioral: Sleep Self-Management""","""18 Years""","""26 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  1) Age range: from 18 to 26 years<br><br>          -  2) Diagnosed with T1D for at least 6 months<br><br>          -  3) No other major health problems (e.g., chronic medical condition or major<br>             psychiatric illness<br><br>          -  4) Not currently participating in any intervention studies<br><br>          -  5) Read/speak English<br><br>          -  6) Have a most recent A1C or eA1C value = 7%.<br><br>        Exclusion Criteria:<br><br>          -  1) Previous OSA diagnosis/high-risk sleep apnea<br><br>          -  2) Current pregnancy<br><br>          -  3) Night shift workers<br><br>          -  4) Habitually sleep > 7 hours on work or school days.<br>      """,NULL,"""Repeated Measures;Non-dominant wrist-worn actigraph to be worn 24/7 (Spectrum Plus);Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark]""","""Self-Care Inventory Revised (15-item);10-Minute Psychomotor Vigilance Test on a PVT-192 device;Paper-based Trail Making Test parts A and B (Executive Function);PROMIS v1.0 (8-item general distress-depression);Diabetes Distress Scale (17-item);Diabetes Symptom Checklist Revised (34-item)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04471844,"""26 September 2023""","""TRIDENT EF-32""","""Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM""","""EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma""","""https://clinicaltrials.gov/ct2/show/NCT04471844""",""" ""","""Doron Manzur, MD""",NULL,"""clinicaltrials@novocure.com""","""+1 603 206 2337""","""""",""" ""","""Doron Manzur, MD""",NULL,"""clinicaltrials@novocure.com""","""+1 603 206 2337""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""N/A""","""9/7/2020""","""December 8, 2020""","""950""","""Recruiting""","""NovoCure GmbH""",NULL,"""Please refer to primary and secondary sponsors""","""United States;Austria;Belgium;Canada;Czechia;France;Germany;Israel;Japan;Switzerland;United Kingdom;Austria;Belgium;Canada;Czechia;France;Germany;Israel;Japan;Switzerland;United Kingdom;United States;Australia""","""Glioblastoma Multiforme""","""Device: Optune®""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Histologically confirmed diagnosis of GBM according to WHO classification criteria.<br><br>          2. Age = 22 years in US and Age = 18 years in Ex-US<br><br>          3. Recovered from maximal debulking surgery, if applicable (gross total resection,<br>             partial resection, and biopsy-only patients are all acceptable)<br><br>          4. Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2<br>             daily x 5 d, q28 days)<br><br>          5. Karnofsky performance status = 70<br><br>          6. Life expectancy = least 3 months<br><br>          7. Participants of childbearing age must use highly effective contraception. An effective<br>             method of birth control is defined as one that results in a failure rate of less than<br>             1% per year when used consistently and correctly. The Investigator must approve the<br>             selected method, and may consult with a gynecologist as needed.<br><br>          8. All patients must understand and voluntarily sign an informed consent document prior<br>             to any study related assessments/procedures being conducted.<br><br>          9. Stable or decreasing dose of corticosteroids for the last 7 days prior to<br>             randomization, if applicable.<br><br>         10. Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery<br><br>         11. Women of childbearing potential must have a negative ß-HCG pregnancy test documented<br>             within 14 days prior to registration<br><br>         12. Is able to have MRI with contrast of the brain<br><br>        Exclusion Criteria:<br><br>          1. Progressive disease (per investigator's assessment)<br><br>          2. Infratentorial or leptomeningeal disease<br><br>          3. Participation in another clinical treatment study during the pre-treatment and/or the<br>             treatment phase of the study<br><br>          4. Pregnancy or breast-feeding.<br><br>          5. Significant co-morbidities at baseline which would preclude maintenance RT or TMZ<br>             treatment, as determined by the investigator:<br><br>               1. Thrombocytopenia (platelet count < 100 x 103/µL)<br><br>               2. Neutropenia (absolute neutrophil count < 1.5 x 103/µL)<br><br>               3. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)<br><br>               4. Significant liver function impairment - AST or ALT > 3 times the upper limit of<br>                  normal<br><br>               5. Total bilirubin > 1.5 x upper limit of normal<br><br>               6. Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)<br><br>               7. History of any psychiatric condition that might impair patient's ability to<br>                  understand or comply with the requirements of the study or to provide consent<br><br>          6. Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic<br>             devices in the brain, or documented clinically significant arrhythmias.<br><br>          7. Evidence of increased intracranial pressure (midline shift > 5mm, clinically<br>             significant papilledema, vomiting and nausea or reduced level of consciousness)<br><br>          8. History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.<br><br>          9. Any other cytotoxic or biologic anti-tumor therapy received prior to enrollment will<br>             be considered exclusion.<br><br>         10. Admitted to an institution by administrative or court order.<br><br>         11. Known allergies to medical adhesives or hydrogel<br><br>         12. A skull defect (such as, missing bone with no replacement)<br><br>         13. Prior radiation treatment to the brain for the treatment of GBM<br><br>         14. Any serious surgical/post-operative condition that may risk the patient according to<br>             the investigator<br><br>         15. Standard TTFields exclusion criteria include<br><br>               1. Active implanted medical devices<br><br>               2. Bullet fragments<br><br>               3. Skull defects<br>      """,NULL,"""Overall Survival (OS)""","""Progression Free Survival (PFS);1- and 2-year survival rates;Overall Radiological response (ORR);Next progression-free survival (PFS2);Progression-free survival at 6 (PFS6) and 12 months (PFS12);Severity and frequency of adverse events;Pathological changes in resected GBM tumors following study treatments;Quality of Life EORTC Questionnaire;Dependence of overall survival on TTFields dose at the tumor;The NANO scale""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04475029,"""26 September 2023""","""2019-004581-18;004581""","""Methadone in Cystectomy Patients""","""Clinical Effectiveness and Safety of Intraoperative Methadone in Patients""","""https://clinicaltrials.gov/ct2/show/NCT04475029""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""N/A""","""9/7/2020""","""July 6, 2020""","""114""","""Completed""","""University of Aarhus""",NULL,"""Please refer to primary and secondary sponsors""","""Denmark""","""Pain, Postoperative;Postoperative Complications;Pathologic Processes;Bladder Cancer;Pain;Signs and Symptoms;Neurologic Manifestations;Neurologic Symptoms;Side Effect of Drug""","""Drug: Methadone;Drug: Morphine""","""18 Years""","""110 Years""","""All""","""<br>        Inclusion Criteria:<br><br>        - All patients (=18 years) scheduled for elective robot assisted cystectomy.<br><br>        Exclusion Criteria:<br><br>          -  American Society of Anesthesiologists (ASA) physical status IV or V<br><br>          -  Prolonged QTc-interval assessed by electrocardiogram (> 440 milliseconds)<br><br>          -  Existing treatment with a high risk of QTc-interval prolongation<br><br>          -  Allergy to study drugs<br><br>          -  Preoperative daily use of opioids<br><br>          -  Inability to provide informed consent<br><br>          -  Severe respiratory insufficiency (oxygen treatment at home)<br><br>          -  Heart failure (ejection fraction < 30%)<br><br>          -  Acute abdominal pain<br><br>          -  Signs of severe liver dysfunction (cirrhosis, inflammation/hepatitis or liver<br>             malignancy)<br><br>          -  Severe kidney insufficiency (estimated Glomerular Filtration Rate < 30 ml/min)<br><br>          -  Treatment with rifampicin<br><br>          -  Phaeochromocytoma<br><br>          -  Treatment with MAO-inhibitor during the last 14 days<br><br>          -  Pregnancy<br><br>          -  Nursing mothers<br><br>          -  Intraoperative conversion to open surgery (secondary inclusion criterion)<br><br>          -  Epidural analgesia in relation to surgical procedure<br>      """,NULL,"""Opioid consumption (morphine mg equivalents);Opioid consumption (morphine mg equivalents)""","""Pain intensity;Opioid consumption (morphine mg equivalents);PONV;Level of sedation;Adverse events;Patient satisfaction from 0-10.;Discharge""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04523493,"""26 September 2023""","""JS001-027-III-HCC""","""Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC""","""A Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study to Compare Toripalimab Combined With Lenvatinib Versus Placebo Combined With Lenvatinib as the 1st-line Therapy for Advanced HCC""","""https://clinicaltrials.gov/ct2/show/NCT04523493""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Interventional""","""Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 3""","""9/7/2020""","""June 29, 2020""","""530""","""Active, not recruiting""","""Shanghai Junshi Bioscience Co., Ltd.""",NULL,"""Please refer to primary and secondary sponsors""","""United States;China;Italy;Poland;Singapore;Ukraine;China;Italy;Poland;Singapore;Ukraine;United States""","""Advanced Hepatocellular Carcinoma (HCC)""","""Combination Product: Toripalimab combined with Lenvatinib;Combination Product: Placebo combined with Lenvatinib""","""18 Years""","""75 Years""","""All""","""<br>        Inclusion criteria:<br><br>          1. Age of 18-75 full years (inclusive), male or female.<br><br>          2. Histopathologically or cytologically confirmed HCC or participants with liver<br>             cirrhosis meet the clinical diagnostic criteria for HCC of the American Association<br>             for the Study of Liver Diseases (AASLD).<br><br>          3. Stage B (intermediate stage) or C (advanced stage) HCC determined in accordance with<br>             Barcelona Clinic Liver Cancer staging system (BCLC stage), be unsuitable for surgery<br>             and/or local therapy, or have progression of disease after surgery and/or local<br>             therapy.<br><br>          4. No previous use of any systemic therapy for HCC (mainly including systemic<br>             chemotherapy, antiangiogenic drugs or other molecular targeted therapy, immunotherapy<br>             containing CTLA-4, PD 1/PD-L1 monoclonal antibody).<br><br>          5. Having = 1 measurable lesion in accordance with RECIST v1.1. Requirement: the selected<br>             target lesion has not been treated locally before, or is located in the area of<br>             previous local therapy and subsequently determined as PD through radiological<br>             examination and in accordance with RECIST v1.1.<br><br>          6. Child-Pugh class A or =7 class B, with no history of hepatic encephalopathy.<br><br>          7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0-1.<br><br>          8. Expected survival =12 weeks.<br><br>          9. Main organ function meets the following requirements: no blood transfusion within 14<br>             days prior to screening, no use of hematopoietic stimulating factor (including G-CSF,<br>             GM-CSF, EPO and TPO etc.) or human albumin preparation.<br><br>         10. In case of HBsAg (+) and/or HBcAb (+), HBV DNA is required to be < 1000 IU/mL (if the<br>             lowest detectable value at the local center is higher than 1000IU/mL, enrollment can<br>             be determined based on the specific condition after discussed with sponsor), and it is<br>             required to continue original anti-HBV therapy in the full course, or start to use<br>             Entecavir or tenofovir in the full course after screening during the study.<br><br>         11. Female patients at childbearing age must receive serum pregnancy test within 7 days<br>             before randomization, have negative result, and are willing to use reliable and<br>             effective contraceptive methods during the trial and within 60 days after last<br>             administration. Male patients whose partners are women of childbearing potential must<br>             agree to use reliable and effective contraceptive methods during the trial and within<br>             60 days after last administration.<br><br>         12. Being voluntary to participate in the study, sufficiently informed consent and sign<br>             the written informed consent form, with good compliance.<br><br>        Exclusion criteria:<br><br>          1. Known cholangiocellular carcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid<br>             hepatocellular carcinoma and hepatic fibrolamellar carcinoma.<br><br>          2. Malignant tumor except HCC within 5 years: however, localized tumor cured in the study<br>             is excluded,including cervical carcinoma in situ, skin basal cell carcinoma and<br>             carcinoma in situ of prostate.<br><br>          3. Hepatic surgery and/or local therapy or treatment with investigational product for HCC<br>             within 4 weeks prior to randomization; palliative radiation therapy for bone<br>             metastatic lesion within 2 weeks prior to randomization; use of Chinese medicine<br>             preparations with anti-liver cancer effect within two weeks prior to randomization.<br>             Toxicity induced by previous therapy (except alopecia) not recovered to = grade 1<br>             (NCI-CTCAE v5.0).<br><br>          4. Prior use of other anti-PD-1 antibody or other immunotherapy targeting PD-1/PD-L1.<br><br>          5. Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious<br>             moderate or severe peritoneal effusion at screening, defined as reaching the following<br>             criteria: having clinical symptoms and pleural and peritoneal effusion detected in<br>             physical examination at screening; or puncture for drainage required for pleural and<br>             peritoneal effusion and/or intracavitary administration during screening.<br><br>          6. History of gastrointestinal hemorrhage within 6 months prior to randomization or clear<br>             tendency of gastrointestinal hemorrhage (including severe esophageal-gastric varices<br>             with hemorrhagic risk, locally active peptic ulcer, persistent fecal occult blood<br>             (+)).<br><br>          7. Having = grade 3 (NCI-CTCAE v5.0) gastrointestinal or non-gastrointestinal fistula at<br>             present.<br><br>          8. Cancer thrombus invasion in the main trunk of portal vein (Vp4) (more than 1/2 of the<br>             lumen), inferior vena cava cancer thrombus or cardiac involvement in accordance with<br>             CT/MRI.<br><br>          9. Serious cardiovascular and cerebrovascular diseases:<br><br>         10. Other obvious hemorrhagic tendency or evidence on important coagulation disorder:<br><br>         11. Medium to large surgical treatment within 4 weeks prior to randomization, not<br>             including diagnostic biopsy.<br><br>         12. Know central nervous system metastasis; cranial and/or spinal MRI is needed for<br>             exclusion if central nervous system metastasis is suspected.<br><br>         13. Serious, uncured wound, active ulcer or untreated bone fracture.<br><br>         14. Vaccination of live vaccine within 30 days prior to randomization.<br><br>         15. Presence of immunodeficiency or receiving long-term systemic steroid therapy within 7<br>             days prior to randomization (daily dose >10mg Prednisone or other equivalent<br>             glucocorticoid), or other immunosuppressive therapy.<br><br>         16. Active autoimmune diseases requiring systemic treatment (i.e., immunomodulatory drug,<br>             corticosteroid or immunosuppressant) in the past two years; however, replacement<br>             therapy (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy<br>             for renal or pituitary insufficiency) will not be considered as systemic therapy and<br>             is allowed to be used.<br><br>         17. History of clear interstitial lung disease or non-infectious pneumonia, unless induced<br>             by local radiotherapy.<br><br>         18. Active tuberculosis or received antituberculosis therapy within 1 year prior to<br>             randomization.<br><br>         19. Any serious acute and chronic infection requiring systemic antibacterial, antifungal<br>             or antiviral therapy at screening, not including viral hepatitis.<br><br>         20. Known history of human immunodeficiency virus (HIV) infection.<br><br>         21. Previously receiving allogeneic stem cell or solid organ transplantation.<br><br>         22. Inability to swallow tablets, malabsorption syndrome or any other condition that<br>             affects gastrointestinal absorption.<br><br>         23. Known history of serious allergy to any monoclonal antibody, anti-angiogenesis drug.<br><br>         24. Other participants who are unsuitable for inclusion as judged by the investigator.<br>      """,NULL,"""Overall survival (OS)""","""ORR;Duration of Response (DOR);DCR;TTP;Progression-free survival (PFS);PFS rate;OS rate;Incidence,severity and prognosis of AEs/SAEs as assessed by NCI-CTCAE v5.0;PK;Immunogenicity""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04015622,"""26 September 2023""","""PROTRACT""","""PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA""","""A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone""","""https://clinicaltrials.gov/ct2/show/NCT04015622""",""" ; ""","""Kim N Chi, MD;Kim N Chi, MD""",NULL,""";kchi@bccancer.bc.ca""",""";6048776000""","""British Columbia Cancer Agency;""",""" ; ""","""Kim N Chi, MD;Kim N Chi, MD""",NULL,""";kchi@bccancer.bc.ca""",""";6048776000""","""British Columbia Cancer Agency;""","""Interventional""","""Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2""","""9/7/2019""","""October 7, 2020""","""100""","""Recruiting""","""British Columbia Cancer Agency""",NULL,"""Please refer to primary and secondary sponsors""","""Canada""","""Metastatic Castration-Resistant Prostate Cancer (mCRPC)""","""Drug: Enzalutamide;Drug: Docetaxel""","""18 Years""","""N/A""","""Male""","""<br>        INCLUSION CRITERIA<br><br>        Patients must meet ALL of the following criteria:<br><br>          1. Willing and able to provide informed consent<br><br>          2. Adult males = 18 years age<br><br>          3. History of histologically confirmed adenocarcinoma of the prostate without evidence of<br>             neuroendocrine or small cell differentiation. If histology is not available, patients<br>             must have metastatic disease typical of prostate cancer (i.e., involving bone or<br>             pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA that<br>             is rising and >20ng/mL at the time prostate cancer was diagnosed clinically<br><br>          4. Consent to analysis of archival tissue collected at diagnosis is mandatory<br><br>          5. Prior surgical orchiectomy or if on LHRH agonist/antagonist then testosterone < 1.7<br>             nmol/L at screening visit (patients must maintain LHRH agonist/antagonist therapy for<br>             duration of study treatment if not surgically castrated)<br><br>          6. Evidence of metastatic disease on bone scan or CT scan<br><br>          7. Evidence of biochemical or imaging progression in the setting of surgical or medical<br>             castration while on abiraterone. Progressive disease for study entry is defined by one<br>             of the following three criteria as per PCWG317:<br><br>               1. PSA progression: minimum of two rising PSA values from a baseline measurement of<br>                  one week interval. Minimum PSA at screening visit is 1.0 ng/mL<br><br>               2. Soft tissue or visceral disease progression: an increase =20% in the sum of the<br>                  diameter (short axis for nodal lesions and long axis for non-nodal lesions) from<br>                  the smallest sum of the diameter since treatment started, or appearance of any<br>                  new lesions (see Appendix B for definition of measurable disease as per RECIST<br>                  1.1 criteria).<br><br>               3. Bone progression: = 2 new lesions on bone scan confirmed on subsequent bone scan<br>                  at least 8 weeks apart (2+2 rule as per PCWG317)<br><br>          8. ECOG performance status 0-2 (see Appendix C)<br><br>          9. Prior treatment with abiraterone, in either castration-sensitive or<br>             castration-resistant setting.<br><br>         10. Eligible for treatment with either enzalutamide or docetaxel as per standard of care<br>             guidelines<br><br>         11. Adequate organ function defined as:<br><br>               1. Absolute neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L and<br>                  hemoglobin = 90 g/L<br><br>               2. Creatinine clearance = 30 ml/min (calculated by Cockcroft-Gault formula, see<br>                  Appendix D)<br><br>               3. Total bilirubin = 1.5 x upper limit of normal (ULN) except for patients with<br>                  known Gilbert's syndrome (direct bilirubin = 1.5 x ULN)<br><br>               4. Alanine aminotransferase (ALT) = 5 x ULN<br><br>         12. Able to swallow study drug and comply with study requirements including provision of<br>             peripheral blood samples at specified time points for correlative studies<br><br>         13. Recovery from all prior treatment-related toxicity to grade = 2 (as per CTCAE 5.0)<br><br>        EXCLUSION CRITERIA<br><br>        Patients must NOT meet any of the following criteria:<br><br>          1. Severe concurrent illness or co-morbid disease that would make the subject unsuitable<br>             for enrolment<br><br>          2. Prior therapy with enzalutamide or other experimental anti-androgens (e.g. ARN-509,<br>             TOK-001)<br><br>          3. Prior systemic chemotherapy with docetaxel or cabazitaxel (with the exception of:<br>             patients who were treated with docetaxel for castration sensitive disease and did not<br>             progress for at least 12 months after completion of docetaxel)<br><br>          4. Active concurrent malignancy (with the exception of non-melanomatous skin cancer, or<br>             other solid tumours curatively treated with no evidence of disease for =3 years)<br><br>          5. Wide-field radiotherapy or radioisotopes such as Strontium-89, or Radium-223 = 28 days<br>             prior to starting study drug (limited-field palliative radiotherapy for up to 5<br>             fractions prior to starting study drug is permitted)<br><br>          6. Brain metastases or active epidural disease (treated epidural disease is permitted)<br><br>          7. Contraindication to prednisone therapy including poorly controlled diabetes mellitus<br><br>          8. History of seizure or seizure disorder, or history of any cerebrovascular event within<br>             6 months of study entry.<br><br>          9. Uncontrolled hypertension Grade =3 (i.e. systolic blood pressure =160 mmHg or<br>             diastolic blood pressure =100 mmHg)<br><br>         10. Gastrointestinal disorder affecting absorption<br><br>         11. Major surgery within 4 weeks of starting study treatment<br>      """,NULL,"""Progression free survival (PFS)""","""Objective response;PSA response rate;Second progression free survival (PFS2);Overall survival (OS);Clinical benefit rate (CBR);Correlation of specific ctDNA-based genomic alterations to treatment response""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04017793,"""26 September 2023""","""IRB # STUDY00007227""","""Mindfulness-Associated Brain Changes in Adults With Autism""","""The Neural Changes Associated With a Mindfulness Intervention for Adults With Autism Spectrum Disorder""","""https://clinicaltrials.gov/ct2/show/NCT04017793""",""" ""","""Brittany B Braden, PhD""",NULL,"""""","""""","""Assistant Professor; Autism and Brain Aging Laboratory Director""",""" ""","""Brittany B Braden, PhD""",NULL,"""""","""""","""Assistant Professor; Autism and Brain Aging Laboratory Director""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). ""","""N/A""","""9/7/2019""","""May 6, 2019""","""108""","""Active, not recruiting""","""Arizona State University""","""Southwest Autism Research and Resource Center (SARRC);Banner Alzheimer's Institute""","""Please refer to primary and secondary sponsors""","""United States""","""Autism Spectrum Disorder""","""Behavioral: Mindfulness Based Stress Reduction;Behavioral: Relaxation Group""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Age 18 to 89 years old, with a special focus on adults with ASD who are going to<br>             college given the additional stress of this phase in life. We are recruiting<br>             participants across a broad age range in order to maximize our ability to inform<br>             interventions for adults with ASD. The upper age limit of 89 years was selected so a<br>             de-identified dataset can be created with all participant ages included.<br><br>          -  ASD diagnosis via gold-standard diagnostic assessments (Autism Diagnostic Observation<br>             Schedule-2).<br><br>          -  Must be able to attend at least 7 of the 8 weekly intervention classes.<br><br>          -  English speaking: Participants must be English-speaking because the screening and<br>             behavioral measures are in English (including the intelligence estimate).<br><br>        Exclusion Criteria:<br><br>          -  Participants with Intelligence Quotient (IQ) scores <70 will be excluded to minimize<br>             variability due to general cognitive functioning.<br><br>          -  Report of any major medical illnesses, histories of seizures, or head trauma with loss<br>             of consciousness. These health factors can cause brain changes that would confound<br>             findings.<br><br>          -  Concerns that the participant may not be able to complete the MRI neuroimaging<br>             requirements for the study, including claustrophobia or metal objects within the<br>             participant's body or eyes. Implanted metal objects may create a safety hazard in the<br>             powerful magnetic field during MRI imaging.<br><br>          -  Pregnant women. MRI has no known effects on pregnancy or fertility. However, since we<br>             are not 100% certain MRI has no effects on a developing fetus, women who are pregnant<br>             may not participate in this study.<br>      """,NULL,"""Beck Depression Inventory - II;Beck Depression Inventory - 2;State-Trait Anxiety Inventory;State-Trait Anxiety Inventory""","""World Health Organization Quality of Life""","""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03213730,"""26 September 2023""","""13-146-PED""","""Perceptual-Cognitive Training After a Mild Traumatic Brain Injury: Towards a Sensitive Marker for Recovery""","""Perceptual-Cognitive Training After a Mild Traumatic Brain Injury: Towards a Sensitive Marker for Recovery""","""https://clinicaltrials.gov/ct2/show/NCT03213730""",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ""","""N/A""","""9/7/2017""","""January 10, 2017""","""63""","""Completed""","""McGill University Health Centre/Research Institute of the McGill University Health Centre""","""Merck Sharp & Dohme LLC""","""Please refer to primary and secondary sponsors""","""Canada""","""Brain Concussion;Post-Concussion Symptoms;Concussion""","""Other: 3D-MOT Neurotracker;Other: Visual Attention Intervention""","""6 Years""","""17 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  The child experienced a head injury (a direct or indirect blow to the head) resulting<br>             in concussion-like symptoms (e.g. headache, nausea, balance problems, tiredness,<br>             visual problems, cognitive issues) in the previous 72 hours<br><br>          -  Parent/legal guardian speak English or French<br><br>          -  The child speak English or French<br><br>        Exclusion Criteria:<br><br>          -  Previous concussion in the last 6 months, or any previous concussion with unresolved<br>             symptoms<br><br>          -  Multi-system injuries requiring admission, operating room, procedural sedation in the<br>             Emergency Department<br><br>          -  Other co-existing injuries, co-morbidities or diagnoses preventing participation to<br>             intervention/assessment of gait and balance<br><br>          -  Pre-morbid or co-morbid condition affecting visual function<br><br>          -  Patient intoxicated at the time of injury<br><br>          -  Significant developmental delay<br><br>          -  Loss of consciousness prior to head injury<br>      """,NULL,"""Post Concussion Symptom Inventory""",NULL,"""                                                  ""","""          """,NULL,NULL,1,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02830308,"""26 September 2023""","""16-DK-0125;160125""","""Evaluation of Adults With Endocrine and Metabolic-Related Conditions""","""Evaluation of Adults With Endocrine-Related Conditions""","""https://clinicaltrials.gov/ct2/show/NCT02830308""",""" ; ; ""","""Marissa F Lightbourne, M.D.;Marissa F Lightbourne, M.D.;For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)""",NULL,""";marissa.lightbourne@nih.gov;prpl@cc.nih.gov""",""";(301) 827-0033;800-411-1222""","""National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);""",""" ; ; ""","""Marissa F Lightbourne, M.D.;Marissa F Lightbourne, M.D.;For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)""",NULL,""";marissa.lightbourne@nih.gov;prpl@cc.nih.gov""",""";(301) 827-0033;800-411-1222""","""National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);""","""Observational""","""""","""""","""9/7/2016""","""July 9, 2016""","""1250""","""Recruiting""","""National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Endocrine Diseases""",NULL,"""18 Years""","""100 Years""","""All""","""<br>        -  INCLUSION CRITERIA:<br><br>          -  Participants with known or suspected endocrine disorder age 18 years and older are<br>             eligible for this protocol. Protocol investigators will make the actual selection of<br>             subjects most appropriate for clinical evaluation.<br><br>          -  Relatives ages 18 years and older may be enrolled if clinically indicated for the<br>             diagnosis of a proband.<br><br>        EXCLUSION CRITERIA:<br><br>          -  Anyone under the age of 18 years old<br><br>          -  Any medical, physical, psychiatric, or social conditions, which, in the opinion of the<br>             investigators, would make participation in this protocol not in the best interest of<br>             the subject. Subjects who are critically ill, unstable, or with severe organ failure<br>             that may affect/limit the endocrine evaluation and place unsustainable demands on<br>             Clinical Center or NIDDK resources.<br>      """,NULL,"""Recruit a diverse population of adult subjects with a known or suspected endocrine or metabolic disorder in order to provide NIDDK investigators and trainees with hands-on experience related to the diagnosis, management, treatment, and follow-up...""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02496663,"""26 September 2023""","""NCI-2015-01053;PHI-77;9898;9898;UM1CA186717;NCI-2015-01053""","""Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor""","""A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor""","""https://clinicaltrials.gov/ct2/show/NCT02496663""",""" ""","""Jonathan W Riess""",NULL,"""""","""""","""City of Hope Comprehensive Cancer Center LAO""",""" ""","""Jonathan W Riess""",NULL,"""""","""""","""City of Hope Comprehensive Cancer Center LAO""","""Interventional""","""Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/7/2015""","""May 11, 2016""","""138""","""Active, not recruiting""","""National Cancer Institute (NCI)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Metastatic Lung Non-Small Cell Carcinoma;Recurrent Lung Non-Small Cell Carcinoma;Stage IV Lung Cancer AJCC v8""","""Procedure: Magnetic Resonance Elastography;Biological: Necitumumab;Drug: Osimertinib;Procedure: Biospecimen Collection;Procedure: Computed Tomography""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Patients with stage IV or recurrent/metastatic histologically confirmed non-small cell<br>             lung cancer (NSCLC)<br><br>          -  NSCLC must harbor at least one of the following EGFR activating mutations: Exon 21<br>             L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q or for EGFR Exon 20 insertion<br>             expansion cohort D, NSCLC must harbor an EGFR Exon 20 insertion performed by a<br>             Clinical Laboratory Improvement Act (CLIA) certified test<br><br>          -  For Dose escalation cohort - progressive disease on at least one prior EGFR-TKI<br>             (previous treatment with 3rd generation EGFR-TKI including osimertinib (AZD9291)<br>             allowed for dose escalation)<br><br>          -  For Dose Expansion Cohort A: patient must 1) have progression of disease on erlotinib,<br>             gefitinib or afatinib as last previous systemic treatment, 2) have biopsy of tumor<br>             taken after progression on erlotinib, gefitinib or afatinib which must be EGFR-T790M<br>             negative confirmed by central testing prior to treatment (if EGFR-T790M status is<br>             unknown, patients may consent for trial and for biopsy and testing for EGFR T790M will<br>             be performed as part of initial biopsy for trial), and 3) be treatment naive to 3rd<br>             generation EGFR-TKI (rociletinib, EGFR inhibitor HM61713 [HM61713] and osimertinib<br>             [AZD9291]) and EGFR monoclonal antibodies<br><br>          -  For Dose Expansion Cohort B (closed to accrual as of 8/30/18): patient must 1) have<br>             progression of disease on a 3rd generation EGFR-TKI such as AZD9291, rociletinib,<br>             HM61713, 2) be treatment naive to an EGFR monoclonal antibody, and 3) have a biopsy of<br>             tumor taken after progression on last EGFR-TKI that indicates loss of EGFR-T790M<br>             (EGFR-T790M negative) confirmed by central testing prior to treatment (if EGFR-T790M<br>             status is unknown, patients may consent for trial and for biopsy, and testing for EGFR<br>             T790M will be performed as part of initial biopsy for trial)<br><br>          -  For Dose Expansion Cohort C: patient must 1) have progression of disease on a 3rd<br>             generation EGFR-TKI such as osimertinib (AZD9291), rociletinib, HM61713, 2) be<br>             treatment naive to an EGFR monoclonal antibody, 3) have a biopsy of tumor taken after<br>             progression on last EGFR-TKI that indicates preservation of EGFR-T790M<br>             post-progression on 3rd generation EGFR-TKI with biopsy confirmation by central<br>             testing prior to treatment (if EGFR-T790M status is unknown, patients may consent for<br>             trial and for biopsy, and testing for EGFR T790M will be performed as part of initial<br>             biopsy for trial)<br><br>          -  For Dose Expansion Cohort D: patient must 1) tumor that harbors an EGFR Exon 20<br>             insertion by a CLIA certified test, and 2) have progressive disease on or after<br>             platinum based chemotherapy, and 3) be treatment naïve to 3rd generation and beyond<br>             EGFR-TKI (i.e., osimertinib [AZD9291], poziotinib, TAK-778) and EGFR monoclonal<br>             antibody; patient who received 1st or 2nd generation EGFR-TKI (such as erlotinib,<br>             gefitinib, afatinib) are eligible provided that they did not achieve a response to<br>             treatment or they did not have a duration of treatment on EGFR-TKI of 6 months or more<br><br>          -  For Dose Expansion Cohort E: patient must have progressive disease on osimertinib<br>             (AZD9291) as first-line EGFR-TKI treatment for metastatic NSCLC; patients must also be<br>             treatment naive to EGFR-monoclonal antibody<br><br>          -  Adequate archival tissue from a biopsy performed after progression of disease on<br>             previous EGFR-TKI or willing to consent for a fresh tumor biopsy; (mandatory for<br>             Cohorts A, B, C; optional for dose escalation and Cohort D, and Cohort E)<br><br>          -  Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors<br>             (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at<br>             least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic<br>             resonance imaging (MRI) within 42 days prior to registration; the CT from a combined<br>             positron emission tomography (PET)/CT may be used only if it is of diagnostic;<br>             laboratory parameters are not acceptable as the only evidence of disease<br><br>          -  Any number of prior therapies is allowed<br><br>          -  Age >= 18 years. NSCLC is exceedingly rare in patients < 18 years of age. Because no<br>             dosing or adverse event data are currently available on the use of and necitumumab in<br>             patients < 18 years of age, children are excluded from this study<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1<br><br>          -  Patients must have the ability to swallow tablets<br><br>          -  Life expectancy of greater 3 months<br><br>          -  Absolute neutrophil count >= 1,500/mcL<br><br>          -  Platelets >= 100,000/mcL<br><br>          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (patients with Gilbert's syndrome<br>             may have serum bilirubin > 1.5 ULN)<br><br>          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase<br>             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])<br>             =< 3.0 x institutional upper limit of normal<br><br>          -  Creatinine =< 1.5 x ULN OR<br><br>          -  Creatinine clearance >= 50 mL/min<br><br>          -  The effects of osimertinib (AZD9291) and necitumumab on the developing human fetus are<br>             unknown; for this reason, women of child-bearing potential and men must agree to use<br>             adequate contraception using one of the methods listed below prior to study entry, for<br>             the duration of study participation, and for 3 months for women and 6 months for men<br>             following the date of the last dose of osimertinib (AZD9291) and/or necitumumab:<br><br>               -  Total abstinence from sexual intercourse (minimum one complete menstrual cycle<br>                  prior to study drug administration);<br><br>               -  Vasectomized male subject or vasectomized partner of female subjects<br><br>               -  Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) prior to<br>                  study drug administration; if the subject is currently using a hormonal<br>                  contraceptive, she should also use a barrier method during this study and for 3<br>                  months after study completion;<br><br>               -  Intrauterine device (IUD);<br><br>               -  Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide<br>                  (contraceptive sponge, jellies or creams)<br><br>               -  Additionally, for all methods above (except for abstinence), male subjects<br>                  (including those who are vasectomized) whose partners are pregnant or might be<br>                  pregnant must use condoms for the duration of the study and for 6 months<br>                  following completion of therapy<br><br>          -  Women of childbearing potential must have a negative urine pregnancy test within 7<br>             days prior to initiation of treatment; women will be considered not of childbearing<br>            """,NULL,"""Maximum tolerated dose (MTD) of necitumumab combined with osimertinib;Incidence of toxicity""","""Objective response rate (ORR) in patients treated at the recommended phase II dose;Progression-free survival (PFS);Disease control rate (DCR) with combination osimertinib and necitumumab""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT00936325,"""26 September 2023""","""09-I-0184;090184""","""Studies in the Pathogenesis of Systemic Capillary Leak Syndrome""","""Studies in the Pathogenesis of Systemic Capillary Leak Syndrome""","""https://clinicaltrials.gov/ct2/show/NCT00936325""",""" ; ""","""Kirk M Druey, M.D.;Hye Jeong C Bolan, R.N.""",NULL,""";bolanhy@mail.nih.gov""",""";(301) 594-1233""","""National Institute of Allergy and Infectious Diseases (NIAID);""",""" ; ""","""Kirk M Druey, M.D.;Hye Jeong C Bolan, R.N.""",NULL,""";bolanhy@mail.nih.gov""",""";(301) 594-1233""","""National Institute of Allergy and Infectious Diseases (NIAID);""","""Observational""","""""","""""","""9/7/2009""","""August 24, 2009""","""270""","""Recruiting""","""National Institute of Allergy and Infectious Diseases (NIAID)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Systemic Capillary Leak Syndrome""",NULL,"""N/A""","""N/A""","""All""","""<br>        -  PARTICIPANT INCLUSION CRITERIA:<br><br>        Subjects with SCLS under 8 years of age are only eligible for components of this protocol<br>        that can occur Off Site and samples can be sent to the NIH. All SCLS subjects must be at<br>        least 8 years old to participate in any other aspects of this protocol at the NIH.<br><br>        Subjects with SCLS may enter study while pregnant and remain on study after becoming<br>        pregnant. At the discretion of the investigator, some components of this protocol will not<br>        occur while subject is pregnant.<br><br>        Diagnosis or suspected diagnosis of Systemic Capillary Leak Syndrome by a physician or<br>        documented history of capillary leak as characterized by one or more of the following:<br><br>          1. Hypotension (systolic blood pressure typically less than 90 mm Hg or diastolic blood<br>             pressure less than 60 mm Hg) or associated symptoms of hypotension (e.g., hypotonia<br>             [collapse], lightheadedness or syncope, incontinence, increased thirst)<br><br>          2. Laboratory evidence of hemoconcentration (e.g., hemoglobin levels above the normal<br>             range [typically greater than17 g/dL], elevated leukocyte counts).<br><br>          3. Clinical evidence of fluid extravasation (e.g. edema) and/or laboratory evidence of<br>             protein extravasation such as serum hypoalbuminemia (less than 3.5 g/dL) either<br>             chronically or during an acute hypotensive episode.<br><br>             Letter of referral, with copies of pertinent medical history and laboratory studies,<br>             from prospective study subject s referring physician. Patients may self-refer, but a<br>             letter of referral from primary physician is still required.<br><br>             Willing to donate blood for sample storage to be used for future research.<br><br>             PARTICIPANT INCLUSION CRITERIA FOR THE SUBJECT'S RELATIVES/HEALTHY VOLUNTEERS:<br><br>             Willing to donate blood for sample storage to be used for future research.<br><br>             Relatives must be at least 3 years old.<br><br>             Healthy volunteers must be at least 18 years old.<br><br>             Relatives may be pregnant or become pregnant while participating in this protocol. At<br>             the discretion of the investigator, some components of this protocol will not occur<br>             while subject is pregnant. No skin biopsies or intradermal testing will be done on<br>             pregnant relatives. Bloodwork volumes may be decreased at the discretion of the<br>             investigator.<br><br>             Healthy volunteers may not be pregnant.<br><br>             Able to give informed consent.<br><br>             PARTICIPANT EXCLUSION CRITERIA:<br><br>             Presence of conditions which, in the judgment of the investigator or the referring<br>             physician, may put the subject at undue risk for travel (including frequent episodes<br>             of severe capillary leak, symptoms not preventable by pre-medication, acute infection,<br>             severe thrombocytopenia [minimum platelet count of 30,000/(proportionaly)L], or<br>             significant cardiovascular disease)<br><br>             Any condition that in the view of the principal investigator would make the subject<br>             unsuitable for enrollment in this study, (i.e. medically unstable, unable to provide<br>             phlebotomy samples).<br><br>             There is an identified cause for hypotensive episodes and/or tissue swelling.<br><br>             PARTICIPANT EXCLUSION CRITERIA FOR THE SUBJECT'S RELATIVES/HEALTHY VOLUNTEERS:<br><br>             Presence of conditions which in the judgment of the investigator or the referring<br>             physician may put the subject at undue risk (i.e. medically unstable, unable to<br>             provide phlebotomy samples).<br><br>             Any condition that in the view of the principal investigator would make the subject<br>             unsuitable for enrollment in this study (i.e. medically unstable, unable to provide<br>             phlebotomy samples).<br>      """,NULL,"""Identify potential causative factors and to explore genetic and/or cellular abnormalities that correlate with clinical features of SCLS.""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05944302,"""26 September 2023""","""MesinU""","""Effect of Eye Movement Desensitization and Reprocessing (EMDR) on Pain in Patients With in Patients Rheumatoid Arthritis""","""Effect of Eye Movement Desensitization and Reprocessing (EMDR) on Pain in Patients With in Patients Rheumatoid Arthritis""","""https://clinicaltrials.gov/ct2/show/NCT05944302""",""" ; ; ""","""serpil yilmaz;mualla yilmaz;müjde moran""",NULL,""";;mujdemoran@mersin.edu.tr""",""";;+905055774978""","""Mersin University;Mersin University;""",""" ; ; ""","""serpil yilmaz;mualla yilmaz;müjde moran""",NULL,""";;mujdemoran@mersin.edu.tr""",""";;+905055774978""","""Mersin University;Mersin University;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). ""","""N/A""","""9/6/2023""","""July 13, 2023""","""64""","""Recruiting""","""Mersin University""",NULL,"""Please refer to primary and secondary sponsors""","""Turkey""","""Therapeutics""","""Behavioral: EMDR group""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Under 18 years of age,<br><br>          -  Receiving another psychosocial therapy on working dates,<br><br>          -  Those who do not agree to participate in the research,<br><br>          -  Pregnancy,<br><br>          -  VAS pain score less than 4,<br><br>          -  Using analgesic medication at least 4 hours ago,<br><br>          -  Having a physical/mental disability or disability and illness that would prevent them<br>             from participating in EMDR,<br><br>        Exclusion Criteria:<br><br>          -  Who cannot complete the EMDR application for any reason (health problem, not being<br>             able to spare time)<br><br>          -  Patients who want to leave the study voluntarily will be excluded from the follow-up.<br>      """,NULL,"""visual analog scale (vas)""","""Personal Information Form""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05945641,"""26 September 2023""","""H23-01009""","""Effect of Low-load Resistance Training vs. High-intensity Interval Training on Local Muscle Endurance""","""The Effect of Low-Load Resistance Training Versus High-intensity/Sprint Interval Training on Local Muscle Endurance, Mitochondrial Content, Mitochondrial Function, and Muscle Capillarization""","""https://clinicaltrials.gov/ct2/show/NCT05945641""",""" ""","""Lucas A Wiens, BSc""",NULL,"""wiensl55@student.ubc.ca""","""7788377665""","""""",""" ""","""Lucas A Wiens, BSc""",NULL,"""wiensl55@student.ubc.ca""","""7788377665""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ""","""N/A""","""9/6/2023""","""September 2023""","""20""","""Not yet recruiting""","""University of British Columbia""",NULL,"""Please refer to primary and secondary sponsors""",NULL,"""Hypertrophy;Muscle Strength;High-Intensity Interval Training;Resistance Training""","""Behavioral: Low Load Resistance training;Behavioral: Sprint/High Intensity Interval Training""","""19 Years""","""30 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          1. Able to understand and communicate in English<br><br>          2. 19-30 years of age<br><br>          3. All No answers on the CSEP Get Active questionnaire or doctors' approval to<br>             participate<br><br>          4. Untrained participants: no structured resistance and/or endurance training over the<br>             past 12-months (i.e., >2 hours per week of structured/periodized training)<br><br>        Exclusion Criteria:<br><br>          1. BMI lower than 18 or greater than 30<br><br>          2. Current use of cigarettes or other nicotine devices<br><br>          3. Any major uncontrolled cardiovascular, muscular, metabolic, and/or neurological<br>             disorders<br><br>          4. Any medical condition impacting the ability to participate in maximal exercise<br><br>          5. Type one or type two diabetes<br><br>          6. Diagnosis of cancer or undergoing cancer treatment in the past 12 months<br><br>          7. Taking blood-thinning medication or the presence of a bleeding disorder<br><br>          8. Drug therapy with any drugs that alter skeletal muscle metabolism (i.e., Metformin,<br>             Benzodiazepines)<br>      """,NULL,"""Change in repetitions completed for 30% pre-training 1- Repetition maximum (Single leg Knee extension);Change in Repetitions completed for 30% pre-training 1- Repetition maximum (Single leg Knee extension);Change in CFPE index (Capillary to fiber ratio normalized to fiber perimeter);Change in Maximal Citrate synthase (CS) Activity""","""Change in Single leg Knee extension 1- Repetition maximum (weight lifted);Change in Single leg Knee extension 1- Repetition maximum (weight lifted);Change in Single leg Knee extension Isometric Maximum Voluntary Contraction;Change in Single leg Knee extension Isometric Maximum Voluntary Contraction;Change in Single leg Knee Flexion Isometric Maximum Voluntary Contraction;Change in Single leg Knee Flexion Isometric Maximum Voluntary Contraction;Change in Single leg Knee Flexion Isokentic Maximum Voluntary Contraction;Change in Single leg Knee Flexion Isokentic Maximum Voluntary Contraction;Change in Single leg Knee Extension Isokentic Maximum Voluntary Contraction;Change in Single leg Knee Extension Isokentic Maximum Voluntary Contraction;Change in Single leg VO2 Peak on Kicking ergometer (ml/kg leg lean mass/min);Change in Single leg Wingate test on kicking ergometer (Max Power);Change in Single leg Wingate test on kicking ergometer (Max Power);Change in Leg lean mass;Change in Vastus Lateralis Cross sectional area (CSA);Change in Type I and II Fiber Cross sectional area (CSA);Change in Capillary to fiber ratio (C/FI)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05934253,"""26 September 2023""","""IZ-4-001""","""The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine""","""The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine: A Comparison vs Tetracaine 0.5% Solution.""","""https://clinicaltrials.gov/ct2/show/NCT05934253""",""" ; ""","""Richard Costine, PharmD;Michelle Fleshner""",NULL,"""rcostine@harrowinc.com;michelle_fleshner@yahoo.com""","""8505097474;""","""""",""" ; ""","""Richard Costine, PharmD;Michelle Fleshner""",NULL,"""rcostine@harrowinc.com;michelle_fleshner@yahoo.com""","""8505097474;""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor). ""","""Phase 4""","""9/6/2023""","""July 15, 2023""","""60""","""Recruiting""","""Harrow Inc""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Antiseptic;Anesthesia, Local""","""Drug: Chloroprocaine ophthalmic gel 3%""","""18 Years""","""99 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Patients over age 18.<br><br>          -  Able to comprehend and sign a statement of informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Ocular surgery (e.g., intraocular, oculoplastic, corneal, or refractive surgical<br>             procedure) performed within the last 3 months or at any time that in the<br>             investigator's clinical judgment if it would interfere with the outcome measures of<br>             this study.<br><br>          -  Clinically significant ocular trauma.<br><br>          -  Diagnosis of lagophthalmos, or other severe eyelid abnormalities (entropion,<br>             ectropion, tumor, edema, blepharospasm, severe trichiasis, severe ptosis.)<br><br>          -  Active ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis,<br>             conjunctivitis) at the discretion of the investigator.<br><br>          -  Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal<br>             infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids<br>             including hordeolum/stye).<br><br>          -  Ocular infection within the last 3 months.<br><br>          -  Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.<br><br>          -  Patients who are under age 18, pregnant or breastfeeding, or who may become pregnant<br>             during participation in the study.<br><br>          -  Monocular patients.<br>      """,NULL,"""Change in colony forming units""",NULL,"""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05938946,"""26 September 2023""","""PBI L608p1""","""Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults""","""A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects""","""https://clinicaltrials.gov/ct2/show/NCT05938946""",""" ; ""","""Pei Kan, PhD;Nicholas Farinola, MD""",NULL,"""peikan@pharmosa.com.tw;""","""886-2782-7561;""","""""",""" ; ""","""Pei Kan, PhD;Nicholas Farinola, MD""",NULL,"""peikan@pharmosa.com.tw;""","""886-2782-7561;""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ""","""Phase 1""","""9/6/2023""","""August 30, 2023""","""64""","""Recruiting""","""Pharmosa Biopharm Inc.""","""Novotech (Australia) Pty Limited""","""Please refer to primary and secondary sponsors""","""Australia""","""Pulmonary Arterial Hypertension""","""Drug: L608 Inhalation Solution;Drug: Placebo solution""","""18 Years""","""65 Years""","""All""","""<br>        Key Inclusion Criteria:<br><br>          1. Men and women aged between 18 and 65 (inclusive) at the time of Screening visit.<br>             Females must not be pregnant or lactating.<br><br>          2. Body Mass Index (BMI) of =18.5 and =30.0 kg/m2<br><br>          3. Non-smokers or former smokers who have smoked = 100 cigarettes in their lifetime and<br>             have not consumed any tobacco or tobacco-containing products for at least 3 months<br>             prior to Screening.<br><br>          4. Females must not be pregnant or lactating and must use acceptable, highly effective<br>             double contraception from Screening until 3 months after the last dose of the<br>             Investigational product.<br><br>        Key Exclusion Criteria:<br><br>          1. Subjects with contraindications or sensitivity to any components of the study<br>             treatment.<br><br>          2. Subjects with medical histories (within 3 months prior to Screening) or ongoing<br>             conditions of any clinically significant and/or any other medical conditions which may<br>             jeopardize the safety of the subjects and/or effect the results of the study at the<br>             Investigator's discretion.<br><br>          3. Subjects with histories or active conditions of unexplained bleeding events,<br>             hemoptysis, abnormal bleeding tendencies, and/or coagulation disorders.<br><br>          4. Subjects who voluntarily participate in this study and sign the informed consent form<br>             prior to any study procedures.<br><br>          5. Subjects with histories or active conditions of asthma, sleep apnea, chronic<br>             obstructive pulmonary disease (COPD), pulmonary fibrosis, bronchiectasis,<br>             bronchospasm, and/or reactive airway. Subjects who have had childhood asthma which<br>             have resolved as deemed by the PI can be considered.<br><br>          6. Subjects with histories or active conditions of myocardial infarction (MI),<br>             cerebrovascular accident (CVA), coronary artery disease (CAD), unstable angina, heart<br>             failure, significant cardiac arrhythmias, congenital or acquired valvular heart<br>             disease with clinically insignificant symptom, suspected lung congestion, and/or<br>             pulmonary arterial hypertension (PAH) causing by venous thromboembolism.<br><br>          7. Subjects with systolic blood pressure < 90 mmHg or > 160 mmHg and/or diastolic blood<br>             pressure < 50 mmHg or > 95 mmHg at Screening or check-in visit.<br><br>          8. Subjects with FEV1 less than 80% predicted, FVC ?80% predicted, or resting oxygen<br>             saturation less than 95% at Screening or check-in visit.<br><br>          9. Subjects with histories of drug or alcohol abuse within 1 year prior to subject<br>             check-in (Day -1). Regular alcohol consumption defined as > 10 standard drinks per<br>             week.<br><br>         10. Consumption of products containing caffeine/methylxanthines, poppy seeds and/or<br>             alcohol within 48 hours before dosing and products containing grapefruit and/or pomelo<br>             (shown to inhibit cytochrome P450 [CYP] 3A4 activity) within 10 days prior to drug<br>             administration.<br><br>         11. Positive results of human immunodeficiency virus (HIV), hepatitis B virus (HBV),<br>             hepatitis C virus (HCV), and pregnancy test.<br><br>         12. Blood donation or significant blood loss (>480 ml) within 3 months prior to Screening.<br><br>         13. Subjects are pregnant or breast feeding.<br>      """,NULL,"""The incidence of dose limiting toxicity (DLT);The incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs);Frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)""","""AUC0-t;AUC0-8;%AUCextrap;Cmax;Tmax;T1/2;CL/F;Vz/F;kel""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05898828,"""26 September 2023""","""001544-C;10001544""","""Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer""","""Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer""","""https://clinicaltrials.gov/ct2/show/NCT05898828""",""" ; ; ""","""David S Schrump, M.D.;Lydiah Mutumbi;National Cancer Institute Referral Office""",NULL,""";lydiah.mutumbi@nih.gov;""",""";(240) 858-7562;888-624-1937""","""National Cancer Institute (NCI);""",""" ; ; ""","""David S Schrump, M.D.;Lydiah Mutumbi;National Cancer Institute Referral Office""",NULL,""";lydiah.mutumbi@nih.gov;""",""";(240) 858-7562;888-624-1937""","""National Cancer Institute (NCI);""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1/Phase 2""","""9/6/2023""","""September 28, 2023""","""50""","""Not yet recruiting""","""National Cancer Institute (NCI)""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Neoplasms;Esophageal Neoplasms;Esophagus Neoplasm;Esophagus Cancer;Neoplasms, Esophageal;Esophageal Cancer (EsC)""","""Drug: Nivolumab;Drug: Entinostat;Biological: Montanide(R) ISA-51 VG Adjuvant;Biological: H1299 Cell Lysates""","""18 Years""","""120 Years""","""All""","""<br>        -  INCLUSION CRITERIA:<br><br>          -  Participants with clinical Stage II (T2/N0-N1; T3/N0) or Stage III (T1-T2/N2,<br>             T3/N1-N2) EsC per 8th edition TNM Staging System who have histologically documented or<br>             suspected residual disease in the esophagus or regional nodes following nCRT.<br>             Diagnosis must be confirmed by the NIH Laboratory of Pathology.<br><br>          -  No prior anti-PD1/anti-PD-L1 therapy for their EsC.<br><br>          -  Participant must be enrolled within 16 weeks following completion of nCRT or<br>             nCRT/surgery<br><br>          -  ECOG performance status of 0-1.<br><br>          -  18 years of age or older<br><br>          -  Participant must be willing to co-enroll on 06C0014 (Prospective Analysis of Genetic<br>             and Epigenetic Alterations in Patients with Thoracic Malignancies) allowing for the<br>             use of tumor or normal tissues for correlative experiments pertaining to this protocol<br>             and related translational research efforts in the Thoracic Surgery Branch (TSB).<br><br>          -  Adequate bone marrow reserve, hepatic and renal function as evidenced by the following<br>             laboratory parameters (all eligibility assessment/enrollment bloodwork must be done at<br>             NIH no more than 2 weeks prior to initiation of study therapy):<br><br>               -  Absolute neutrophil count greater than 1500/mm^3<br><br>               -  Platelet count greater than 100,000/mm^3<br><br>               -  Hemoglobin greater than 8 g/dL (participants may receive transfusions to meet<br>                  this parameter)<br><br>               -  INR <= 1.5 x ULN<br><br>               -  Total bilirubin <1.5 x upper limits of normal (except those with Gilberts<br>                  disease)<br><br>               -  Serum creatinine less than or equal to 1.6 mg/mL or the eGFR (calculated per<br>                  institutional standards) must be greater than 60 mL/min/1.73m^2<br><br>          -  Oxygen saturation equal to or greater than 92% on room air within 2 weeks of<br>             initiation of study therapy.<br><br>          -  Seronegative for HIV antibody by bloodwork performed at NIH no more than 4 weeks prior<br>             to initiation of study therapy.<br><br>          -  Seronegative for active hepatitis B, and seronegative for hepatitis C antibody by<br>             bloodwork performed at NIH no more than 4 weeks prior to initiation of study therapy.<br>             If hepatitis C antibody test is positive, then participant must be tested for the<br>             presence of antigen by RT-PCR and be HCV RNA negative.<br><br>          -  Women of childbearing potential and men must agree to use adequate contraception<br>             (hormonal or barrier method of birth control; abstinence) within 28 days prior to<br>             initiation of study therapy, for the duration of study participation and up to 5<br>             months after the last dose of study therapy.<br><br>          -  Participants who are breastfeeding or plan to breastfeed must agree to<br>             discontinue/postpone breastfeeding while receiving investigational treatment and for 5<br>             months after the last dose study therapy.<br><br>          -  Participants must be able to understand and willing to sign an informed consent.<br><br>        EXCLUSION CRITERIA:<br><br>          -  Participants who are receiving any other investigational agents<br><br>          -  Participants with a history of pneumonitis will be excluded unless cleared by<br>             Pulmonary Medicine consultants<br><br>          -  Participants requiring chronic systemic treatment with steroids above physiologic<br>             doses.<br><br>          -  Participants receiving warfarin anticoagulation, who cannot be transitioned to other<br>             agents such as enoxaparin or dabigatran, and for whom anticoagulants cannot be held<br>             for up to 24 hours.<br><br>          -  Participants with uncontrolled hypertension (>160/95) at screening, unstable coronary<br>             disease evidenced by EKG evidence of cardiac ischemia or uncontrolled arrhythmias,<br>             unstable angina, decompensated CHF (>NYHA Class II), or myocardial infarction within 6<br>             months prior to initiation of study therapy.<br><br>          -  Participants with any of the following pulmonary function abnormalities: FEV, < 35%<br>             predicted; DLCO < 35% predicted (post-bronchodilator); based on assessment performed<br>             no more than 4 weeks prior to initiation of study therapy.<br><br>          -  Active COVID infection<br><br>          -  Participant pregnancy.<br><br>          -  Other malignancy requiring treatment with the exception of localized skin cancer<br>             amenable to topical therapies<br><br>          -  Uncontrolled intercurrent illness occurring within 3 months prior to initiation of<br>             study therapy that would limit compliance with study requirements. Intercurrent<br>             illness may include any conditions uncovered during screening assessments (physical<br>             examination, laboratory assessments, etc.) that, in the judgment of the investigator,<br>             precludes participation because it could present disproportionate risk to the<br>             participant<br>      """,NULL,"""Phase I Component: To determine the safe dose of adjuvant H1299 lung cancer cell lysate vaccines with Montanide(R) ISA-51 VG administered in conjunction with entinostat and nivolumab in participants with locally advanced esophageal cancers (EsC)...;Phase II Component: To assess the frequency of immunologic responses to purified cancer-testis (CT) antigens in EsC participants receiving adjuvant vaccinations with H1299 cell lysate/Montanide(R) ISA-51 VG in combination with entinostat and niv...""","""Phase I Component: To assess the frequency of immunologic responses to purified cancer-testis (CT) antigens in EsC participants receiving adjuvant vaccinations with H1299 cell lysate/Montanide(R) ISA-51 VG in combination with entinostat and nivo...;Phase I + II Component: To assess safety of adjuvant H1299 lung cancer cell lysate vaccines with Montanide(R) ISA-51 VG administered in conjunction with entinostat and nivolumab in participants with locally advanced esophageal cancers (EsC) with...;Phase II Component: To determine progression free survival (PFS) in EsC participants receiving the investigational adjuvant vaccine regimen""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05909761,"""26 September 2023""","""EUPAS105613;VIB0551.P4.S4""","""Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy""","""An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (Inebilizumab-cdon) During Pregnancy""","""https://clinicaltrials.gov/ct2/show/NCT05909761""",""" ; ""","""Medical Monitor;Amanda Piquet, MD""",NULL,"""clinicaltrials@horizontherapeutics.com;AMANDA.PIQUET@CUANSCHUTZ.EDU""","""1-866-479-6742;303-724-4319""","""""",""" ; ""","""Medical Monitor;Amanda Piquet, MD""",NULL,"""clinicaltrials@horizontherapeutics.com;AMANDA.PIQUET@CUANSCHUTZ.EDU""","""1-866-479-6742;303-724-4319""","""""","""Observational""","""""","""""","""9/6/2023""","""July 17, 2023""","""60""","""Recruiting""","""Horizon Therapeutics Ireland DAC""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Neuromyelitis Optica Spectrum Disorder;Pregnancy Related""","""Drug: UPLIZNA""","""N/A""","""N/A""","""Female""","""<br>        Inclusion Criteria:<br><br>          -  Provide informed consent<br><br>          -  Are a female of reproductive potential with a confirmed or suspected diagnosis of<br>             NMOSD<br><br>          -  Have been exposed to UPLIZNA during pregnancy as defined by receipt of any dose during<br>             pregnancy or within 6 months preceding conception<br><br>        Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply<br>      """,NULL,"""Number of newborns with Major Congenital Malformations (MCMs);Number of newborns with Preterm birth;Number of newborns with low birth weight;Number of stillbirths""","""Number of newborns with Minor Congenital Malformations;Number of infants with developmental milestone abnormalities;Number of infants with neurologic abnormalities;Number of infants with immune system development abnormalities;Number of Spontaneous Abortions;Number of Induced or Elective Abortions""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05909904,"""26 September 2023""","""BGB-HNSCC-201""","""Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma""","""A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma""","""https://clinicaltrials.gov/ct2/show/NCT05909904""",""" ; ""","""Study Director;Study Director""",NULL,""";clinicaltrials@beigene.com""",""";1-877-828-5568""","""BeiGene;""",""" ; ""","""Study Director;Study Director""",NULL,""";clinicaltrials@beigene.com""",""";1-877-828-5568""","""BeiGene;""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 2""","""9/6/2023""","""July 21, 2023""","""160""","""Recruiting""","""BeiGene""",NULL,"""Please refer to primary and secondary sponsors""","""United States;Australia;China;Taiwan;Australia;China;Taiwan;United States""","""Head and Neck Squamous Cell Carcinoma;Head and Neck Cancer""","""Drug: Tislelizumab;Drug: BGB-A425;Drug: LBL-007""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Participants with histologically or cytologically confirmed R/M HNSCC that is<br>             considered incurable by local therapies<br><br>               1. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx,<br>                  and larynx<br><br>               2. Participants should not have had prior systemic therapy administered in the R/M<br>                  setting; systemic therapy which was completed prior to randomization/enrollment<br>                  if given as part of multimodal treatment for locally or locoregionally advanced<br>                  disease is allowed<br><br>          -  Participants must have positive PD-L1 expression (Combined Positive Score [CPS] = 1)<br><br>          -  Have at least 1 measurable lesion as defined per RECIST v1.1<br><br>          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1<br><br>          -  Adequate hematologic and organ function as indicated by specific laboratory values<br>             within 7 days of first dose of study drug<br><br>          -  Willing to use a highly effective method of birth control for the duration of the<br>             study and for = 120 days after the last dose of study drug(s)<br><br>        Exclusion Criteria:<br><br>          -  Recurrent or metastatic carcinoma of the nasopharynx (any histology), squamous cell<br>             carcinoma of unknown primary, squamous cell carcinoma that originated from the skin<br>             and salivary gland primary tumor or non-squamous histologies (eg, mucosal melanoma)<br><br>          -  Prior therapy with an anti-PD-1, anti-PD-L1, PD-L2, T-cell immunoglobulin and mucin<br>             domain containing-3 (TIM-3), LAG-3, or any other antibody or drug specifically<br>             targeting T-cell costimulation or immune checkpoint pathways<br><br>          -  Any active malignancy = 2 years before randomization/enrollment except for the<br>             specific cancer under investigation in this study, those with a negligible risk of<br>             metastasis or death, and any locally recurring cancer that has been treated curatively<br>             (eg, resected basal or squamous cell skin cancer, superficial bladder cancer,<br>             localized prostate cancer, and carcinoma in situ of the cervix or breast)<br><br>          -  History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung<br>             diseases including pulmonary fibrosis, and acute lung diseases<br><br>          -  A history of severe hypersensitivity reactions to other monoclonal antibodies or has<br>             experienced a severe immune-mediated adverse event (imAE), an imAE that led to<br>             treatment discontinuation, or a cardiac or ocular imAE of any grade with prior<br>             immunotherapy<br><br>        Note: Other inclusion and exclusion criteria may apply<br>      """,NULL,"""Objective Response Rate (ORR)""","""Progression-free Survival (PFS);Duration of Response (DOR);Clinical Benefit Rate (CBR);Disease Control Rate (DCR);Number of Participants with Adverse Events;Overall Survival (OS);Number of Participants with Anti-Drug Antibodies (ADAs)""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05909995,"""26 September 2023""","""2023-503243-34-00;INCB 99280-205""","""Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors""","""A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors""","""https://clinicaltrials.gov/ct2/show/NCT05909995""",""" ""","""Incyte Corporation Call Center (US)""",NULL,"""medinfo@incyte.com""","""1.855.463.3463""","""""",""" ""","""Incyte Corporation Call Center (US)""",NULL,"""medinfo@incyte.com""","""1.855.463.3463""","""""","""Interventional""","""Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ""","""Phase 1""","""9/6/2023""","""August 29, 2023""","""100""","""Recruiting""","""Incyte Corporation""",NULL,"""Please refer to primary and secondary sponsors""","""United States;Australia;Brazil;Canada;Korea, Republic of;Mexico;Norway;Slovakia;South Africa;Sweden;Turkey;Australia;Brazil;Canada;Korea, Republic of;Mexico;Norway;Slovakia;South Africa;Sweden;Turkey;United States""","""Melanoma;Hepatocellular Carcinoma (HCC);Renal Cell Carcinoma (RCC);Microsatellite Instability - High (MSI-H);Mismatch Repair Deficient (dMMR);Colorectal Carcinoma (CRC)""","""Drug: INCB 99280 with Ipilimumab""","""18 Years""","""N/A""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Prior systemic therapy, diagnoses and disease setting as follows:<br><br>               -  For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or<br>                  anti-PD-(L)1 therapy and one of the following,<br><br>                    -  Unresectable or metastatic cutaneous melanoma, or<br><br>                    -  Unresectable of metastatic Child-Pugh Class A NDD not eligible for surgical<br>                       and/or locoregional therapy, or<br><br>                    -  Intermediate or poor-risk advanced clear cell RCC, or<br><br>                    -  MSI-H or dMMR metastatic CRC and able to provide fresh or archival tumor<br>                       tissue for central confirmation of MSI-H or dMMR.<br><br>               -  For Part 2 (dose expansion), IO treatment -naïve, e.g., no prior receipt of an<br>                  anti PD-1, anti-PD-L1 or PD-L1, anti-CTLA-4, GITR, LAG3, TIM3, OX-40, IL-2, 4-1BB<br>                  or other immune modulator, and have not received prior systemic therapy and one<br>                  of the following,<br><br>                    -  Unresectable or metastatic Child-Pugh Class A HCC not eligible for surgical<br>                       and/or locoregional therapy, or<br><br>                    -  Intermediate - or poor-risk advanced clear cell RCC.<br><br>               -  ECOG performance score of 0 or 1.<br><br>               -  Life expectancy > 3 months, in the opinion of the investigator.<br><br>               -  Histologically confirmed solid tumors with measurable disease per RECIST v1.1.<br><br>                    -  Exception: HCC may be diagnoses based on cross-sectional multiphasic<br>                       imagining using the AASLD criteria.<br><br>               -  Willingness to avoid pregnancy or fathering children.<br><br>        Exclusion Criteria:<br><br>          -  Known history of an additional malignancy.<br><br>          -  Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal<br>             disease.<br><br>          -  Toxicity from prior therapy that has not recovered.<br><br>          -  Received thoracic radiation within 6 months of the first dose of study treatment.<br><br>          -  Participation in another interventional clinical study while receiving INCB099280.<br><br>          -  Impaired cardiac function of clinically significant cardiac disease.<br><br>          -  History of evidence of interstitial lung disease including non-infections pneumonitis.<br><br>          -  Presence of gastrointestinal condition that may affect drug absorption<br><br>          -  Any autoimmune disease requiring systemic treatment in the past 5 years.<br><br>          -  Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy at a daily<br>             dose exceeding 10 mg of prednisone or equivalent<br><br>          -  Active infection requiring systemic therapy.<br><br>          -  History of organ transplantation, including allogeneic stem cell transplantation.<br><br>          -  Receipt of system antibiotics within 28 days of first dose of study treatment.<br><br>          -  Probiotic usage is prohibited during the screening and throughout the study treatment<br>             period.<br><br>          -  Received a live vaccine within 28 days of planned start of study drug.<br><br>          -  Laboratory values outside the Protocol-defined ranges.<br><br>        Other protocol-defined Inclusion/Exclusion Criteria may apply.<br>      """,NULL,"""Occurence of DLTs;Incidence of TEAEs;Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs""","""Concentration of INCB099280 in plasma;Objective response;Disease control;Duration of Response""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT05910528,"""26 September 2023""","""RVT 3101-201""","""RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease""","""A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RVT-3101 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease""","""https://clinicaltrials.gov/ct2/show/NCT05910528""",""" ""","""Suzanne Vyvoda""",NULL,"""info@telavanttx.com""","""8015567244""","""""",""" ""","""Suzanne Vyvoda""",NULL,"""info@telavanttx.com""","""8015567244""","""""","""Interventional""","""Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ""","""Phase 2""","""9/6/2023""","""July 24, 2023""","""105""","""Recruiting""","""Telavant, Inc.""",NULL,"""Please refer to primary and secondary sponsors""","""United States""","""Crohn Disease""","""Drug: RVT-3101""","""18 Years""","""75 Years""","""All""","""<br>        Inclusion Criteria:<br><br>          -  Moderately to severely active CD as defined by Crohn's Disease Activity Index (CDAI)<br>             and Simple Endoscopic Score for CD (SES-CD), assessed by central read<br><br>          -  Elevated very soft or liquid stool frequency and/or abdominal pain<br><br>          -  Must have no response, insufficient response, loss of response and/or intolerance to<br>             at least 1 conventional therapy (e.g. corticosteroids) or advanced therapy<br><br>          -  Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic<br>             colitis, infectious colitis, radiation colitis or active diverticular disease<br><br>        Exclusion Criteria:<br><br>          -  Short gut syndrome<br><br>          -  Presence of an ostomy or ileoanal pouch<br><br>          -  Bowel resection or diversion with ~6-months<br>      """,NULL,"""Proportion of participants achieving clinical remission by CDAI""","""Proportion of participants achieving endoscopic response;Proportion of participants achieving clinical response by CDAI;Proportion of participants achieving endoscopic remission;Proportion of participants achieving clinical remission by CDAI and endoscopic response;Incidence of treatment-emergent adverse events (TEAE), serious adverse events (SAE) and AE leading to discontinuation""","""                                                  ""","""          """,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
